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Abstract 
Die in der Magnetresonanztomographie (MRI) verwendeten Kontrastmittel werden 
weitestgehend in der Diagnose oder in der Grundlagenforschung als bildgebende Methode 
eingesetzt. Meistens um den MRI-Kontrast positiv zu verstärken, dabei werden hauptsächlich 
Gd
3+
 basierte Systeme verwendet. Um ein besseres Verständnis von biologischen Prozessen 
zu erhalten, wurden intelligente Kontrastmittel (engl. SCAs: smart contrast agents) 
entwickelt, welche in der Lage sind physiologische Veränderungen durch Veränderung des 
MR-Signals sichtbar zu machen. Um die Herausforderungen zu überwinden, welche sich 
während einer in vivo Routineuntersuchung mit SCAs ergeben, wie die Lokalisierung , 
Quantifizierung, niedrige MR-Signale etc., besteht eine mögliche Strategie darin, solche 
Kontrastmittel mit verschiedenen funktionellen Molekülen, wie Dendrimeren, Nanopartikeln, 
Proteine oder Fluoreszenzmarker, zu verknüpfen. Um an bekannte SCAs funktionelle 
Moleküle anzuheften, kommt es darauf an bei der Modifizierung solcher SCAs die 
physikalisch-chemischen Eigenschaften beizubehalten die für deren Funktion essentiell sind.  
Der erste Teil dieser Dissertation beschreibt die Synthese und die Charakterisierung von pH 
sensitiven SCAs, an denen entweder ein aliphatischer (GdL
1
) oder ein aromatischer (GdL
2
) 
Linker angeheftet ist, mit angehängten Phosphatarm. Die longitudinale Relaxation von GdL
1
 
und GdL
2
 wird um 146% beziehungsweise um 31% verstärkt, falls der pH-Wert von 9 auf 5 
abnimmt. Diese beiden SCAs wurden zu einem biotinylierten System umgesetzt, GdL
3
 und 
GdL
4
, und deren Wechselwirkungen mit Avidin untersucht. Über die 
Untersuchungsmethoden, des "fluorescence displacement"-Assay und der MRI E-Titration, 
konnte ein 3:1 Bindungsmode von GdL
3-4
 zu Avidin mit einer genauso hohen 
Bindungsaffinität gezeigt werden, wie bei dem ursprünglichen Avidin-Biotin-Komplex. 
Diese hohe Bindungsaffinität konnte über einen kompetitiven Assay mittels MRI bestätigt 
werden. Der Avidin-GdL
3-4
-Komplex der folglich erhalten wurde, zeigte Unterschiede in r1 
als auch r2 im Bezug auf die pH-Abhängigkeit. Diese Ergebnisse zeigen neue Möglichkeiten 
für die Modifikation und Verbesserung von SCAs um diese geeigneter für die in vivo 
Anwendung zumachen. 
Der zweite Teil dieser Dissertation beschäftigt sich mit der Modifikation von bereits 
beschrieben Ca
2+
 ansprechbaren bismakrozyklischen Kontrastmitteln. Das modifizierte SCA 
(Gd2L
5
) wurde über die Insertion von aromatischen Linkern erhalten, die funktionelle 
Gruppen mit primären Aminen tragen, die für eine weitere Derivatisierung geeignet sind. Mit 
1.2 Äquivalenten an Ca
2+
 konnte gezeigt werden, dass Gd2L
5
 eine um 97% höhere 
 
 
longitutinalen Relaxation erreicht. Dies deutet daraufhin, dass die Eigenschaften für die 
Relaxation in Gd2L
5
 gut erhalten blieben. Die Aminogruppe des Linkers L
5
 wurde außerdem 
in eine Isothiocyanat-Gruppe umgewandelt und so L
6
 erhalten. Dies erweitert die Nutzung 
der Liganden, da die reaktive Gruppe dazu genutzt werden kann, um zu einer effizienten 
Funktionalisierung von L
6 
zu führen. Diese Sonde bietet neue Möglichkeiten, diese an 
funktionelle Moleküle anzuheften, welche geeignet sind für eine in vivo Anwendung mit 
Hilfe der Linker.  
Im letzten Kapitel wird die Synthese von L
5
 beschrieben, wobei eine Methode der 
Festphasensynthese angewendet wurde, benutzt wurde dabei die Phthalamid/tert-Butyl-
Chemie. Dies ist der erste Bericht bei dem Bismakrozyklen mit Hilfe einer 
Festphasenmethode erhalten wurden. Diese Strategie wurde angewandt um den Zeitaufwand 
zu minimieren, welcher durch die Aufreinigung von polaren Intermediaten in wässriger Phase 
anfällt. Nach der erfolgreich demonstrierten Synthesen von L
5
, wurde der Ca
2+
 ansprechbare 
bismakrozyklische Ligand L
7
, der zwei aromatische Linker an jedem Makrozyklus trägt, 
erfolgreich synthetisiert.. Diese Synthesestrategie erlaubt es prinzipiell innerhalb einer kurzen 
Zeit eine große Anzahl analoger Moleküle zu synthetisieren und so eine Molekülsammlung 
zu erstellen. Zudem erlaubt die strukturelle Modifikation an der Festphase die Insertion 
verschiedener Linker, sowie das Anbringen geeigneter Marker um die in vivo Anwendung zu 
verbessern. 
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Chapter 1: Introduction 
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1.1 Imaging 
The information about molecular abnormalities that ultimately result in disease or certain 
critical physiological events are of paramount importance in medical research and clinics. In 
order to understand the mechanism of these processes as well as to plan therapy, precise and 
truthful evaluations are necessary, which is the goal of molecular imaging. This key 
discipline of biomedical sciences is essential in monitoring the biological processes at cellular 
and subcellular level facilitating diagnosis, therapy monitoring, drug discovery and 
development. More specifically one could say it helps in understanding protein-protein 
interactions and enzymatic conversions. In addition it can be used to provide more detailed 
information regarding the structure of proteins and enzymatic function or its activity. By 
creating 2D or 3D images of tissues in live subjects, various properties of a potential 
pharmaceutical such as efficacy, metabolism, excretion and toxicity can be investigated, in a 
short time causing a minimal amount of disturbance to the system. This stream involves the 
use of highly sensitive instrumentation and contrast mechanism. The different techniques or 
modalities are summarized with their advantages and limitations in Table 1.
1
 
Among all modalities listed below; MRI is unique due to its ability to non-invasively produce 
high spatiotemporal resolved images of the soft tissues, without the use of ionizing radiation. 
This allows imaging without damaging or destroying tissues in living animals in real time. A 
single MRI experiment can extract enormous amounts of information compared with other 
modalities. Today MRI has become the modality of choice in number of diseases such as 
stroke, neurodegenerative disorders and cardiovascular diseases. This technique involves 
measuring the change in signal originating mainly from water protons in large magnetic field.  
1.2 Basics of MRI 
MRI operates on the principle of nuclear magnetic resonance (NMR, well known technique 
to analyze the organic molecules and few inorganic species too). Nuclei can be studied in 
NMR if they have a nuclear spin quantum number, I more than zero (I ≠ 0) in other words the 
nuclei having unequal number of protons or neutrons. Commonly studied nuclei with spin 
quantum number I = 
  
 
 (e.g. 
1
H, 
13
C, 
19
F, 
31
P). 
1
H is the most favorable nucleus for MRI 
because of its great abundance in biological materials present in water. Nuclei having spin 
angular momentum behave as small tiny magnets rotating around their center, producing 
Table 1-1: Key modalities used in molecular imaging approaches. 
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Imaging Technique Advantages Disadvantages 
Positron emission 
tomography (PET) 
High sensitivity; isotopes can 
substitute for naturally occurring 
atoms; quantitative; translational 
research 
PET cyclotron or generator 
needed; relatively low spatial 
resolution; exposure of subject 
to harmful radiation; expensive 
Single photon 
emission computed 
tomography 
(SPECT) 
Many molecular probes available; 
can image multiple probes 
simultaneously; may be adapted to 
clinical imaging systems; excellent 
sensitivity 
Relatively low spatial 
resolution; ionizing radiation; 
semi-quantitative; relatively 
expensive 
Optical imaging Can be used repeatedly without 
harm; High sensitivity; quick, easy, 
inexpensive, and relatively high 
output; user friendly 
Limited depth of penetration; 
current 2D imaging only; 
clinical translation very limited 
Magnetic resonance 
imaging (MRI) 
Highest spatial resolution; no 
ionizing radiation burden 
Relatively low sensitivity; high 
cost; Contrast agent may be 
needed 
Computed 
tomography (CT) 
Bone and tumor imaging; anatomic 
imaging 
Limited 'molecular' 
applications; limited soft tissue 
resolution; radiation 
Ultrasound Images can be generated in real time; 
Inexpensive; high temporal 
resolution; quantitative; no radiation; 
clinical utility 
Low spatial resolution; 
difficult to image extravascular 
targets; limited depth 
penetration; only anatomical 
information 
 
magnetic fields. The direction of this field is random, but when placed in a large external 
magnetic field, B0, the population of spins split into a number of discrete energy levels 
determined by I. Nuclei having I = 1/2 only have two energy levels; When the angular 
moment aligns into the direction of B0 it is called as lower energy state, N
+
, while when 
alignment is against B0 it is called as higher energy state, N
-
. Boltzmann’s equation provides 
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the relationship between these two states (Eq.1-1) where ∆E is the energy difference between 
the spin states, k is Boltzmann’s constant, 1.3805x10-23 J/K and T is temperature in Kelvin. 
This equation indicates the population of spins in each energy state is dependent on the 
temperature. 
 
             Eq. (1-1) 
 
  
In an external magnetic field, torque is created due to coupling between the nuclear spin and 
angular momentum. As a result spinning nuclei precess around the direction of the B0. 
Known as the frequency of precession, or Larmour frequency, ω is directly proportional to 
strength of B0 (Eq. 1-2) where γ is the gyromagnetic ratio, in MHz/Tesla and is characteristic 
of each nuclei. 
 
      Eq. (1-2) 
 
There is always excess number of spins in lower energy state at equilibrium (although 
number is very small) hence the net magnetization is in the direction of B0. When B0 is 
perpendicular to x- and y-axis and parallel to z-axis, then at equilibrium net magnetization 
will be in the direction of z-axis which is also called as longitudinal magnetization and Mz   
0, magnitude of Mz can be obtained by Curie law which shows that macroscopic 
magnetization is directly proportional to the magnetic field strength B0 while Mx and My 
components or transverse components of magnetization will not be present at this time, Mx = 
0, My = 0. If electromagnetic energy, of the same magnitude as the difference in energy 
between the spin levels, is emitted near the spins, in the form of radio frequency (RF pulse), it 
generates an extra magnetic field B1 in the direction perpendicular to the B0. As a result the 
net magnetization component Mz turns away from the z-axis. When RF signal is turned off, 
the displaced Mz-component returns to its equilibrium value slowly, this mechanism is called 
as longitudinal relaxation or T1-relaxation (T1 is time required to return to the initial value of 
Mz) or spin-lattice relaxation because of its origin in the interactions of the spins with their 
surroundings (Eq. 1-3 and Figure 1-1) 
 
          
       Eq. (1-3) 
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Figure 1-1: Graphical representation of T1 recovery curve. 
 
At the same time after the RF pulse or signal, Mxy component present in the xy-plane 
decreases to its equilibrium value of zero due to dephasing of the signal; this process is called 
transverse or spin-spin relaxation because its origin in the spin-spin characterized by T2, the 
time required for the Mxy component to return to its initial value of zero (Eq. 1-4 and Figure 
1-2) where TR is the time between two successive RF pulses and        is the spin-spin 
decay factor characterized by the time constant T2. 
 
          
              Eq. (1-4) 
 
 
Figure 1-2: Graphical representation of T2 decay curve. 
 
In practice there are two factors which contribute to the decay of transverse magnetization, 
molecular interactions and distortions in the homogeneous external magnetic field B0. 
Combination of these two is called as time constant T2* (Eq. 1-5). 
 
 
  
  
 
  
 
 
         
 Eq. (1-5) 
 
Thus the contrast observed in MRI is dependent on the combined magnetic moment M and 
hence on the spin density of nuclei under study, T1 and T2 (T2*).
2
  
Despite having a number of advantages MRI has low sensitivity, which can be overcome by 
using the contrast agents (CAs), paramagnetic diagnostic magneto-pharmaceuticals. The 
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pioneering work of Bloch and Lauterbur began the use of contrast agents in the MRI to 
enhance the image contrast for a better understanding of physiological and 
pathophysiological events.
3, 4
 Over the last couple of decades the field has matured with a 
significant number of applications in humans. Up to 45% of all clinical MRIs were performed 
using CAs.
5
 This also generated a tremendous amount of interest in the scientific community 
regarding the function of these agents and their application in vivo. 
Paramagnetic CAs alter the relaxation rate of local water protons which is reflected by a 
change in the intensity of the MRI signal. The signal intensity increases with an increase in 
longitudinal relaxation rate, R1, (R1=1/T1) and decreases with increasing transverse relaxation 
rate, R2, (R2=1/T2). The T1-weighted images are obtained by using the pulse sequences which 
focuses on R1 at the same time T2-weighted images are obtained from R2. CAs are categorized 
according to the extent by which they alter R1 as well as R2. Gd and Mn based agents have a 
more profound effect on R1 hence they are used to enhance T1 weighted images, where as 
systems such as iron oxide nanoparticles are used to enhance T2 weighted images.  
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1.3 Classification of CAs 
CAs can be classified different ways according to their biodistribution and image 
enhancement properties. In terms of biodistribution agents can be classified as extracellular, 
blood pool or organ specific, they are also categorized according whether they predominantly 
shorten T1 or T2 times as  T1 and T2 agents respectively.
2
 Furthermore, according to their 
magnetic properties they can be categorized as i) superparamagnetic and ii) paramagnetic 
contrast agents. 
 
1.3.1 Superparamagnetic contrast agents 
Water soluble crystals of iron oxide such as Magnetite (Fe3O4) or Maghemite (γ-Fe3O4) have 
been used as superparamagnetic CAs. The core diameter is in the range of 4–10 nm. In such 
crystals iron ions (Fe
2+
 or Fe
3+
) are magnetically ordered and contribute to the net magnetic 
moment of particle. Known as superparamagnetism, this leads to a remarkable shortening of 
T2 or T2* relaxation times resulting into darkening of the MR image (T1 is also shortened but 
focus remains on T2 effects because of larger change in magnitude). These CAs are generally 
used as intravascular or blood pool agents as they mainly reside into the intravascular space. 
To avoid aggregation and to enhance their biodistribution, particles are coated with 
biodegradable and non-toxic material. Iron oxide particles can be further subdivided as 
monocrystaline iron oxide nanoparticles (MION) with a mean diameter less than 20 nm, 
ultrasmall iron oxide particles (USPIO) with mean diameter less than 50 nm and 
superparamagnetic iron oxide (SPIO) refers to iron oxide cores with mean diameter greater 
than 50 nm.
2, 6-8
 
These particles are popular because of two main reasons 1) In T2-weighted images they give 
the most change in signal per unit of metal ion Fe
2+
/Fe
3+
and 2) the presence of biodegradable 
iron leads to non-toxic CA for in vivo imaging since the iron can be metabolized in the 
biochemical pathways of the cells. In addition, easy synthesis by controlled precipitation of 
iron oxide in an aqueous solution of Fe
2+
/Fe
3+
 and coating material can produce quantitative 
amounts of material. Long vascular half-life and the absence of extravascular leakage are also 
attractive features of these agents. Using different coating material, particles can be 
manipulated for specific functions and targets. Dextran coated iron oxide particles are used 
for the visualization of the vascular or central nervous system as well as to identify malignant 
Chapter 1 
 
9 
 
lymph nodes, liver tumors and brain tumors. In vivo monitoring of gene-expression, stem 
cells is possible using superparamagnetic iron oxide nanoparticles.
9
 Feridex, I. V. is the 
contrast agent approved by U.S. Food and Drug Administration (US-FDA) for clinical usage 
for the evaluation of lesions of the liver.
10, 11
 
1.3.2 Paramagnetic contrast agents  
Generally gadolinium (Gd
3+
) and manganese (Mn
2+
) complexed in organic multidentate 
ligands are used as paramagnetic CAs. They are chosen because of their useful magnetic 
properties arising due to presence of unpaired electrons in their outermost shell. Mn
2+ 
has five 
unpaired electrons while Gd
3+ 
has seven unpaired electrons in 3d and 4f orbitals respectively. 
Long electronic relaxation time, τ1e, plays critical role in selection of these metals and the 
presence of high number of unpaired electrons in outer electronic shell provides enough long 
electronic relaxation time. Compared to Mn
2+
 complexes, Gd
3+ 
complexes have been 
extensively used in research and clinics. Gd
3+ 
is favored over other lanthanide metal ions such 
as Dy
3+
 or Ho
3+
 despite having higher magnetic moment, due to their asymmetric ground 
state. Approximately 95% of total contrast enhancement MRI experiments in clinics were 
performed using Gd
3+
 based CAs.
12
 But Gd
3+
 ion have high toxicity, uncontrolled 
biodistribution as well as involvement in blocking of certain ion channels which prohibit 
being administered directly in vivo. For example, aqueous Gd
3+
 has LD50 (LD50 = is the 
measure of toxicity, dose that causes death in 50% of the animals) in the range of 0.1–0.2 
mmol/Kg to small animals. Toxicity arises due to the comparable ionic radii of Gd
3+ 
to Ca
2+
 
(1.2 and 1.1 Å respectively)
13
 which interferes with the Ca
2+
 signaling channels. Therefore it 
is necessary to administer Gd
3+
 in the form of complexes formed with multidentate organic 
ligands with a coordination number of either eight or nine (CN 8 or 9), to ensure high 
stability and reduce toxicity dramatically.
2, 13
 Few Gd
3+
 based CAs have been approved by 
US-FDA over the years in clinical application. These are low molecular weight, and non-
specific extracellular agents. Gd
3+
 encapsulated in polyaminocarboxylate containing organic 
molecules such as DTPA (diethylenetriaminepentacetate), DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetate) and their derivatives (Figure 1-3). DTPA and 
DOTA form thermodynamically and kinetically stable complexes with Gd
3+
. The 
thermodynamic stability constant for Gd-DTPA and Gd-DOTA are logKGdL = 22.1 and 25.6 
respectively.
14
 Normally derivatization of DTPA reduces its stability but it is still considered 
safe in vivo. Kinetic inertness is also crucial, Gd(DTPA-BMA) has a high stability at 
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logKGdL>18, but it is kinetically labile especially in acidic environment and has resulted in 
conditions such as nephrogenic systemic fibrosis.15 
In addition to optimal contrast enhancement an ideal CA should possess additional properties 
such as high water solubility, rapid clearance from body, high thermodynamic and kinetic 
stability, suitable pharmacokinetics, low toxicity etc. These all essential constraints should be 
considered while designing a paramagnetic contrast agent.
16
 The ability of CA to shorten T1 
and T2 is expressed in terms of relaxivity r1 and r2 respectively. This is direct measure of 
efficiency of the CAs (Eq. 1-6) where T1,2dia. is relaxation time of the solvent (water) in 
absence of paramagnetic species generally called as diamagnetic contribution which is 
constant for water, C is concentration of paramagnetic probe. 
 
 
    
 
 
        
        Eq. (1-6) 
 
If one plots a 1/T1,2 versus concentration of paramagnetic species, a straight line is obtained 
with slope equal to relaxivity r1/r2, with units mM
-1
s
-1
. Hence relaxivity, r1/r2 is directly 
proportional to the concentration of paramagnetic probe. This is valid only for dilute 
solutions of the probes, in the absence of intermolecular interaction of probes. Paramagnetic 
chelates influence the relaxation of water protons by dipole-dipole interaction between the 
nuclear spins and the fluctuating local magnetic field originated from unpaired electron spin. 
The distance between the paramagnetic metal ion and water molecules is inversely 
proportional to transmitting the paramagnetic effect.  
 
Chapter 1 
 
11 
 
 
 
Figure 1-3: Commonly used ligands for Gd
3+
 chelation for clinically approved Gd(III) contrast agents.  
 
Three different types of interaction between the paramagnetic species and water molecules 
contribute to the total relaxation.The inner sphere water molecules which directly bind to the 
metal ion in the inner coordination sphere and exchange with the bulk solvent. Some 
hydrophilic parts of the chelate form hydrogen bonds with water molecules and increase their 
residence time in second coordination sphere. Moreover water molecules of bulk experience 
paramagnetic effect, when they diffuse in the surroundings of paramagnetic species in outer 
coordination sphere. This effect is called as outer-sphere relaxation. Therefore relaxivity is 
expressed as the combined effect of inner sphere and outer sphere relaxation (Eq. 1-7). where 
IS, SS and OS in superscripts stands for inner sphere, second sphere and outer sphere 
respectively.
17
 
 
      
             Eq. (1-7) 
 
The longitudinal inner-sphere relaxation rate can be obtained from Eq. 1-8; in this equation 
   is the mole fraction of solvent coordinated to the metal ion,    is mean water residence 
time and     is relaxation time of the bound water protons. 
 
 
  
   
 
      
 Eq. (1-8) 
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The value     can be obtained by using Solomon-Bloembergen-Morgan (SBM) 
18-20
 theory 
by following Eq. 1-9, where γ is the proton gyromagnetic ratio, g is the electronic g-factor, S 
is the total electron spin of the metal ion,    is the Bohr magneton, r is the proton-metal ion 
distance,    and     are the electronic and proton Larmor precession frequencies, 
respectively. 
 
 
   
 
             
 
    
 
    
    
    
  
    
    
    
   Eq. (1-9) 
 
The molecular correlation time,   , is determined by following parameters: rotational 
correlation time   , the electronic correlation time    , and the proton residence time    (Eq. 
1-10) where i = 1, 2.  
 
 
   
 
 
  
 
 
   
 
 
  
 Eq. (1-10) 
 
The theory in the abovementioned equations demonstrates that optimizing a number of 
microparameters is necessary to obtain high relaxivities r1/r2, such as increasing the hydration 
number q, optimization of distance between metal ion and proton, decreasing the proton 
residence time, increasing the rotational correlation time, electronic relaxation times and 
strength of applied magnetic field. These parameters directly or indirectly contribute in inner- 
and outer-sphere relaxation mechanism (Figure 1-4). Optimization of such parameters would 
increase the efficacy of the CA, lowering required dose for the same signal. In addition to 
enhancing the signal, tuning of parameters allowed scientists to design smart or responsive 
contrast agents (SCA) (see below). Among all the parameters the hydration number q, 
rotational correlation time   , and residence time of the proton    can be most readily 
altered. 
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Figure 1-4: Schematic representation of factors contributing towards the relaxivity of CA. Monoaqua complex 
of Gd
3+
 is shown; q = 1 and    = 1/kex. 
 
1.4 Tunable molecular parameters contributing to longitudinal relaxivity 
1.4.1 Hydration number, q 
Hydration number q is the number of water molecules directly bond to the paramagnetic 
metal ion. It has profound influence on inner-sphere relaxation mechanism as relaxivity 
increases with increase in q. But increasing hydration number may have adverse effect on the 
thermodynamic and/or kinetic stability of complex. In addition formation of ternary 
complexes with endogenous anions (carboxylates or phosphates, present in high 
concentrations in vivo) significantly reduces the signal from of bishydrated complexes. Hence 
it is necessary to balance both stability and q while designing CA. Note all clinically 
approved CAs are mono-hydrated, for example [Gd(DTPA)(H2O)]
2-
 and  [Gd(DOTA)(H2O)]
-
. Despite these issues, Raymond and co-workers introduced new bishydrated ligands based on 
TREN-HOPO (tris(2-aminoethyl)amine-hydroxypyridinone).
21
 This type of complexes have 
q =3 with good stability and low affinity towards the endogenous anions. Aime et al. reported 
novel heptadentate ligand the 6-amino-6-methylperhydro-1,4-diazepine-1,4,N
6
,N
6
-
tetraacetate (AAZTA) (Figure 1-5).
22
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Figure 1-5: Structure of ligands for Gd(III) complexes with q=2. 
 
In research, a derivative of DOTA, DO3A (1,4,7,10-tetraazacyclododecane-1,4,7-
tricarboxylic acid) is widely used for Gd
3+ 
chelation, where the free amine site could be 
utilized to install a number of useful linkers to modify the application of agent. The stability 
is good (logKGdL> 20) with hydration number q=2.
23
 Formation of ternary complexes with 
endogenous anions such as carbonate, phosphate, citrate or even coordinating functionalities 
of proteins reduces the in vivo relaxivity of these type of complexes.
24
  
 
 
Figure 1-6: Structure of DO3A ligand. 
 
The determination of hydration number provides an insight to understanding the mechanism 
of relaxivity change. Many experimental techniques are extensively used for this purpose. 
Joop Peters and co-workers
25
 reported Dy
3+
 induced shifts of 
17
O in directly bond H2
17
O in 
NMR. The slope of straight line in between 
17
O shift and chelate concentration directly 
measures the q. The authors used [Dy(H2O)8]
3+
 as reference with known number of directly 
bond water molecules for calculations. 
In another approach Horrocks et al
26, 27
 devised the laser-induced luminescence method to 
determine hydration number. They have obtained hydration number; relating difference in 
luminescence life time measurement in H2O and D2O solution of Tb
3+
 or Eu
3+
 complexes. 
The equation used in this technique is recently revised
28, 29
 with correction factor for outer 
sphere effects which is 0.25 for Eu
3+ 
(Eq. 1-11) where    is proportionality constant specific 
to given lanthanide ion and   is luminescence lifetime. They have also correlated the number 
of directly bound water molecules from the crystal structure with the difference in the 
lifetimes in H2O and D2O 
 
The point of attachment 
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         Eq. (1-11) 
 
These methods are indirect as Ln
3+
 complexes were investigated other than Gd
3+
 complexes. 
More recently Caravan et al.
30
 investigated new method with use of pulsed 
17
O Mims 
electron–nuclear double resonance (ENDOR) spectroscopy for the direct determination q of 
Gd
3+
 complexes. Spectra of metal complexes in frozen aqueous solutions at approximately 
physiological concentrations can be obtained either in the presence or absence of protein 
targets. 
1.4.2 Rotational correlation time,     
The longitudinal relaxivity values of Gd
3+
 complexes increases with increase in the   . But 
this phenomenon is field dependant and occurs most efficiently between the Larmor 
frequencies of 10–70 MHz when    is in between 10–50 ns. Above this field strength (>100 
MHz) different mechanism follows. Here shorter    is more important (<10 ns) with 
intermediate values of   .
31
 Different types of strategies are used to slow down the rotation of 
Gd
3+
 complexes such as i) covalently attachment of complexes to macromolecules such as 
spherical dendrimers, linear polymers etc. In one of the example Gd
3+ 
complexes conjugated 
to PAMAM(polyamidoamine) dendrimers of 1
st
 to 4
th
 generation were studied. The 
relaxivities were almost doubled over 1
st
 generation to 4
th
 generation of dendrimer but to a 
lesser extent than expected.
32
 In another study a Gd
3+ 
complex attached to the modified 
dextran polymer revealed minimal increase in the relaxivity despite the large increase in 
molecular weight. This could be caused due to movement of the polymer chain or flexibility 
of linear polymer. Hence more rigid macromolecules are required to achieve optimum value 
of relaxivity.
33
 ii) In different approach non-covalent bonding of the complex to protein like 
serum albumin is used to slow down the rotation. Clinically used MS-325 (Figure 1-3) 
attached to human serum albumin (HSA) using a hydrophobic diphenylcyclohexyl moiety 
increases the relaxivity up to 8 fold at 20 MHz and 37 °C.
34
 Merbach and coworkers reported 
longitudinal relaxivity 15.8 mM
-1
s
-1
 at 200 MHz, 37 °C. Self-assembled 
Fe[Gd2bpy(DTTA)2(H2O)4]3
4- 
agent displayed four times higher in vivo relaxivity than 
commercially available GdDOTA (Figure 1-7).
35
 Even though it is crucial parameter, there is 
no direct method to measure   . It can be obtained by fitting the data from 
1
H NMRD 
(nuclear magnetic relaxation dispersion) curves. 
2
D or 
13
C relaxation measurement on the 
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ligands or electron paramagnetic resonance (EPR) spectra of vanadyl (VO
2+
) can also be 
used.
2
  
1.4.3 Residence time of the coordinated water/proton,     
The residence time of water and proton is same at around neutral pH. Increasing acidity or 
basicity of the solution catalyses proton exchange faster and enhances it.
36, 37
 Optimal value 
of    is dependent on magnetic field strength and    of the complex.    should be as short in 
the range of 10–30 ns for  
 
 
Figure 1-7: Schematic structure representation of mettalostar [Fe[Gd2bpy(DTTA)2(H2O)4]3]
4-
.
 
 
 
macromolecular CAs at 60 MHz or 1.5 T. For higher field applications 1–10 ns will be more 
suitable.
31
 This phenomenon can be determined by variable temperature or pressure 
17
O 
NMR relaxation rate measurements.
2
 
Complex charge, solvent accessibility, steric effects around water binding site of complexes, 
abundance of isomers are key factors that affect the value of   . Negatively charged Gd
3+
 
complexes of DOTA or DTPA-like ligands demonstrate shorter    than corresponding 
neutral or positively charged species. The amide substituent also influences   . Square 
antiprismatic (SAP) or twisted square antiprismatic (TSAP) isomers observed in Ln(DOTA) 
complexes and their derivative have different    values. Reports display 10–100 times faster 
water exchange for TSAP isomer over SAP. Therefore structures that favor one isomer over 
the other will have consequences for the residence time.
2, 17, 38
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The mechanism of exchange of water involves either an associative, dissociative process or 
interchange processes too. In case of bishydrated ligands the associative mechanism shortens 
the   . For example HOPO or AAZATA based complexes have    in the range of 
nanoseconds.
22, 39
 
Besides these parameters second-sphere parameters has significant role in relaxivity. There 
are examples of complexes without inner-sphere water complexes that show relaxivity as 
high as monohydrated commercial agents. DOTA like complexes with four phosphoric acid 
arms have second-sphere as well as outer-sphere water which contributes to the relaxivity.
40
 
This phenomenon was proved in many phosphoric acid containing DO3A based Gd
3+
 
complexes which display higher relaxivity than DOTA analogue.
41
 But it is difficult to 
predictively alter outer-sphere water hence it was not utilized in designing responsive contrast 
agents.
2
 
In order to generate new types of contrast agents which not only will enhance anatomical 
images but also report the molecular or cellular events in vivo, smart (responsive) contrast 
agents (SCAs) are currently being developed that alter their MR signal, through modification 
of one or more of  the abovementioned parameters.  
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1.5 Smart Contrast Agents 
SCAs display changes in relaxivity with changes in its microenvironment. This change in 
relaxivity r1 can be obtained by tuning one of the previously mentioned parameters such as q, 
   or   . Field independent large relaxivity changes can be achieved by altering hydration 
number. The functional group of the ligand interacts differentely causing change in hydration 
number leads to changes in relaxivity value. In another approach researchers slowed down 
the rotation of CAs in solution attaching them to macromolecules such as peptides, proteins, 
dendrimers, different biomolecules etc. Here special attention is essential as slower rotation 
would result in decrease in    which would compensate the relaxivity change. Few examples 
of the SCAs are demonstrated in following sections with more detail discussion in case of pH 
activated and Ca
2+
 responsive SCAs in following chapters. 
1.5.1 pH activated smart contrast agents 
Change in the local pH in living organism is generally sign of pathological disorders. Tumor 
tissues display slightly acidic pH (pH 6.8—6.9) when compared to normal tissues.42 This 
necessitates the development of different methods to accurately measure pH in living animals 
for early diagnosis of the malignant tissues. Acid/base ionization properties of certain 
functional groups of organic molecules attached to the ligand are utilized in a general 
approach to design pH-sensitive CA. Depending on protonation state of these functional 
groups; they are coordinate or decoordinates with Gd
3+
 metal center resulting into relaxivity 
change. Several pH responsive contrast agents have been reported by number of research 
groups.
23, 43, 44
 Sherry and coworkers published the first pH sensitive MRI contrast agent 1-2 
in 1999 (Figure 1-8).
45
  Following it, a number of pH sensitive CAs were studied in in vivo 
model environments. Evolution and application of these agents is discussed in detail in 
chapter 2 (see below). 
 
Figure 1-8: Chemical structure of pH sensitive contrast agent. 
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1.5.2 Cation sensitive smart contrast agents  
Metal ions play crucial role in growth and development of living organisms. But irregularities 
cause number of acute diseases such as diabetes, certain neurodegenerative diseases. To 
better understand a number of physiological events particularly in the brain it is essential to 
understand the metal ion concentration in vivo. Number of MRI based probes to detect metal 
ions such as Ca
2+
, Zn
2+
,Cu
+/2+
, Fe
2+/3+
 have been developed and studied.
23, 46-48
 Selectivity for 
one particular metal ion over others, endogenous anions or biomolecules is most important 
criteria which should be considered while designing such probes. Binding affinity of metal 
ion to CA or its biocompatibility are other critical aspects to consider when designing CA.  
Incorporating calcium binding unit (DOPTA ligand system) in between two Gd-DO3A 
macrocycles, T. Meade and coworkers published the first Ca
2+
 sensitive in 1999.
49
 Relaxivity 
increased from 3.3 mM
-1
s
-1
 to 5.8 mM
-1
s
-1
(75%, at 500 MHz, 25 °C, 1-3). In the absence of 
Ca
2+
 carboxylic acid arms of BAPTA or APTRA derivatives 
 
 
Figure 1-9: Representative example of Ca
2+
 sensitive contrast agents 
 
coordinate to the Gd
3+
, hindering the access of metal ion to water. But in presence of Ca
2+
 
these carboxylates coordinate to Ca
2+
 leaving open access to water to Gd
3+
. This phenomenon 
yielded changes in q, and hence relaxivity. Moreover our laboratory reported excellent 
changes in relaxivity exploring different types of ligand system to bind Ca
2+
.
50-56
 Ca
2+
 ion 
sensitive CAs are discussed in more detail in following chapter 3 (see below). 
 
Chapter 1 
 
20 
 
 
Figure 1-10: Representative examples of Cu
+/2+
 sensitive contrast agents 
 
A number of copper sensitive CAs have been studied by the group of Christopher Chang. Gd-
DO3A derivatives with Cu
2+/+
 binding moieties such as iminodiacetate derivative or thioether 
derivatives are utilized (Figure 1-10). Gd-DO3A with iminodiacetate derivative 1-5
 
displayed 
a 41% increase in longitudinal relaxivity from 3.76 mM
-1
s
-1
 initial to 5.29 mM
-1
s
-1
 (400 MHz, 
25 °C) on addition of Cu
2+
. The binding affinity to Cu
2+
 was in the micromolar range (Kd = 
167 µM). This agent has selectivity to Cu
2+
 over other biological relevant metal ions except 
Zn
2+
. With the addition of a 10 fold excess of Zn
2+
 authors observed change in relaxivity 
which is important finding since in vivo Zn
2+
 will interfere in assigning of Cu
2+
 ion 
concentration.
57
 In an attempt to improve the selectivity over Zn
2+
, incorporation of thioethers 
in Gd-DO3A 1-6 for binding to copper ions resulted not only in better selectivity over Zn
2+
 to 
Cu
+
 but relaxivity increased from r1 = 1.5 mM
-1
s
-1
 to 6.9 mM
-1
s
-1 
(60 MHz, 37 °C) upon 
addition of one equivalent of Cu
+
. The Kd values are reported in the picomolar range. Change 
in q from 0 to 2 was the responsible for relaxivity change revealed from dysprosium induced 
17
O shift experiments and NMRD fitting profiles. Incorporation of one carboxylate on copper 
binding unit, 1-7, led to binding affinity of Cu
2+
 over Cu
+ 
in femtomolar range.
58
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Figure 1-11: Representative examples of Zn
2+
 sensitive contrast agents. 
 
A series of Zn
2+
 sensors were synthesized and studied by number of research groups. Initially 
Nagano’s group reported two Gd-DTPA based Zn2+ sensors. These sensors have good 
selectivity over other metal ions. These are based on the turn-off principle means as upon 
addition of Zn
2+
 metal ion the relaxivity decreases from its initial value. A probe was reported 
with a DTPA derivatives in between two picolylamine units (Figure 1-11). In 1-8 the 
relaxivity decreases from 6.06 to 3.98 mM
-1
s
-1
 (300 MHz, 25 °C, pH 8, 33% decrease)
 
with 
addition of one equivalent of Zn
2+
 and returns to its initial value with further addition of 
another equiv. of Zn
2+
 ion. In 1-9 two picolyl units were replaced by acetate group. Here the 
relaxivity decrease is 30% with addition of one equiv. of Zn
+2
. However the stability of these 
complexes was too low for further studies.
59
 In another strategy a Gd-DO3A derivative with 
an iminodiacetate moiety was linked via propyl and ethyl linkers. The results revealed an 
increase in r1 from 2.3 to 5.1 mM
-1
s
-1
 (60 MHz at 37 °C, 121%) with addition of one 
equivalent of Zn
2+
 in the complex with propyl linker 1-10. This agent was sensitive towards 
Cu
2+
 too, since upon addition of 1 eq. of Cu
2+
 there was change in relaxivity from 3.1 mM
-1
s
-1
 
to 5.1 mM
-1
s
-1
 (60 MHz, 37 °C). Sensitivity to Ca
2+
, Mg
2+ 
was not observed. The observed 
relaxivity change was a direct outcome of an increase in q from 0.3 to 1.0 in absence and 
presence of Zn
+2
 respectively. Moreover the binding constant (logKA = 3.6) was in suitable 
range to utilize the agent in vivo.
60
 The complex with ethyl linker was almost insensitive to 
the addition of Zn
2+
. Sherry and coworkers used Gd-DOTA-BPEN 1-11 as a Zn
2+
 sensor. At 
23 MHz and 37 °C, a 20% change in relaxivity was displayed with binding constant logKA = 
7.5. Titrations in the presence of HSA showed a 165% change in r1 at 23 MHz, a result of 
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binding to HSA in presence of Zn
2+
 which increases the τR value. There are reports of 
potassium and magnesium responsive probes too.
61, 62
 Supramolecular heterobimetallic Fe-
Gd complexes have been reported.
63-66
 These CAs have not designed as responsive CAs but 
to increase the relaxivity decreasing rotational correlation time τR (see above). 
1.5.3 Enzyme activated smart contrast agents 
Enzymes are highly specific biomolecules which catalyze a number of biochemical 
processes. It is of profound importance to understand where specific enzymes localize and 
how they function within the body or cells. Extensive attempts have been made to understand 
a number of enzyme processes such as bond cleavage which in turn results into change in 
relaxivity of CA. The general approach exploited was either q change or change in affinity 
towards specific proteins such as HSA to slow down tumbling of CA.  The first example was 
studied by Meade and coworkers. A Gd-DOTA complex bearing a β-galactopyranose unit 
was synthesized and studied in the presence of β-galactosidase enzyme. β-galactopyranose 
serves as umbrella over the Gd
3+
 inhibiting the interaction of water in absence of enzyme. β-
galactopyranose is then cleaved irreversibly by the enzyme allowing water to interact with 
the metal ion. Hence a change in relaxivity was observed (low to high) as result of change in 
q during the process.
67
 This complex with a slight modification was successfully employed in 
visualization of gene expression in vivo using MRI.
68
 The same group also extensively 
studied oncologically significant β-glucuronidase activated Gd-DO3A type of CA.69 A Gd-
DO3A based complex 1-12 carrying pendant acetoxymethyl esters, sensitive to procine liver 
esterase was studied by Lowe and coworkers. This SCA showed an 84% change in relaxivity 
r1 (20 MHz at 25 °C) when procine liver esterase cleaves the esters complex and transforms 
CA into negatively charged species, which also suppresses the carbonate binding and 
increases the hydration states hence relaxivity.
70
 The q change was assessed by lifetime 
measurement of corresponding Eu
3+
 complexes. Another approach is to increase rotational 
correlation time    using enzyme catalyzed HSA binding or polymerization known as 
receptor-induced magnetization enhancement (RIME). For this endeavor a Gd-DTPA 
conjugate with tri-lysine peptide, 1-13 and a human carboxypeptidase, thrombin activatable 
fibrinolysis inhibitor (TAFI) were investigated. TAFI cleaves the lysine residues and converts 
the complex such to bind strongly with HSA. This increased the relaxivities over 100% (20 
MHz at 24 °C) by the RIME phenomenon.
71
  Recently a Gd-DOTA complex with galactose 
protected tyrosine −OH functionality was investigated. β-galactosidase promoted cleavage of 
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sugar moiety; the complex was polymerized by tyrosinase activated melanin which increases 
relaxivity in the field range of 0.5–1.5T.72  
 
 
 
Figure 1-12: Representative examples of enzyme activated contrast agent. 
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1.6 Aim of Project 
A number of SCAs have shown remarkable signal changes in in vitro analysis. Despite this 
there are few that can proceed to the in vivo applications. The real challenges in this 
progression are a result of a more complex in vivo environment. Firstly, endogenous anions 
such as carbonate, phosphates, citrate decrease the relaxivity extensively in DO3A based 
SCAs forming ternary complexes.
23
  Some coordinating moieties of proteins decrease free 
access of water unlike in in vitro conditions through a similar mechanism. Furthermore the 
diffusion over time through extracellular space of SCAs decreases its local concentration 
resulting in a corresponding decay of MRI signal over time. In such circumstances it is not 
possible to assess if the changes in the MRI signal are a direct outcome of response to 
biological event or simply a change in concentration of SCA or interference of endogenous 
anions/proteins. Moreover low target recognition, agglomeration and non-specific 
accumulation of SCAs in different tissues are other major obstacles in in vivo application of 
SCAs.  In addition to this single imaging modality, MRI is unable to provide information on 
all aspects of structural and functional targeted biological phenomenon.  
These obstacles could be overcome by using conjugates of SCAs with different types of 
functional molecules such as nanoparticles, dendrimers, liposomes, viruses, fluorescent tags, 
peptides, targeting vectors, antibodies etc. Another strategy can be combination of different 
imaging modalities such as optical or PET to assess in vivo concentration or structural and 
functional changes of probes. This approach allows the confirmation of observed biological 
phenomenon using an independent measurement. Most importantly in order to attach SCAs 
to functional molecules it is necessary to modify the current in vitro analyzed and potential 
SCAs without affecting its physico-chemical properties in particular its smart activity. 
The aim of this project is to synthetically modify the recentely developed, potential SCAs 
without changing their physicochemical properties in order to introduce coupling unit and 
attach of them to the functional molecules utilizing a new coupling unit. Furthermore this 
hybrid will be evaluated in vivo in rodents and primates to track down the physiological 
events such as change in concentration in Ca
2+
 ion during neuronal signaling. The attempts to 
fulfill the aim are discussed in this thesis. 
The chapter 2 focuses on the synthetic modification and characterization of DO3A based pH 
sensitive contrast agents appended with a phosphonate pendant arm by inserting two different 
types of linking units either with an aliphatic or aromatic linker with primary amine as 
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functional group. The general idea of this project was to design a common synthetic strategy 
to majority of DO3A based smart contrast agents to further functionalize with ones choice. 
The pH sensitive agents were resynthesized with linking units, and studied its 
physicochemical properties using different analytical techniques such as NMR or 
fluorescence spectroscopy. Using newly introduced linking units, modified pH responsive 
agents were further attached to biotin to obtain biotinylated agents and studied with and 
without avidin at different pH in MRI scanner. 
Chapter 3 deals with the use of newly developed synthetic strategy from chapter 2 to insert 
linking unit in one of Ca
2+ 
sensitive agent. DO3A based bismacrocyclic complex carrying 
EGTA derivative in between two macrocycles as Ca
2+
 chelator has the potential for Ca
2+
 
detection in neuronal signaling. This molecule has a high relaxivity response with Ca
2+
 as 
result of change in hydration number and selectivity over other endogenous metal ions such 
as Mg
2+
. This SCA was successfully modified by the introduction of linker moiety in one of 
the macrocycles to couple it to functional molecules. A number of synthetic strategies were 
attempted to optimize the unique synthetic strategy to produce synthetically challenging 
bismacrocyclic ligand in large amounts with highest purity. The synthesis of complex and 
study of change in longitudinal relaxivity with Ca
2+
 of modified Ca
2+
 responsive agent is 
discussed in this chapter.  
The chapter 4 describes the utilization of well established synthetic strategy by peptide 
chemists, solid phase peptide synthesis (SPPS) for modification of Ca
2+
 sensitive 
bismacrocyclic complex with two coupling units on macrocycle. This method enables the 
delivery of synthetically challenging ligand in a short time avoiding the difficult and time 
consuming purifications of intermediate compounds. Moreover this synthetic strategy would 
be more useful to synthesize the different synthetic analogues with slight structural changes 
for optimization of potential contrast agent. In this attempt aromatic linkers were added on 
both macrocycles that could be attached to various functional molecules for further in vivo 
application. 
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Chapter 2: Synthesis and characterization of pH-sensitive, biotinylated 
MRI contrast agents and their conjugates with avidin 
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2.1 Introduction 
The critical role of pH in many physiological and pathophysiological events in living 
organisms is well established. Many of the major deadly diseases are associated with a 
variation in pH such as stroke, inflammation, infection, tumors, kidney failure, cancer etc. 
For instance many malignant tissues have a slightly acidic pH in the range of 5.85–7.68 in 
humans while in rodents the range is 5.80–7.52.73 This change in pH is direct consequence of 
oxygen deficiency and many other essential nutrients that cause the uncontrolled growth of 
cells. This leads to the production of lactic acid under anaerobic conditions and the hydrolysis 
of ATP (adenosine-5′-triphosphate) in an energy-deficient microenvironment. Combined this 
leads to the acidic pH in tumors.
74, 75
 Furthermore the pharmacokinetic properties of many 
drugs depend on the local pH that they experience.
76
 Therefore, it has become of paramount 
importance to accurately determine the local pH in live human tissues. Many efforts have 
been made in this direction; some involve the use of a pH electrode by inserting it directly 
into tissues under study.
77
 This approach is invasive and only restricted to in vitro analysis 
since such measurements in in vivo are complicated by an unknown component from 
damaged cells and blood from the ruptured capilarries.
78
 Another approach is non-invasive 
and particularly useful for in vivo measurements using molecular probes that are weak acids 
or bases.
42, 79
 These probes change their spectral properties in different pH environments 
which can be traced by spectroscopic techniques. Optical pH indicator dyes, EPR sensitive 
probes or
 31
P NMR are generally utilized in such applications.
79-82
  Although these are non-
invasive, they have many limitations such as low resolution, lack of sensitivity, low depth of 
penetration etc.
83
  
In light of the above limitations attention was moved towards the MRI technique which 
combines the highest spatiotemporal resolution with non invasive measurement to overcome 
these issues. Therefore, significant efforts have been undertaken by researchers to develop pH 
responsive MRI contrast agents. These SCAs contain functional groups which change their 
protonation state around neutral pH, such as phosphonates or arylsulphonamides. As 
mentioned earlier (Chapter 1), Sherry and coworkers developed the first pH responsive agent 
for MRI based on a tetraamide phosphonate derivative of DOTA (DOTA-4AMP), GdL
1
, was 
reported more than a decade ago followed by DO3A derivative containing sulphonamide 
pendant arm (DO3A-SA, 2-1) with different substituents on benzene ring (Figure 2-1). These 
SCAs contain functional groups which change their protonation state around neutral pH, the 
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general mechanism reported involves alteration of the coordination environment around the 
metal center at different pH, which affects the number of proximate water molecules, 
resulting in a change in signal. In 1-2, hydrogen bonds formed after protonation of the 
phosphonate play a crucial role catalyzing the exchange of protons between inner and outer 
sphere water, resulting in a change in signal as a function of pH. The mechanism of action of 
DO3A-SA 2-1, is different: at acidic pH the protonation of the nitrogen allows water to 
approach Gd
3+
, whereas at basic pH deprotonation of nitrogen results in its coordination to 
the metal center, reducing hydration number q and hence relaxivity by hindering the access of 
water molecules to the inner sphere.
84
 However there is an upmost need for SCAs with a 
response that can be combined with additional properties such as controlled biodistribution or 
determination of its exact local concentration in vivo. Such requirements necessitate 
additional synthetic modifications to SCAs and therefore special attention should be given 
towards the changes in the physico-chemical properties of SCAs, to ensure their relaxivity 
changes, while crucial issues such as the kinetic and thermodynamic stability are retained. 
For instance, the in vivo biodistribution of probes varies considerably with slight changes in 
their structures.
85, 86
 
 
Figure 2-1: pH sensitive agent with sulphonamide pendant arm. 
 
Proceeding in this direction, Sherry and co-workers attached a modified version of SCA 2-2
 
to a PAMAM G5 dendrimer to improve the MR signal by increasing the molecular weight of 
the conjugate (Figure 2-2).
87
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Figure 2-2: Few examples of early modifications of pH responsive probes. 
 
The relaxivity of the conjugate increased 100% from pH 6 to pH 9.6 due to the increase in τR. 
However, due to its isoelectric point at pH ~6, this dendrimeric SCA precipitates from 
solution. In another approach, a dual-modal MR-PET agent 2-3 was prepared in which 
quantification of the local probe concentration was accomplished by the presence of the PET 
active 
18
F nucleus, within the phosphonate-containing SCA, enabling pH mapping.
83
 Other 
attempts involved modification of the sulfonamide based pH sensitive agent. Namely, the 
accessibility of its phenolic oxygen allowed the coupling of the functional molecule to a poly-
β-cyclodextrin containing 19F reporter. Here an adamantane derivative was introduced on the 
phenolic oxygen to achieve an effective non-covalent coupling to the poly-β-cyclodextrin, 
where the 
19
F signal intensity is used to quantify the amount of SCA (Figure 2-2, 2-4).
88
 Our 
group recently reported a DO3A based, pH responsive probe appended with a phosphonate 
arm 2-5 (DO3APP, Figure 2-3).
41
 It was shown that coordination of the phosphonate arm to 
the metal center results on a decrease in pH. In this work, we report further synthetic 
modifications on the propylphosphonate containing SCAs which involve the introduction of a 
side linker to allow the coupling of SCAs to a diverse range of functional molecules such as 
dendrimers, nanoparticles, proteins, peptides or fluorescent tags. Most significantly the 
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physico-chemical properties of SCAs, in particular its response (the pH dependent r1 
changes), must be retained after coupling to the linker. Consequently, the properties of SCAs 
and the other functional molecules could be used together to further characterize the function 
of the SCAs in vitro and in vivo, broadening the scope of their application.   
 
Figure 2-3: i) Structure, ii) relaxivity response to pH and iii) mechanism of action of DO3APP. 
 
2.2 Ligand design 
Keeping these objectives in mind we wanted to develop a common synthetic strategy to 
modify the majority of DO3A based SCAs to further functionalize them easily without losing 
their essential properties. Therefore we have chosen the 1,7-bis(tert-butoxycarbonylmethyl)-
1,4,7,10-tetraazacyclododecane (bis-tert-butyl DO2A) derivative of cyclen in which one of 
the secondary amines was alkylated with linking moiety keeping the other free for the 
attachment of a sensor unit (Figure 2-4, top). Here we have chosen the contrast agent 
containing a phosphonate pendant arm as pH sensor (DO3APP).  Thus we have designed two 
novel cyclen based ligands L
1
 and L
2
 (Figure 2-4). Their synthesis involved incorporating 
aliphatic (derivative of 6-aminohexanoic acid) and aromatic linkers (derivative of 4-(p-amino 
phenyl) butyric acid) onto cyclen derivatives ultimately producing ligands L
1
 and L
2
 
respectively. These linkers were added on the cyclen nitrogen positioned trans to the 
propylphosphonate pendant arm, thus keeping these two pendant moieties as distant as 
possible to avoid any interference in the desired activity. Both linkers possess a primary 
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amine as the terminal group, suitable for coupling to molecules containing free carboxylic 
acids, or electrophilic groups. 
 
 
 
  
 
Figure 2-4: i) Schematic representation of DO3A derivative containing linker ii) Structures of designed ligands 
with linking units. 
 
Moreover, the aniline group in L
2
 can be converted to an isothiocyanate to enable further 
coupling to molecules with free amines. To demonstrate the applicability of the newly 
developed SCAs, we incorporated biotin and studied the properties of the biotinylated SCAs 
and their avidin conjugates regarding a pH-response. The biotin-avidin system has a specific 
interaction with an extraordinary affinity, being stable over larger range of pH and 
temperatures in vivo.
89
 This system is thus an excellent tool for the targeted delivery or 
accumulation of the SCA in vivo to boost the signal. 
2.3 Results and Discussion 
2.3.1 Synthesis of complexes GdL
1
 and GdL
2
 
The preparation of L
1
 was accomplished by synthesizing aliphatic linking unit 2-8 (Scheme 
2-1). 6-amino hexanoic acid 2-6 was heated with phthalic anhydride at 170 °C for 2 h which 
provided phthalimide protected amine with free acid 2-7.
90
 Acid 2-7 was subjected to an  
bromination in thionyl chloride and tert-butyl protection to afford 2-8 using an established 
procedure.
91
 1,7-Bis(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane (bis-tert-
butyl DO2A) 2-10 was prepared following the procedure reported previously.
92
 The key 
reaction of the synthesis was the selective mono-alkylation of 2-10 with the newly 
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synthesized bromide 2-8 to obtain the tris-alkylated cyclen derivative 2-11, achieved under 
high dilution conditions in acetonitrile, with sodium bicarbonate. The final alkylation of 2-11 
was accomplished using diethyl (3-bromo propyl) phosphonate in acetonitrile in the presence 
of potassium carbonate to afford 2-12 in good yields. The deprotection of amine was 
attempted with ethelenediamine in 2-propanol with reflux conditions and the reaction was 
monitored by ESI-MS analysis. A number of attempts were made to purify the resulting 
product 2-13 with silica, basic and neutral alumina column chromatography but due to highly 
polar nature of product as well as formation of number of side products, we were unable to 
isolate 2-13 in high purity. Therefore we have decided to change the amine protecting group, 
starting with the commercially available H-Lys(Z)-OH with Cbz protected amine. This was 
diazotized with sodium nitrite, and brominated using potassium bromide and tert-butyl 
protection of carboxylic acid with 2,2,2-trichloroacetimidate gave us similar linker 2-15 with 
required protected form of the amine (Scheme 2-2).
93 
 
 
Scheme 2-1: Synthesis of LnL
1
  Reagents and conditions: (i) Phthalic anhydride, 170 °C; (ii) SOCl2, Br2, tert-
BuOH, TEA; (iii) 3, NaHCO3, CH3CN; (iv) Diethyl(3-bromopropyl)phosphonate, K2CO3, CH3CN; (v) 
Ethylenediamine, iso-PrOH, reflux. 
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At the same time the aromatic linker 2-17 was prepared according to a modified literature 
procedure,
70
 achieving a higher yield (77% vs. 48%) than previously reported.
94
 After 
isolating the two linkers; L
1
 and L
2
 were obtained successfully in high yields by using two 
similar synthetic routes. Selective mono alkylation of 2-10 in both the cases was achieved 
following the same procedure as already described for aliphatic linker with phthalamide 
protecting group. Similarly the final alkylation with diethyl (3-bromo propyl) phosphonate in 
acetonitrile at 70 °C on 2-18 and 2-21 gave rise to 2-19 and 2-22 respectively. Hydrogenation 
of 2-19 with Pd/C in ethanol provided free amine 2-20. Treatment of 2-20 with 
bromotrimethylsilane and subsequently formic acid at 60 °C, yielded the ligand L
1
. Similarly 
the nitro group of 2-22 was converted into the amine to produce 2-23 by hydrogenation using 
Pd/C as a catalyst in ethanol. Deprotection was carried out as described for L
1
 to afford L
2
, 
except that TFA is used instead of formic acid. Both ligands L
2
 and L
2
 were characterized by 
means of 
1
H, 
13
C, 
31
P NMR and HR-ESI mass spectrometry. 
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 Scheme 2-2: Synthesis of L
1
 and L
2
. Reagents and conditions: i) NaNO2, KBr, 1N HBr, tert-butyl 2,2,2-
trichloroacetimidate, CHCl3; ii) SOCl2, Br2, tert-butyl 2-2-2-trichloroacetimidate, CHCl3; iii) NaHCO3, CH3CN; 
iv) NaHCO3, CH3CN; v) Diethyl(3-bromopropyl)phosphonate, K2CO3, CH3CN; vi) H2, Pd/C, EtOH; vii) 
BrSi(CH3)3, CH2Cl2, viii) formic acid (for L
1
) or TFA (for L
2
), CH2Cl2. 
 
Complexation of ligands L
1
, L
2
 with lanthanide chlorides (GdCl3•6H2O, EuCl3•6H2O) was 
carried out using a standard procedure (see materials and methods section) to obtain the 
desired complexes at neutral pH. The successful formation of complexes was confirmed by 
means of ESI-MS and the spectra contained appropriate isotope pattern distribution, 
characteristic for Gd
3+
 or Eu
3+
 complexes. 
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2.3.2 Relaxometric experiments 
A relaxometric study of complexes GdL
1-2
 was performed at 7 T (300 MHz) and 25 °C. The 
T1 relaxation times were recorded at pH 9, 7 and 5 using different concentrations of 
complexes ranging from 3 mM to 1 mM. The pH was adjusted using solid lithium hydroxide 
and para-toluenesulfonic acid to avoid dilution of GdL
1-2
 solutions, the exact concentration 
of which was determined by the bulk magnetic susceptibility shift method.
95
  The r1 
relaxivity at each pH is obtained as a slope of the linear regression curve for concentrations of 
GdL
1-2
 plotted against relaxation rate (R1). The relaxivities of both GdL
1-2
 at the acidic pH 
were slightly higher than for the parent DO3APP compound (Figure 2-5).
41
   
 
 
Figure 2-5: The pH dependence of the proton relaxivity (r1) of GdL
1
 and GdL
2
 (7 T, 25 
o
C) compared to 
DO3APP (7 T, 21 
o
C). 
 
In both cases we observed a continuous increase in relaxivity from pH 9 to 5. A total increase 
in r1 of 147% from pH 9 to 5 was recorded for GdL
1
 (32% from pH 7 to pH 5), whilst total 
increase of 31% in r1 was observed for GdL
2
 over the same pH range. The change in 
relaxivity with a change in pH is the same as that observed in the parent compound. 
Protonation of the phosphonate in acidic pH induces movement of the pendant arm and 
allows more water molecules to interact with the metal center resulting in a higher relaxivity.  
2.3.3 Luminescence emission experiments 
The two responsive complexes were characterized further by investigating their Eu
3+
 
analogues. The 
31
P NMR spectra of EuL
1
 and EuL
2
 were recorded at pD 5 and 7 (Annexure 
I). A pH-dependant low field chemical shift of approximately 2 ppm in both complexes 
indicates that a similar mechanism responsible for the r1 changes is occurring as observed for 
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DO3APP.
41
 Time resolved luminescence decay experiments were performed on complexes 
EuL
1
 and EuL
2
 to evaluate the change in the inner sphere hydration at different pH (Table 2-
1). The experiments were carried out on 5 mM solutions of EuL
1-2
 in H2O and D2O. The 
hydration number was estimated using equation 1-11 where    is 1.2 ms and the correction 
factor for the contribution of the second sphere is –0.25 ms-1.29 
 
Table 2-1: Emission lifetimes and estimated q values of EuL
1 
at neutral and acidic pH/pD 
Compound τ (ms) 
H2O 
τ (ms) 
D2O 
q 
pH/pD 7 0.56 1.69 1.1 
pH/pD 5 0.42 1.51 1.8 
 
For EuL
1
 the apparent q value increases from 1.1 to 1.8 as the pH decreases from 7 to 5. The 
observed change is in good agreement with the findings of relaxivity experiments on the 
corresponding Gd
3+
 complex, confirming that the change in r1 is directly influenced by 
changes in q. Determination of the q value for EuL
2
 was not possible due to the low intensity 
of emission and low solubility of the complex at high concentrations (> 3-4 mM). One of the 
reasons for the weak emission could be the presence of the highly electron donating aniline 
derivative in close proximity of metal center which quenches/deactivates the Eu emissive 
state,
96
 whereas the hydrophobic aromatic ring of the linker might decrease the solubility but 
given the similar r1 change we have assumed the mechanism is similar. 
The relaxometric and luminescence emission experiments performed on the modified 
phosphonate complexes confirm that the synthetic modifications in close proximity of the 
metal centre do not negatively affect the coordination of Ln
3+
, hence the pH responsive 
properties (similar to the DO3APP parent compound) are retained. This enabled us to pursue 
further investigations involving L
1-2
 towards their potential MRI application with other 
biomolecules such as proteins (see below). 
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Scheme 2-3: Synthesis of L
3
 and L
4
. Reagents and conditions: i) Biotin, EDCI•HCl, DMAP, DMF; ii) 
BrSi(CH3)3, CH2Cl2; iii) TFA, CH2Cl2. 
2.4 Biotinylation of GdL
1-2 
The high affinity avidin-biotin conjugate is a widely studied system used in many therapeutic, 
diagnostic, and pharmacological applications.
97-99
 Avidin is a tetrameric protein with a high 
molecular mass (66k Dalton) and has an extremely high binding affinity towards biotin (Kd~ 
1.7×10
-15
) over wide pH range.
89
  Once biotinylated, the avidin conjugate of our SCAs can be 
delivered to specific regions in vivo, or the biotinylated SCAs alone could be used for 
selective cell-targeting.
100
 Hence, we have synthesized two biotinylated molecules L
3
and L
4
 
in a two step procedure commencing with the ester-protected ligands 2-20 and 2-23 (Scheme 
2-3). They were coupled to biotin using EDCI•HCl and DMAP in DMF at room temperature, 
where the reaction was monitored by ESI-MS. The ligands were obtained following the 
deprotection of phosphonate and carboxylic acids using bromotrimethylsilane and 
trifluoroacetic acid respectively. Following the characterization of the ligands, their Gd
3+
 
complexes were prepared as described previously (see materials and methods section). 
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2.5 Fluorescence displacement assay 
The binding affinity of the newly synthesized molecules GdL
3-4
 to avidin was measured 
using a fluorometric assay based on the displacement of the fluorescent probe 2-
anilinonaphthalene-6-sulfonic acid (ANS), employing the method developed by Horowitz 
and coworkers.
101
 Briefly, ANS is strongly fluorescent when attached to avidin whereas the 
unbound dye has only a low fluorescence intensity. Since the binding affinity of ANS to 
avidin is lower than binding affinity of biotin to avidin, the addition of biotin displaces ANS 
from the avidin binding pocket resulting in the quenching of the fluorescence in the sample. 
The fluorescence displacement assay was performed in parallel on biotin, GdL
3
 and GdL
4
. 
Upon addition of biotin or a biotinylated probe to the mixture of avidin and ANS, the 
fluorescence intensity decreased reaching a sharp inflection point at 3 equivalents of biotin or 
GdL
3-4
 (Figure 2-6). After this point there was no further drop in intensity observed even 
after the addition of several equivalents of biotin or GdL
3-4
. The measured stoichiometry is in 
line with the results previously reported by Horowitz and can be associated with the affinity-
purified avidin obtained from commercial sources.
101
  
 
 
 
 
 
 
 
 
 
 
 
 
 
This assay shows that only three binding sites are available in the studied avidin to interact 
with ANS and these three molecules of dye can be replaced by biotin or biotinylated SCAs. 
However, the titration curves of GdL
3-4
 are comparable to biotin indicating the binding 
affinities of both compounds are as strong as biotin. The calculated stability constants (see 
Materials and methods section) with Ks values 5.1x10
13
, 7.1x10
13
 and 8.0x10
13
 for biotin, 
 
Figure 2-6: Fluorescence titration of the avidin-ANS complex with biotin and GdL
3-4
. 
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GdL
3
 and GdL
4
, respectively, suggest that the binding affinities of biotin and biotinylated 
SCAs are not significantly different from each other. 
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Figure 2-7: E-titrations of GdL
3
 (left) and GdL
4
 (right) with avidin at 3T MRI scanner (21 
o
C, HEPES, pH 
7.4). The lines correspond to the fit assuming n=3 and   
  (Av(GdL
3
)3)=7.1x10
13
 or   
  (Av(GdL
4
)3)=8.0x10
13
 
obtained from the fluorescence displacement assay. The R
2
 values were 0.9817 and 0.9924 for r1 and r2 
respectively for GdL
3
, whereas 0.9583 and 0.9438 for r1 and r2 respectively for GdL
4
. A better fit (R
2
=0.9936 
and 0.9963 for r1 and r2 respectively) for GdL
4 
could be obtained when n is also fitted (n=2.4 and 2.3 for r1 and 
r2 respectively). 
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Figure 2-8: pH-dependant r1/r2 response of GdL
3
 (left) and GdL
4
 (right) in the absence of avidin (3T MRI 
scanner, 21 
o
C). Values are presented as mean ± SEM of five independent experiments. The lines represent the 
result of the sigmoidal fit and are displayed to aid a better visualization of the pH dependent r1/r2 decrease. 
2.6 MRI phantom experiments 
To confirm the observations of the fluorescence displacement assays, we followed the 
longitudinal and transverse relaxation rates (R1, R2) in samples with a constant concentration 
of GdL
3-4
 in HEPES buffer and varying concentrations of avidin in a method known as an E-
titration.
102
 These mixtures were incubated at 37 °C for 2 h and their relaxation times T1 and 
T2 were measured using a 3T (123 MHz) MRI scanner following the procedure and 
parameters as described in materials and methods section. A linear increase in r1/r2 with the 
addition of avidin compared to the unbound probe was observed until all biotinylated 
complexes are bound to avidin. A further increase in avidin concentration has no further 
effect on r1/r2 (Figure 2-7). The MRI phantom experiments confirm that biotinylated 
complexes bind to avidin. The increase in the r1/r2 of conjugates is the direct consequence of 
the τR increase, which is commonly observed for macromolecular contrast agents at magnetic 
fields relevant for clinics.
103
 The plateaus of r1/r2 values were observed at 0.3–0.4 equiv of 
avidin which matches our observations from the fluorometric assay, indicating three of the 
binding sites are occupied in avidin. 
In the subsequent step we studied the pH response of GdL
3-4 
in the absence and presence of 
avidin. We mixed GdL
3-4
 and avidin in a 3:1 ratio. The pH was adjusted over a wide range 
from 5.5 to 9.0 using buffers like MES, HEPES and CHES with 25 mM concentration. 
Longitudinal T1 and transverse T2 relaxation times were again obtained at 25 ºC in a 3T MRI 
scanner. A decrease in relaxation times T1 and T2, hence an increase in r1 and r2, was 
observed for both complexes when the pH decreased from 9 to 5.5 (Figure 2-9). The GdL
3
-
avidin conjugate showed an increase from 10.2 to 13.1 mM
-1
s
-1
 (28%) and from 38.9 to 60.6 
mM
-1
s
-1
 (56%) of r1 and r2 respectively. Within the same pH range, the GdL
4avidin 
conjugate showed an increase from 11.1 to 12.4 mM
-1
s
-1
 (12%) and from 41.2 to 55.5 mM
-1
s
-
1
 (35%) of r1 and r2 respectively. When comparing these values with those obtained under 
same conditions (3T scanner, pH 5.5–9) for GdL3-4 in absence of avidin, the relative changes 
in relaxivities are comparable, except that the absolute r2 values are much higher in the GdL
3-
4avidin conjugates (Figure 2-8). The results suggest that the investigated SCAs remained 
responsive not only by the further synthetic modifications (biotinylation of GdL
1-2
 to GdL
3-
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4
), but GdL
3-4
 are capable of a specific and strong binding to the avidin while retaining their 
MR activity. Finally, the observed r1/r2 changes are the most pronounced from the weakly 
acidic to weakly basic pH making GdL
3-4
 promising prototype SCAs for further 
investigations in vivo in the physiological pH range. 
 
2.7 Competitive MRI assay 
We performed a competitive assay with biotin to further characterize the binding affinity of 
the biotinylated SCAs towards avidin and estimate their in vivo potency. GdL
3-4
 were mixed 
with avidin in a fixed 3:1 ratio (HEPES buffer, pH 7.4). Different concentrations of biotin 
were added and the mixtures were incubated for five hours (for detail see Materials and 
Methods section). If the binding affinity of SCA is lower than biotin, GdL
3-4
 should be 
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Figure 2-9: pH-dependant r1 (left) and r2 (right) response of GdL
3
 (top) and GdL
4
 (bottom) with avidin at 3T 
MRI scanner (21 
o
C). The avidin:GdL
3-4
 molar ratio was 1:3. Values are presented as mean ± SEM of five 
independent experiments. The lines represent the result of the sigmoidal fit and are displayed to aid a better 
visualization of the pH dependent r1/r2 decrease. 
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displaced by biotin from the avidin binding pocket, resulting in a decrease in relaxivity, in 
particular r2. Following the incubation, the longitudinal and transverse relaxation times were 
measured in a 3T MRI scanner. We observed a minor decrease in relaxivities only after 
addition of 100 times excess of biotin whereas the r1/r2 did not change at lower 
concentrations of biotin (Figure 2-10). Such results are expected given the equilibrium 
exchange of biotinylated GdL
3-4
 at high concentrations of biotin. However, these findings 
confirm that the binding affinity of GdL
3
 and GdL
4
 to avidin is as high as of biotin. 
Furthermore, they imply the stability of MRI signal changes caused by SCAs either in its 
premixed solution with biotin, or in the presence of endogenous biotin in vivo. 
 
2.8 Conclusions 
We have synthesized and characterized two novel macrocyclic gadolinium based pH 
responsive contrast agents with an aliphatic or aromatic linker. Relaxometric and 
luminescence studies at different pH confirmed that for both agents the main 
physicochemical properties related to the pH dependant MRI response were retained after 
inserting the linking unit and are comparable to their parent compound. Furthermore, they 
were coupled to biotin and the response of the newly prepared responsive MRI agents was 
studied in more detail. The binding affinity of these complexes with avidin was showed to be 
as effective as biotin itself through fluorescence displacement or competitive MRI assays. 
MRI phantom experiments in the presence of avidin revealed the relaxivity was changing 
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Figure 2-10: Competitive MRI assay of avidin:GdL
3
 (1:3, 125 µM GdL
3
, left) and avidin:GdL
4
 (1:3, 125 µM 
GdL
4
, right) with varying concentrations of biotin at 3T MRI scanner (21 
o
C). 
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along with the change in pH at physiologically relevant values. These complexes offer a 
useful pathway towards target-specific SCA for in vivo applications. The major aim of the 
project was achieved since enabling to modify the DO3A type pH sensor for further 
functionalization. Future directions will involve applying this strategy in introducing various 
functional molecules such as proteins, peptides, receptor ligands or fluorescent tags to SCAs 
of various kinds (e.g. pH- or ion-responsive) making them suitable for their application in 
vivo.
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Chapter 3: Synthetic modification of Ca
2+
 responsive bismacrocyclic 
contrast agent and study of its response towards Ca
2+ 
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3.1 Introduction 
Metal ions such as Cu
+
/Cu
2+
, Fe
2+
/Fe
3+
, Zn
2+
 and Ca
2+
 are essential for the growth and 
development of living organisms. The deficiencies of such ions may cause acute diseases 
such as diabetes, neurodegenerative disorders or cancer. Therefore, it is crucial to precisely 
determine fluctuations in concentration of these metal ions during physiological and 
pathological events in vivo. In particular Ca
2+
 plays key role in cellular processes since 
thousands of processes rely on calcium influx. Its dual task as secondary messenger as well as 
an electric current carrier in brain makes it a more valuable metal ion over others in 
describing cognitive function. Neuronal activities lead to critical changes in Ca
2+
 
concentration.
104
  Basic aspects of neuronal regulation and abnormalities in signaling in 
diseased states could be investigated further by understanding Ca
2+
 signaling pathways in 
neurons. Ca
2+
 not only influences gene expression, neurotransmitter release, neuronal 
functions but also neuronal growth, its development, survival and death.
105
 Several signaling 
pathways in the brain increase cytosolic Ca
2+
 concentration up to 0.5–1.0 mM, drawing it 
from the endoplasmic reticulum (ET) or extracellular space inducing large concentration 
gradients across their membranes. Various voltage-sensitive Ca
2+
 channels and ligand-ligand 
cation channels such as nicotinic receptor, methyl-d-aspartate receptor or IP3 triggered 
redistribution from intracellular stores help Ca
2+
 influx inside the cell. Ca
2+
 acts as second 
messenger by modulating the activity of number of mediators such as calmodulin. The Ca
2+
-
calmodulin conjugate activates more than 20 eukaryotic enzymes like cyclic nucleotide 
PDEs, adenylate cyclase etc. The conventional interaction of calmodulin requires a rise in 
Ca
2+
 concentration since four binding sites of Ca
2+
 should be occupied to activate it. Hypoxia 
and ischemia induce a large elevation in intracellular Ca
2+
 concentrations in some cerebral 
neurons.
106
 
Hence understanding the Ca
2+
 concentration in real time would add immense value in the 
neuroscientific application in tracking dynamic changes in it during neuronal signaling.  With 
this aim, a number of research groups developed Ca
2+
 sensitive fluorescent dyes
107
 for optical 
imaging. As mentioned previously optical imaging has limiting depth penetration as well as 
limitations such as the production of photobleaching side products of the fluorescent probes 
restricting their application in vivo. MRI has advantage over optical imaging since it has 
unlimited depth of penetration and several MRI probes are stable in vivo. Therefore MRI 
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could be the potential tool to follow in vivo concentration changes in Ca
2+ 
with better 
spatiotemporal resolution using Ca
2+
 sensitive CAs. 
To this end, Li et al proposed first potential MRI contrast agent (Figure 1-9) which is based 
on Gd
3+ 
and DOPTA ligand system, with a Ca
2+
 dissociation constant of 0.96 µM, where the 
relaxivity of the complex increases by approximately 80% when Ca
2+
 is added.
49
 Even 
though it is a potential candidate for in vivo imaging till date there are no further reports from 
the authors of its in vivo utilization. Our laboratory proceeds in this direction, synthesizing 
and applying Ca
2+
 sensitive CAs in rodents and ultimately primates to directly detect and 
quantify Ca
2+
 concentration, and hence neuronal activity using MRI.  With this aim in one of 
early report Dhingra et al reported a Gd
3+–DOPTRA derivative (Figure 1-9). This agent 
shows around a 100% change in relaxivity upon addition of Ca
2+
. Further relaxivity studies in 
physiological fluids such as ACSF and AECM proved that agent would be potential 
candidate for in vivo application even though there is considerable drop into the change in 
relaxivity due to anion binding to Gd which blocks water access considerably.
52
  
Furthermore Mamedov et al published detailed study of DO3A based Gd
3+
 complex 
appended with bisphosphonate unit
56
 which are known to be effective Ca
2+ 
chelators with 
formation constants in the high micromolar to low millimolar range.
108, 109
 This agent 
displays unusual behavior with Ca
2+
 addition as its relaxivity decreases. This is explained as 
the outcome of a Ca
2+
 ion assisted aggregation which is commonly observed phenomenon in 
probes carrying such functional groups.
110
 Further in vivo evolution of this agent 
demonstrated that the complex strongly interacted with brain parenchyma limiting its 
diffusivity. Moreover bismacrocyclic Gd
3+
 complexes were studied, 
53, 111
 which are either 
two DO3A type macrocyles bridged by a BAPTA bisamide or EDTA/DTPA bisamide Ca
2+ 
chelators (Figure 3-1). These agents have been investigated thoroughly, although most of 
these have low sensitivity towards the Ca
2+
 ion (10–30% change in relaxivity with Ca2+ 
addition until saturation of signal) as well as low selectivity over other metal ions. The Gd
3+
 
complex containing two macrocycles connected by modified EGTA linker along with an 
ethyl or propyl spacer provided the best results, with more than an 80% (propyl spacer) 
overall change in relaxivity with addition of one equivalent of Ca
2+
 ion in HEPES buffer 
(11.75 T, 25 °C, Figure 3-2). The association constants for both complexes, logKA is around 
4–5 which suggests that reversible interaction of the agent is possible during the Ca2+ 
fluctuations in vivo. This was confirmed using EDTA since addition of EDTA to a solution of 
CA saturated with Ca
2+
 retains the increased relaxivity to the initial value. Unlike other SCAs 
this has better selectivity over other endogenous metal ion Mg
2+
. Moreover, the study of 
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complexes in brain extracelluar matrix (BEM) was encouraging as a change in relaxivity in 
relevant range of Ca
2+
 in brain (0.8–1.2 mM) displayed 10% change in relaxivity. 
 
Figure 3-1: Few examples of Ca
2+
 responsive contrast agents.  
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With such promising in vitro results, an assessment of its function in vivo was attempted. It 
was found that major issues hinders its ability to report changes with higher spatiotemporal 
resolution, faster onsets, greater spatial or structure specificity. Namely, MRI signal is 
dependent on Ca
2+
 concentration as well as concentration of SCA. To assess the 
concentration of SCA one needs to measure the diffusion of molecule in tissues and correlate 
the observed signal. Therefore it is necessary to have enough concentration of SCA for long 
time scale or its diffusion should be decreased substantially. The other issues are 
determination of the exact concentration SCA in vivo as well as localization to demonstrate 
the changes in MR signal are due to change in Ca
2+
 concentration rather than a change in 
SCA concentration.  
To increase the concentration and/or decrease diffusion this agent can be delivered with a 
high pay load on functional molecules such as dendrimers, nanoparticles or delivery vectors. 
For tracking the exact in vivo concentration, the SCA can be attached to a 
19
F containing 
moiety.  Here dual frequency 
1
H and 
19
F MRI can be utilized. 
19
F MRI signal will allow the 
exact concentration of SCA in vivo to be determined, independent of Ca
2+
 ion concentration. 
Furthermore, if 
18
F is introduced through this linker, one could follow the probe 
 
Figure 3-2: Structure of bis-macrocycles containing modified EGTA linker (top). Relaxometric Ca
2+
 titration in 
the buffer with ethyl spacer (n = 1, left) and with propyl spacer (n = 2, right) at 11.75 T and 25°C. 
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concentration using PET signal. Another strategy would be the conjugation of the SCA with 
USPIO nanoparticles to convert it into ratiometric probe, where T2 from iron oxide 
nanoparticle will remain constant and T1 from probe which will change as a function of Ca
2+
 
concentration, thus rendering the MR signal independent of probe concentration therefore, to 
attach such functional molecules to the SCA one needs to synthetically modify the existing 
responsive bismacrocycles without changing their physico-chemical properties particularly 
their response to Ca
2+
 ions (Figure 3-3).  
 
 
 
Figure 3-3: Schematic representation of Ca
2+
 sensitive CA with linker molecule. 
 
3.2 Ligand design 
With this objective in mind we have decided to synthetically modify the above mentioned 
molecule with a propyl spacer inserting a linking unit and studying the response to Ca
2+
 ions 
before attaching it to a functional molecule. We had already developed and utilized two 
different types of linking units (Chapter 2) in pH responsive agents. With similar synthetic 
approach we have decided to insert one of the linker in Ca
2+
 sensitive agent (Figure 3-4).  
 
 
 
Figure 3-4: Structure of designed ligand L
5
. 
 
 
The choice for aromatic linking unit over aliphatic linker was made on following basis: 
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i) aromatic amine could be used to couple to carboxylic acids using simple acid amine 
coupling reaction with coupling agents such as EDC, DCC etc,  
ii) the aromatic amine can also be converted to more reactive and stable nucleophilic 
isothiocynate group, which can react with amines at high pH. Therefore one amine gives us 
the potential to attach this molecule to a variety of functional molecules, 
 iii) aromatic linker would provide a suitable chromophore for spectroscopic detection during 
HPLC purification,  
iv) aromatic linker provide more rigidity to the molecule which would help to ensure the 
functional molecules are at a suitable distance from the Ca
2+
 chelator or Gd
3+
 centers to 
minimize the interference of functional molecules in sensor moieties. Namely, flexible linker 
like aliphatic linker may allow the functional molecule and Gd
3+
 centers to come closer by 
conformational changes which might obstruct the relaxivity change. 
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3.3 Results and discussions 
3.3.1 Retrosynthetic analysis of L
5 
 
 
 
 
Figure 3-5: Retrosynthetic analysis of L
5
 containing alkylation reactions. 
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Retrosynthetic analysis of ligand L
5
 is shown as the figure 3-5. It suggests the preparation of 
three distinct units and later their union by sequential N-alkylation reactions. This led to the 
synthesis of three different building blocks, 3-7, 3-8 and 3-9.  
3.3.2 Synthesis of L
5
, strategy 1 
Bromide 3-8 was synthesized following the same pathway as reported in literature.
50
 Amine 
3-9 was prepared by selective mono protection of diamine 3-10 on one of the symmetric 
secondary amine using benzyl chloride in acetonitrile at room temperature with a moderate 
yield. The mono protection of diamine 3-10 with benzyl chloroformate to give amine 3-12 
was attempted, however with too low yield. Compound 3-13 was investigated with the 
objective to increase the yield as well to explore the different deprotection conditions but no 
significant improvement was achieved in case of yield (Figure 3-6). Hence we proceeded 
with benzyl protected amine 3-9. Alkylation of amine 3-9 with bromide 3-8 in acetonitrile 
and potassium carbonate at 70 °C produced 3-11. Reductive debenzylation of amine with 
Pd(OH)2 in ethanol under a H2 atmosphere produced scaffold 3-6 with good yield (Scheme 3-
1). 
 
 
Scheme 3-1: Synthesis of scafold 3-6. Reagents and Conditions: i) BnCl, Cs2CO3, CH3CN; ii) 3-8, 
K2CO3, CH3CN; iii) H2, Pd(OH)2, NH4OH(aq.), EtOH.  
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Figure 3-6: Examples of monoprotected EGTA derivatives. 
 
The synthesis of scaffold 3-7 commenced with the alkylation of tris alkylated derivative 2-21 
(chapter 2) with N-(3-bromopropyl)phthalimide to afford tetra alkylated derivative 3-14. The 
deprotection of phthalamide gave rise to amine 3-15. Treatment of acetic anhydride to 
primary amine 3-15 produced the desired scaffold 3-7 (Scheme 3-2). With the enough 
amounts of scaffolds in hand we were set to carry out the final alkylation to obtain ligand in 
fully protected form. 
 
 
 
Scheme 3-2: Synthesis of scafold 3-7. Reagents and conditions: i) N-(3-bromopropyl)phthalimide, K2CO3, 
CH3CN; ii) Ethylenediamine, iso-PrOH, 90 °C; iii) Chloroacetic anhydride, NaHCO3, dioxane, water.  
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Scheme 3-3: Synthesis of Gd2L
5
. Reagents and conditions: i) K2CO3, CH3CN, 70 °C. 
 
We have treated scaffold 3-6 and 3-7 in acetonitrile with K2CO3 as base (Scheme 3-3). These 
conditions did not provide any appreciable amount of desired product. We believe this is due 
to an intramolecular alkylation of scaffold 3-6 to give product 3-16 (Figure 3-7), resulting in 
no desired product. This was confirmed by ESI-MS analysis. This may be due to the highly 
electron withdrawing nitro group present at para position of benzylic methylene making this 
carbon center more acidic. In the presence of a base this is acting as better nucleophile than 
the secondary amine of 3-7. Furthermore, due to steric reasons the intramolecular reaction is 
favored over the intermolecular reaction. 
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Figure 3-7: Structure of undesired product formed in Scheme 3-3. 
 
Therefore we decided to inhibit the withdrawing effect of para-nitro group in scaffold 3-6 by 
converting it into a Boc protected amine. The synthesis was accomplished by reducing nitro 
group of already synthesized intermediate 3-14 into amine 3-17 using Pd/C catalyzed 
reduction under H2 atmosphere (Scheme 3-4).  
 
 
Scheme 3-4. Synthetic modification of scafold 3-7 to 3-20. Reagents and Conditions: i) H2, Pd/C, EtOH; ii) 
(Boc)2O, NaHCO3, dioxane water; iii) Ethylenediamine, i-PrOH, 90 °C; iv) Chloroacetic anhydride, NaHCO3, 
dioxane, water. 
 
The amine 3-17 was protected using Boc anhydride in a dioxane and water mixture at room 
temperature to afford 3-18. The primary amine 3-19 was obtained after pthalamide 
deprotection of 3-18 with ethylenediamine in refluxing iso-propanol. A number of attempts 
were made to purify intermediates 3-18 and 3-19 using silica gel and alumina column 
chromatography, but due to the highly polar nature of compounds as well as the comparable 
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polarity between products and side products separation was not possible. Therefore we 
proceeded with the subsequent acylation without purification. Chloroacetic anhydride used 
for acylation of primary amine 3-19 yielded the desired scaffold 3-20. With suitable 
quantities of the reagents 3-6 and 3-20 we proceeded with the N-alkylation reaction in 
acetonitrile. The desired compound 3-21 was obtained in a moderate yield, where traces of 
undesired product 3-16 were not observed. The ligand precursor was subjected to 
simultaneous deprotection of all the acids and amine in a mixture of trifluroacetic acid and 
dichloromethane at room temperature to yield L
5
. Purification of the product appeard tedious 
because of highly polar nature of bismacrocycle. The possible reason may be presence of 
many tert amines which favours more thermodynamically stable salt formation as well as 
formation of some conformationally more stable undesired products. This synthetic strategy 
therefore proved to be less suitable to produce the ligand in reasonable amount and purity. 
Therefore a new synthetic pathway was designed with the appropriate retrosynthetic plan 
(Figure 3-8).  
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3.3 Synthesis of L
5
, strategy 2 
The final ligand is anticipated to be obtained by coupling the previously synthesized amine 
intermediate 3-19 and carboxylic acid scaffold 3-22 using coupling agents such as DCC, 
HATU, or HBTU. 
 
 
 
Scheme 3-5. Synthesis of bismacrocyclic complex Gd2L
6
. Reagents and Conditions: i) K2CO3, KI, CH3CN, 
70 °C, 16h; ii) TFA, CH2Cl2, 16h; iii) CSCl2, CCl4, H2O, pH 2–3, 30 min.; iv) GdCl3•6H2O, H2O, pH 6–7, 60 
°C, 16h. 
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Figure 3-8: Retrosynthetic analysis of L
5
 using coupling reaction 
 
The synthesis of scaffold 3-22 commenced with the selective monoalkylation of diamine 3-10 
with benzyl bromoacetate and cesium carbonate in acetonitrile for three days at room 
temperature. 
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Scheme 3-6: Synthesis of acid 3-22. Reagents and Conditions: i) Benzyl bromoacetate, Cs2CO3, CH3CN, 72h; 
ii) 3-8, K2CO3, CH3CN, 70 °C; iii) H2, Pd/C, EtOH, 16h. 
 
 
Treatment of monoalkylated secondary amine 3-24 with 3-8 in the presence of potassium 
carbonate, and in acetonitrile at 70 °C gave the benzyl protected acid 3-25. The acid 3-22 was 
obtained by hydrogenation of 3-25 catalyzed by Pd/C in ethanol (Scheme 3-6). The acid 3-22 
and amine 3-19 were treated with HBTU in DMF at room temperature for 16 h yielding the 
ligand precursor 3-26. The reaction mixture was washed multiple times with water after 
removal of DMF under reduced pressure, followed by multiple attempts to purify using silica 
gel or different types of alumina column chromatography. Unfortunately none of 
abovementioned efforts resulted into pure product 3-26. Therefore, we continued to the next 
reaction with trifluroacetic acid to obtain ligand in dichloromethane. Herein we used RP-
HPLC to purify ligand but unfortunately product and impurities exhibited same retention 
time, Rt, on C18 column. With careful observation of the analytical data it was revealed that 
the excess of amine 3-19 was necessary for completion of reaction. This excess amine was 
eluting with product through normal phase and reverse phase column chromatography.  
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Scheme 3-7: Synthesis of bismacrocyclic ligand L
5
. Reagents and Conditions: i) HBTU, DMF, 16 h ii) TFA, 
CH2Cl2, 16 h. 
 
Therefore we decided to replace the amine 3-19 that we coupled with 3-22. We have simply 
removed phtalamide protection on nitro derivative 3-14 to afford required amine 3-27 by 
heating it in isopropyl alcohol at 90 °C with nitro group. With present approach we decreased 
the number of synthetic steps to produce 3-19 by two, avoiding the reduction of nitro group, 
as well as protection of obtained amine (Scheme 3-8). 
 
 
 
Scheme 3-8: Synthesis of amine 3-27. Reagents and Conditions: i) Ethylenediamine, iso-PrOH, 90 °C, 16 h, 
reflux. 
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Scheme 3-9: Synthesis Gd2L
5
. Reagents and Conditions: i) HBTU, DMF, 30 min; 
ii) TFA, CH2Cl2; iii) H2, Pd/C, EtOH, H2O, 16 h; iv) GdCl3•6H2O, pH 6–7, H2O, 60 °C. 
 
The coupling of acid 3-22 and amine 3-27 was carried out in DMF in presence of HBTU at 
room temperature to yield bismacrocycle 3-28.  The attempted purification was unsuccessful 
hence 3-28 was subjected to deprotection in trifluroacetic acid and dichloromethane to give 
the nitro derivative 3-29. RP-HPLC was carried out to purify 3-29. The product was 
hydrogenated in ethanol and water mixture catalyzed by Pd/C to afford L
5
 (Scheme 3-9). L
6
 
was afforded by reaction with thiophosgene in water at room temperature to while 
maintaining pH between 2–3 for 20 minutes. The gadolinium complexation of the ligand was 
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carried out as described in the materials and methods section. This synthetic approach 
provides us with a reasonable and reproducible amount of ligand L
5
 with the highest purity.  
3.4. Relaxometric Ca
2+
 titration in HEPES buffer 
A relaxometric study of complex Gd2L
5
 was performed at 7 T (300 MHz) and 25 °C. The T1 
relaxation times were recorded at pH 7.4 using 3.0 mM Gd
3+
 solution of complex in 100 mM 
HEPES buffer. An aqueous solution of Ca
2+
 (in 0.1 eq. portions) was added until 2.0 
equivalents with respect to Gd2L
5
.
 
In the absence of Ca
2+
 the initial relaxivity observed was 
3.6 mM
-1
s
-1
 which increased by 97% with stepwise addition of Ca
2+
 to 7.1 mM
-1
s
-1
. The r1 
enhancement was maximal at 1.2 equiv of Ca
2+
 and remains constant with further Ca
2+ 
addition. The observed r1 increase demonstrates the high sensitivity of the agent to Ca
2+
. The 
reversibility of the Gd2L
5–Ca2+ interaction was checked by the addition of an equimolar 
amount of EDTA with respect to the Ca
2+
. The addition of EDTA re-established the 
relaxivity to its initial value, proving the reversible binding of the agent to the Ca
2+
. A strong 
chelator such as EDTA removes the Ca
2+
 bound to the low affinity chelator system (Figure 3-
9 and Table 3-1). 
 
 
 
Figure 3-9: The Ca
2+
 dependent relaxivity response of Gd2L
5
 in HEPES buffer (7T, 25 °C). 
 
It has already been established that the mechanism involved in this change in relaxivity 
involves a change in hydration number with addition of Ca
2+
 ions. Increase in inner sphere-
hydration number q with addition of Ca
2+
 is responsible for change in relaxivity in this class 
of complexes. The parent europium complex has demonstrated increase in q with addition of 
Ca
2+
 from 0.5 to 0.9. Therefore we assume that the same mechanism of activity is involved 
here for change in relaxivity. 
Addition 
of EDTA 
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Table 3-1: Titration of Gd2L
5
 with Ca
2+
. 
  
[SCA]mM [Ca
2+
]/mM [Ca
2+
]/[SCA] T1/ms r1/mM
-1
s
-1
 
1.50 0.00 0.0 89.68 3.60 
1.49 0.15 0.1 86.92 3.73 
1.49 0.30 0.2 82.78 3.94 
1.48 0.44 0.3 78.90 4.16 
1.48 0.59 0.4 73.88 4.47 
1.47 0.74 0.5 69.44 4.78 
1.46 0.88 0.6 64.63 5.16 
1.46 1.02 0.7 60.51 5.54 
1.45 1.16 0.8 57.27 5.89 
1.45 1.30 0.9 54.14 6.26 
1.44 1.44 1.0 51.39 6.62 
1.44 1.58 1.1 49.60 6.89 
1.43 1.72 1.2 48.51 7.08 
1.43 1.85 1.3 48.11 7.17 
1.42 1.99 1.4 47.88 7.23 
1.42 2.12 1.5 47.74 7.28 
1.41 2.26 1.6 47.97 7.27 
1.40 2.39 1.7 48.03 7.29 
1.40 2.52 1.8 48.02 7.32 
1.39 2.65 1.9 48.15 7.32 
1.39 2.78 2.0 48.27 7.33 
 
3.5 Conclusions 
In summary, we have successfully introduced a linker unit in a bismacrocyclic Ca
2+
 sensitive 
contrast agent. The synthetic strategy produced the ligand successfully in over 20 reaction 
steps. The other feature of the synthesis includes the optimization of key reaction like the 
mono alkylation of one of the secondary amine. Unification of two macrocyles with bridging 
modified EGTA was successfully achieved using a peptide coupling reaction. The response 
of SCA to Ca
2+ 
ion was retained in the modified contrast agent without loss of stability. The 
modified SCA shows a 97% increase in relaxivity with the addition of 1.2 equivalents of Ca
2+
 
with respect to the SCA which proves insertion of linker in the bismacrocylce doesn’t have 
negative impact on its activity towards the Ca
2+
 metal ion. This synthetic strategy is 
encouraging for use in different responsive or anatomical probes based on DO3A macrocycle 
for further functionalization. This synthetic modification can provide a new pathway to attach 
this type of SCAs to number of functional molecules for the in vivo applications of obtained 
multifunctional hybrids. 
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Chapter 4: Synthetic modification of Ca
2+
 sensitive smart contrast agent 
using solid phase synthesis
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4.1 Introduction 
The inspirational Nobel Prize winning idea of Prof. Bruce Merrifield was to use solid 
support
112
 to carry out the synthesis of peptides, which revolutionized the field of organic 
synthesis since the 1960s. Lately, many synthetic laboratories ranging from academia as well 
as to industry have started to develop new strategies suitable for use with solid support. The 
popularity of solid phase synthesis in the organic synthetic community is due to the efficacy 
of the method and obtaining product without the laborious intermediate purification steps. All 
the synthetic steps are carried out under heterogeneous conditions, between soluble reagents 
in the liquid phase and soluble peptide on solid support. Using this technique more than 100 
amino acids can be coupled in very short time to deliver peptides with high purities. 
4.1.1 Solid phase synthesis (SPS) 
The SPS technique comprises the anchoring of first building block on a solid support with 
suitable protecting groups, followed by removal of one protecting group and the addition of 
the second reactant. These two steps are repeated until the desired product is constructed and 
finally it is cleaved from the solid support. The reactions can be carried out simply by mixing 
and shaking of the reagents in suitable solvents in the presence of suitable 
activators/catalysts. This leads to an exploration of combinatorial synthesis to produce 
libraries of peptides or small organic molecules for screening and to develop structure-
activity relationship in medicinal chemistry.
113, 114
 The major advantages of using solid phase 
synthesis are as follows: 
i) Ease of method. Since the synthesis is occurring on the solid support; excess reagents can 
be used to drive the reaction to completion. Excess reagent can be washed from product 
(which is immobilized on solid support) with suitable solvent, where simple filtration is 
enough to remove excess reagent as well as some by-products. 
ii) No intermediate purification and analysis. The entire reaction sequence can be carried 
out without isolation, purification and analysis of intermediate steps; only final product needs 
to be purified. In turn, this eliminates many time consuming and laborious processes used in 
traditional liquid phase synthesis. 
iii) Low mechanical loss. All reaction sequences can be carried out in the same reaction 
container which minimizes the mechanical loss of reaction product.  
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iv) Automation. The simple synthetic technique can be automated using a computer assisted 
synthesizer. 
Although there are a number of advantages, the success of solid phase synthesis depends on 
the appropriate selection of the solid support, linker that anchors the first reactant on the solid 
support, the combination of different protection/deprotection strategies and purification of 
final product after cleavage from the solid support. 
Merrifield first synthesized a tetrapeptide using SPPS methodology.
112
 The first amino acid 
was attached to the solid support through ester linkage of carboxylic acid group of the C-
terminal amino acid. In the subsequent step the amine group was deprotected and coupled to 
second amino acid using DCC coupling agent, followed by deprotection and coupling to the 
next amino acid. This cycle was repeated until the desired tetrapeptide on solid support was 
obtained, which was cleaved in the final step by saponification or using HBr. Polystyrene 
cross linked with 2% divinyl benzene was used as solid support and DMF as solvent. 
Subsequently an automatic peptide synthesizer was developed which delivered a protected 
linear polypeptide of 124 amino acid residues with the sequence of bovine pancreatic 
ribonuclease A (RNase A).
115, 116
 Following these reports, scientists attempted synthesis on 
solid support with varying supports,
117, 118
 linkers,
119-122
 conditions,
120, 123, 124
 different 
protection-deprotection approaches
125
 and various peptide bond formation strategies.
126-128
  
Furthermore there are number of reports published in last decade on the use of SPPS in 
attachment of macrocycles such as NOTA, DOTA to peptides where peptides are selected 
with a specific role to act as a carrier or targeting vector of the macrocycle with metal ion.
129-
139
 Despite the large number of advantages, to the best of our knowledge there is no report of 
formation and functionalization of a bismacrocyclic DO3A derivative on solid support. As 
mentioned in the previous section (Chapter 3), there were significant challenges involved in 
the synthesis of the modified Ca
2+
 responsive agent, primarily due to the challenging 
purifications of intermediates and products, despite the efficiency of the transformations. To 
circumvent the above mentioned issues, we chose to use solid support for the synthesis of 
these types of bismacrocycles. Using SPS we could exclude time consuming intermediate 
purifications and further functionalize the ligand with peptides, fluorescent tags etc. Hence 
we designed the ligand structure for the bismacrocyclic compound (L
7
) containing two linker 
units on each macrocycle which will be utilized to attach them to different tags. 
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Figure 4-1: Schematic representation of ligand L
7
 and its modified version L
8
 carrying two different tags on 
each macrocycle. 
 
4.2 Ligand design and retrosynthetic plan 
We have designed a novel synthetic strategy which would yield the Ca
2+ 
sensitive 
bismacrocycle with two identical linkers on each macrocycle on a solid support.  In addition 
this strategy would enable us to produce a number of bismacrocyclic analogues in a very 
short period of time. The first retrosynthetic plan was straight forward since three scaffolds 
are added one after another in the following order, the first macrocycle on solid phase, then 
the Ca
2+
 chelator (a derivative of EGTA), finally the second macrocycle (Figure 4-3). The 
unification of all three scaffolds will be achieved with a peptide coupling reaction in presence 
of agents such as EDC, DCC, DIC, or HATU. 
As mentioned earlier the few of the most crucial aspects are the choice of resin and linker. 
Since the resin is regarded as co-solvent in SPS, it should meet two important requirements: 
i) It should be compatible with the reagents and solvents used in the sequence of reactions to 
avoid premature cleavage of intermediates from the solid support and ii) It should provide the 
required functional group on the final molecule after deprotection. Other requisites include 
insolubility; swelling, loading, low price etc. Following a search of the literature we found 
the commercially available 2-(3,5-dimethoxy-4-formylphenoxy)ethyl polystyrene resin with 
backbone amide linker (BAL)
140, 141
 having an aldehyde functional group (Figure 4-2). The 
main advantage of this approach is that, the aromatic primary amine group from the scaffold I 
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can be attached to the resin via reductive amination. Thus the formed amine would be stable 
throughout the following acid amine coupling and deprotection steps involved in synthesis. 
Finally the molecule can be detached by using 50% mixture of TFA and dichloromethane 
retaining the primary amine. However 2-chlorotrityl chloride resin can also be used for the 
similar purpose since the anchoring of first scaffold containing aromatic primary amine can 
be achieved by alkylation reaction in presence of bases such as DIPEA, TEA, collidine and 
can be cleaved using TFA at the end. In order to choose more suitable resin for this project, 
small screening was carried out in two above mentioned resins by anchoring scaffold I and 
subsequent deprotection of pthalimide. In both cases complete conversion was observed but 
we decided to continue further with 2-chlorotrityl chloride resin since the anchoring of 
scaffold I is easier as compared to BAL resin. 
 
 
 
Figure 4-2: Schematic presentation of resins. 
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Figure 4-3: Retrosynthetic analysis of bismacrocycle containing two different tags on each macrocycle attached 
through aromatic linkers 
 
After selection of resin the main task was to synthesize the required scaffolds in sufficient 
quantities to complete the synthesis on solid phase. Intermediate 3-14 from the previous 
chapter 3 can be used as scaffold I. We note that the aliphatic amine was masked as a 
pthalimide (despite of Fmoc or other base labile protecting group alternatives), although it is 
known that strong conditions are needed to remove pthalimide protection. Fmoc strategy was 
avoided since entirely new synthetic pathway would be required to prepare the scaffold. 
As a proof of principle we decided to synthesize ligand L
5
 on solid support. Retrosynthetic 
plan would be anchoring of first macrocycle on solid support followed by removal of 
aliphatic amine protection and then coupling of amine and acid (scaffold II) using coupling 
agent. Finally detachment of product from solid support as well as removal of acid protection 
would yield L
5
 (Figure 4-4). 
  
4.3 Results and discussion 
4.3.1 Synthesis of L
5 
Synthesis of L
5
 was accomplished by using the intermediate 3-14 as scaffold I and 
intermediate 3-22 (both from previous chapter 3) as scaffold II (Scheme 4-1). Scaffold I 
which is primary amine was incorporated on swollen 2-chloro trityl chloride resin in  
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Figure 4-4: Retrosynthetic analysis of L
5
 on solid support. 
 
dichloromethane and DIPEA as base by substitution reaction. In order to maximize the 
loading of the macrocycle, the procedure was repeated twice. The successful loading of the 
first macrocycle on the resin was confirmed by ESI-MS which, was performed after coupling 
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and extensive washing of the resin using DMF and dichloromethane followed by deprotection 
of few solid beads in 50% TFA in dichloromethane. The formed secondary amine of 4-12 
was blocked by Boc protection in presence of excess trimethylamine and Boc anhydride in 
DMF at room temperature to obtain 4-10. This additional protection was necessary to 
diminish the formation of side products with the excess of activated acid used in coupling 
conditions. The success of this reaction is difficult to determine as deprotection with TFA 
will also remove Boc group resulting in the same mass of the deprotected molecule 4-12. The 
removal of pthalimide was accomplished by the same procedure as described before (Chapter 
2) in presence of ethylendiamine in refluxing iso-propanaol to yield 4-8. The conversion was 
efficient since we observed only the product peak after washing and deprotection on an 
analytical control. Coupling of 4-8 to acid 3-22 was achieved with the coupling agent HBTU 
and base DIPEA in DMF for 16 h, to obtain ligand precursor 4-11. This reaction was carried 
out twice to maximize the conversion. ESI-MS confirmed the formation of product and 
absence of starting material. Deprotection of tert-butyl and Boc was achieved using 50% 
TFA in dichloromethane. Ligand L
5
 was obtained after precipitation of obtained crude from 
cold diethyl ether. The NMR analysis is consistent with the analysis of L
5
 obtained in liquid 
phase (Chapter 3). This led us to conclude that the applied synthetic strategy is successful. 
After that we moved to the synthesis of L
8
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Scheme 4-1: Synthesis of L
5
 on solid support. Reagents and conditions: i) DIPEA, CH2Cl2, 16h; ii) 
(Boc)2O, DIPEA, CH2Cl2, 16h; iii) Ethylenediamine, iso-PrOH, 90 °C, 16h; iv) 3-22, HBTU, DIPEA, DMF, 
16h; v) 50% TFA, CH2Cl2, 16h. 
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4.3.2 Synthesis of L
8
 
As mentioned earlier the main task was to synthesize required scaffolds (II and III) in 
sufficient quantity. The EGTA derivative acting as the Ca
2+ 
chelator and bridging the two 
macrocycles was obtained from the synthetic pathway as shown in Scheme 4-2. The 
previously used diamine 3-10 was selectively monoalkylated using benzyl bromoacetate and 
cesium carbonate in acetonitrile at room temperature over two days to yield the amine 4-13. 
The dialkylated derivative 4-14 was obtained by alkylating 4-13 with methyl bromoacetate 
and potassium carbonate at 70 °C. Hydrogenation in ethanol catalyzed by Pd/C produced the 
required acid 4-15 (scaffold II of L
8
). 
 
Scheme 4-2: Synthesis of EGTA derivative as scaffold II (4-15). Reagents and conditions: i) Benzyl 
bromoacetate, Cs2CO3, CH3CN, 48h; ii) Methyl bromoacetate, K2CO3, CH3CN, 70 °C; iii) H2, Pd/C, EtOH, 16h. 
 
 
Scaffold III is the extension of intermediate 3-14, protected with allyl chloroformate. 
Deprotection of pthalimide using a previously described protocol afforded scaffold III (4-17) 
(Scheme 4-3). 
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Scheme 4-3: Synthesis of amine 4-17. Reagents and conditions: i) Allyl chloroformate, NaHCO3, Dioxane, 
water; ii) Ethylenediamine, iso-PrOH, 90 °C, 16h. 
 
 
With scaffolds II and III on hand, we attempted the synthesis of target molecule on resin. 
The coupling of intermediate 4-8 and scaffold 4-15 was achieved with the coupling agent 
HBTU and base DIPEA in DMF for 16 h, to obtain ester 4-7. This reaction was carried out 
twice to maximize the conversion. ESI-MS confirmed the formation of product and absence 
of starting material (Scheme 4-4). 
 
Scheme 4-4: Synthesis of methyl ester 4-7 on solid support. Reagents and conditions: i) 4-15, HBTU, DIPEA, 
DMF, 16h. 
 
The saponification of methyl ester to produce acid 4-7 (Scheme 4-7) was attempted by 
number of methods (Table 4-1). 
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Scheme 4-5: Synthesis of an acid 4-21 on resin. 
 
 
Table 4-1: Summary of attempts made to hydrolyze methyl ester 4-7. 
Reagents and Conditions Results 
1. LiOH, THF, Methanol, H2O (2:2:1), rt, 16h Complete conversion, shrinking of resin 
2. LiOH (sat.aq.), THF, Methanol, rt, 16h Complete conversion, shrinking of resin 
3. NaOH, Methanol, rt, 16 h Moderate conversion, shrinking of resin 
4. K2CO3(sat. aq.), THF, Methanol, rt, 16h Complete conversion, shrinking of resin 
5. K2CO3, THF, Methanol, rt, 16h. No conversion 
6. LiOH, THF, Methanol, rt, 16h No conversion 
 
Each reaction summarized in Table 4-1 was monitored by ESI-MS after cleavage of product 
with 50% TFA in dichloromethane. In all attempts whenever water was used shrinking of 
resin was observed with almost complete loss of product from resin. In addition, no 
conversion was observed using a number of bases in absence of water. However with the 
obtained resin bound acid we proceed to next reaction which is coupling of carboxylic acid 4-
5 from resin and amine of scaffold III (4-17).  
We attempted number of conditions to achieve the coupling to get the desired compound 4-4, 
none of which were successful (Table 4-2). 
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Scheme 4-6: Synthesis of fully protected bismacrocycle with linkers on solid support. 
 
Table 4-2: Summary of attempts made to couple acid 4-5 and amine 4-17. 
Reagents and Conditions Results 
1. HATU, HOBt, DIPEA, DMF, rt, 16h No conversion. 
2. HBTU, HOBt, DIPEA, DMF, rt, 16h No conversion. 
3. EDC•HCl, DMAP, DMF, rt, 16 h No conversion 
4. DCC, CH2Cl2, rt, 16h No conversion. 
5. DIC, CH2Cl2, rt, 16h No conversion. 
6. PyBOP, DIPEA, CH2Cl2, rt, 16h No conversion. 
7. PyBrOP, DIPEA, CH2Cl2, rt, 16h No conversion. 
 
The reason for this failure might be that the growing chain on the solid support sterically 
hinders carboxylic acid, which inhibits its coupling to the amine. Therefore, we  proposed 
new synthetic strategy to obtain the bismacrocycle.  In this, we could couple the EGTA 
derivative and second macrocycle (scaffolds II and III), followed by the deprotection of 
methyl ester in solution phase and coupling to the first macrocycle 4-8 on solid support. 
We accomplished the synthesis of acid 4-19 with two scaffolds II and III in solution phase 
(Scheme 4-7). Mono-methyl protected acid 4-9 was coupled with amine 4-17 in the presence 
of HBTU in DMF at room temperature to afford 4-18. Saponification of methyl ester 4-18 to 
produce acid or scaffold 4-19 was achieved using lithium hydroxide in a mixture of THF, 
methanol and water. Due to highly polar nature of products, number of attempts were failed 
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to purify intermediates as well as products using existing purification techniques. Hence we 
proceed with crude mixture of 4-19 for further reactions. 
 
 
 
Scheme 4-7: Synthesis of acid 4-19. Reagents and conditions: i) HBTU, DMF, 16h; ii) LiOH, THF, methanol, 
H2O, 16h. 
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Scheme 4-8: Synthesis of L
7
. Reagents and conditions: i) 4-19, HBTU, DIPEA, DMF, 16h; ii) Pd(PPh3)4, 
morpholine, DMF, 16h; ii) 50% TFA, CH2Cl2, 16h. 
 
With acid 4-19 on hand, we completed the synthesis of the bismacrocycle on 2-chlorotrityl 
chloride resin (Scheme 4-8) following a scheme similar to scheme 4-1. Acid 4-19 was 
coupled in DMF to amine 4-8 on solid support using HBTU as coupling agent. Deprotection 
of Alloc with Pd(PPh3)4 in DMF and morpholine as a cation scavenger provided amine 4-3 
on solid support for further addition of functional molecule such as dyes, cell penetrating 
peptides or cargo molecules (Tag 1). This is the most important intermediate of the sequence 
to further functionalize the bismacrocycle using amine coupling chemistry on solid support.  
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To prove the success of desired synthetic strategy, we carried out deprotection of the 
bismacrocycle from the resin as well as concomitant deprotection of tert-butyl and Boc in 
50% trifluroacetic acid and dichloromethane to afford L
7
. Every reaction step in the sequence 
was confirmed by ESI-MS after cleavage in trifluroacetic acid and dichloromethane mixture. 
ESI-MS confirmed the formation of the final ligand L
7
. Final analysis of L
7
 showed small 
impurities even after RP-HPLC purification and yield is also poor which could be because of 
crude mixture of acid 4-19 (Scheme 4-7) used in final coupling. Hence further attempts are 
necessary to get pure 4-19 in order to get pure L
7
.  
4.4 Conclusions  
In conclusion, we have developed a facile route to modify a Ca
2+
 responsive contrast agent. 
The ligand L
5
 consisting of a bismacrocycle appended with aromatic linker unit was 
synthesized on a 2-chloro trityl chloride resin. This is the first attempt to use solid support to 
synthesize a bismacrocycle. The key feature of this approach is the successful demonstration 
of phthalimide-strategy for amine protection. Phthalimide was successfully removed using 
ethtylenediamine in refluxing iso-propanol on solid support. Importantly, after reflux, 
phthalimide protected reactant was not observed in ESI-MS leading to the conclusion that the 
deprotection went almost to completion. Further L
7 
bismacrocycle appended with two 
aromatic linker units on each cyclen backbone and free aniline as functional group were 
synthesized successfully. This strategy will enable us to deliver series of analogues of Ca
2+
 
responsive agents as well as other bismacrocyclic responsive agents in a short period just by 
changing the building blocks. The technique is simple and useful exploiting combinatorial 
chemistry to potentially deliver libraries of molecules. Further functionalization of the agents 
could be done more easily than through solution phase techniques. 
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Chapter 5: Summary, conclusions and outlook 
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The aim of work presented in this thesis was to synthetically modify responsive MRI contrast 
agents by appending with linker moieties comprising appropriate functional groups on it to 
further couple with various functional molecules. 
The first part of thesis presented synthetic modifications of DO3A based phosphonate side 
arm appended pH sensitive CA. With convenient similar multistep synthetic routes lanthanide 
complexes of L
1
 (with aliphatic linker) and L
2
 (with aromatic linker) were prepared. Key 
feature of the synthesis was the selective monoalkylation of bis-tert-butyl DO2A with linkers. 
The relaxometric study of GdL
1–2
 at different pH (basic, neutral and acidic) revealed that the 
pH response in GdL
1–2
 is retained. GdL
1
 showed 147% change in longitudinal relaxivity r1 
(with change in pH from 9 to 5) while 31% change in r1 of GdL
2
 observed within same range 
of pH change. The change in r1 of GdL
1
 is observed due to change in hydration number q at 
different pH which was confirmed using time resolved emission lifetime measurement. Biotin 
was introduced in modified agents to obtain biotinylated contrast agents GdL
3
 (with aliphatic 
linker) and GdL
4
 (with aromatic linker) for targeted imaging. The binding affinity of GdL
3–4
 
towards avidin was studied using two independent methods. Fluorescence displacement assay 
performed using ANS dye displayed only three binding sites were present in studied avidin 
for coupling with biotinylated complexes. Conditional stability constant Ks of biotin and 
biotinylated complexes showed binding affinities are as comparable as biotin obtained using 
titration curves of avidin and biotin/GdL
3–4
.
 
These results were further confirmed by E-
titrations performed in following r1  and r2. 
 
 
 
MRI phantom experiments of GdL
3–4
 with and without avidin following r1 and r2 were 
carried out at different pH ranging from acidic to basic. GdL
3–4 
in the presence and absence 
of avidin exhibited increase in r1 and r2 with decreasing pH from 9 to 5.5. GdL
3
-avidin 
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conjugate showed 21% and 49% increase in r1 and r2 respectively. While GdL
4
-avidin 
conjugate displayed 12% and 30% increase in r1 and r2 respectively. The competitive MRI 
assay indicated an excess of biotin would not replace the biotinylated complexes from avidin 
which confirms the feasibility of complexes in vivo conditions. This study is pathway for 
development of target specific SCAs for in vivo application. The strategy can be used to 
modify the majority of DO3A based responsive MRI probes.  
Chapter 3 described synthetic modification of bismacrocyclic Ca
2+
 sensitive probe inserting 
the aromatic linker on one of the cyclen backbone of it. Synthesis of ligand L
5
 has been 
accomplished in more than 20 reaction steps. Key step of synthesis involved selective mono 
protection of one of amine from identical secondary amines of EGTA derivative. Terminal 
amino group from the linker was successfully converted into isothiocynate group to obtain 
ligand L
6
. Gd2L
5 
displayed 97% change in relaxivity towards Ca
2+
 which proved the 
preservation of Ca
2+ 
response after synthetic modification (complete retention in relaxivity 
property). 
 
 
Gd2L
5
 opens the door to form new conjugated systems with several functional molecules 
including dendrimers, peptides, fluorescent tags, and nanoparticles according to the desired 
application.  
In many in vivo applications one of the biggest obstacles to use such probes routinely is its 
diffusion over time from region of interest and hence decreases in signal intensity during 
measurement. In order to decrease the diffusion and to increase the local concentration, use of 
conjugates of probes with dendrimers of higher generations will be helpful.  To facile 
formation of such conjugates, Gd2L
5
 would be better since it can be attached to dendrimer 
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more efficiently via newly introduced linker and assess its applicability in vitro and in vivo 
models.  
Furthermore, the modified agent can be attached to the USPIO nanoparticles, well known as 
T2 agents to form ratiometric probe of T1/T2 since T2 from nanoparticle would remain constant 
and T1 will change as a function of Ca
2+
 concentration. This will provide a MRI signal 
independent of probe concentration 
Alternatively, newly introduced linker from SCA can be utilized to attach NMR active atom 
containing molecules such as perfluorocarbons or their derivatives where 
19
F can be served to 
quantify the SCA in vivo. In such diverse applications modified SCA Gd2L
5
 would serve as 
excellent probe to further functionalization. 
Chapter 4 reported synthesis of L
5
 on solid support applying phthalimide/tert-butyl 
chemistry. This is first report of synthesis of bismacrocycle on solid support. Furthermore 
ligand L
7
 which is modified version of L
5
 comprising two aromatic linkers on each 
macrocycle was successfully synthesized. Further optimizations are needed such as coupling 
conditions, purification procedure to obtain the ligand in sufficient quantity with high purity.  
  
 
 
This is one of convenient strategy to obtain and attach the Ca
2+
 responsive agent to a 
functional molecule which will, in conjugation with agent, report useful information in vivo. 
Addition of two different dyes as tag 1 and tag 2 will yield excellent conjugate to study the 
FRET (fluorescence resonance energy transfer) response with a change in Ca
2+
 concentration. 
This approach would provide easy way to obtain multimodal targeted probe. Moreover, in 
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order to make the probe target specific facile attachment of delivering or targeting vectors 
would be affordable using described methodology.  
Overall, we have successfully modified DO3A based multi targeted responsive contrast 
agents by inserting linking units in it. Efficient and easy labeling of such agents with wide 
range of functional molecules are possible using aforementioned strategies. Furthermore the 
demonstrated methodology would be excellent tool to obtain multimodal imaging probes for 
biomedical applications. 
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Chapter 6: Materials and methods 
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6.1 Materials and Methods 
6.1.1 Chemicals and working techniques 
All chemicals and reagents were purchased from commercial sources and were used without 
further purifications. The anhydrous solvents dichloromethane, acetonitrile, methanol, 
dimethylformamide were purchased from Acros Organics. H-Lys(Z)-OH (2-14), 4-(4-nitro 
phenyl butyric acid (2-16) and biotin were purchased from Sigma-Aldrich, Germany. Cyclen 
(2-9) was purchased from CheMatech, France. Avidin was purchased from Merck, Germany. 
ANS was purchased from Life Technologies GmbH, Germany. bis-tert-butyl DO2A (2-10) 
and DO3A-propyl amine bromide (DO3A-PA bromide) was synthesized using reported 
procedure.
142
 Unless otherwise mentioned all reactions were carried out under a nitrogen 
atmosphere, all glass wares were washed with mixed acid solution and rinsed with distilled 
water and acetone prior to use and the flasks were dried in hot oven (60 °C). Air and water 
sensitive reagents were kept under an inert atmosphere of nitrogen. Distilled water was used 
for the reaction work up and milliQ water was used after the last deprotection steps. The 
compounds are not described in the experimental sections were synthesized according to 
reported procedures. 
6.1.2 Reverse phase high performance liquid chromatography (RP-HPLC) 
HPLC was performed at room temperature on a Varian PrepStar Instrument, Australia, 
equipped with PrepStar SD-1 pump heads. UV absorbance was measured using ProStar 335 
photodiode array detector at 214 nm and 254 nm. This detector is equipped with a dual-path 
length flow cell which enables measurement of absorbance of analytical and preparative 
samples without changing the flow cell. All solvents used were of HPLC grade and were 
bought from different commercial sources and used without further purification.  
Reversed phase analytical HPLC was performed in a stainless steel Atlantis C18 column (4.6 
mm × 150 mm, particle size 5 μm) with a flow rate of 1mL/min.  
Reverse phase semi-preparative HPLC was also performed on similar type of column but 
with bigger size (19 mm × 150 mm, particle size 5 μm) with flow rate of 10 mL/min.: 
The following elution methods of 30 minutes were used, 
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Method A 
80% solvent A (water, 0.1% HCOOH and 20% solvent B (acetonitrile, 0.1% HCOOH) 
isocratic for 5 minutes to 80 % solvent B until 17 minutes, isocratic till 23 minutes then again 
20% till 27 minutes and isocratic till 30 minutes.  
Method B 
Method B was same as Method A except solvent B was methanol with 0.1% HCOOH.  
Method C 
80% solvent A (water, 0.1% HCOOH and 20% solvent B (acetonitrile, 0.1% HCOOH) 
isocratic for 5 minutes to 95 % solvent B until 17 minutes, isocratic till 23 minutes then again 
20% till 27 minutes and isocratic till 30 minutes. 
6.1.3 NMR-spectroscopy 
1
H, 
13
C, 
31
P NMR of all ligands and intermediates as well as 
31
P NMR of Eu
3+
 complexes 
NMR analysis were carried out using a Bruker 300MHz. 
1
H, 
13
C and 
31
P NMR spectra were 
performed in deuterated solvents and chemical shifts were assigned by comparison with the 
residual proton and carbon resonance of the solvents and tetramethylsilane as the internal 
reference (δ = 0). 31P NMR was done using 85% H3PO4 (δ = 0) as external reference.  Data 
are reported as follows: chemical shift (multiplicity: s = singlet, d = doublet, t = triplet, dd = 
double of doublet, br = broadened, J = coupling constant (Hz), integration, peak assignment 
in italic form). 
6.1.4 Mass spectrometry 
ESI low resolution mass spectra (ESI-MS) were recorded on a SL 1100 system (Agilent, 
Germany) with ion trap detection in positive and negative mode. ESI high resolution mass 
spectras (ESI-HRMS) were performed on a Bruker Daltonics Apex II FT-ICR-MS (Bruker, 
Germany). MS values were reported as ESI-MS: calculated for the related compound by 
found mass. 
6.1.5 Chromatographic methods 
Flash column chromatography was performed using flash silica gel 60 (70-230 mesh) and 
alumina (basic and neutral) from commercial sources. Analytical thin layer chromatography 
(TLC) was performed on aluminum sheet silica gel plates with 0.2 mm thick silica gel 60 
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F254 (E. Merck, Germany) using different mobile phase. The compounds were visualized by 
UV at 254 wavelength light and TLC plates were developed in Iodine chamber, and different 
staining agents such as ninhydrin solution, Dragendorff reagent etc. 
6.1.6 Luminescence lifetime measurement 
Luminescence steady-state and time resolved measurements were performed on 
QuantaMasterTM 3 PH fluorescence spectrometer from Photon Technology International, 
Inc. (USA). The steady state measurements were performed in H2O (25 °C, at pH 7 and 5) at 
a concentration of 5 mM for EuL
1, 2
. Excitation and emission slits were set to 2 nm and 1 nm. 
Datasets are an average of 15 scans. The time resolved measurements were performed in H2O 
and D2O (25 °C, at pH 7 and 5). Excitation and emission slits were set to 15 and 5 nm 
bandpass respectively, with 10 μs resolution. Datasets are recorded with a 100 μs delay and 
are an average of 10 scans. Each reported value is the mean of three independent 
measurements and obtained curves are fitted to the first order exponential decay with R
2
 > 
0.99. 
6.2 Preparation of Ln
3+
 complexes 
GdL
1-4
 and EuL
1-2
 were prepared from the respective solution of the ligand (1.0 equiv) and 
the aqueous solution of GdCl3•6H20 for L
1-4
 or EuCl3•6H20 (1.0 equiv) for L
1-2
. For each 
complex the lanthanide salt solution was added portion wise over 6 h. Once the ligand could 
no longer be observed by ESI-MS, the reaction mixture was stirred at 60 °C for an additional 
16 h. The pH value of the solution was periodically checked and adjusted to 6.5-7.0 by using 
an aqueous solution of sodium hydroxide (0.5 M). The solutions were then treated with 
Chelex

 100 sodium form for 4 h at room temperature to remove any excess lanthanide ion. 
The absence of free Gd
3+
/Eu
3+
 was confirmed with the xylenol orange test. The complexes 
were characterized by ESI-LRMS in negative mode and the appropriate isotope pattern 
distribution for Gd
3+
 and Eu
3+
 was obtained. GdL
5
 was also prepared by the same method 
except an aqueous solution of 2 equiv of GdCl3•6H20 was added to L
5
.   
6.3 Relaxometric experiments 
The relaxivities of the complexes GdL
1-2
 are an average of three measurements at 
concentrations ranging from 1-3 mM in H2O. The solution pH was adjusted with solid LiOH 
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and p-TsOH. For each measurement the exact concentration of the Gd
3+
 complex was 
determined using the bulk magnetic susceptibility shift technique.
95
 While relaxivities of 
complex GdL
5
 as well as relaxivities with Ca
2+
 titration are at 1.5 mM concentration of 
probe. 
6.4 Fluorescence displacement assay 
Stock solutions of avidin and ANS were prepared at concentrations 4 µM and 40 µM, 
respectively, in 0.15 M sodium phosphate buffer at pH 7. Buffered solutions of avidin (1 mL, 
4 µM) and ANS (1 mL, 40 µM) were mixed 1:1 (v/v) and the resulting conjugate was titrated 
with biotin/ GdL
3
/GdL
4
 (320 µM) in 5 µL aliquots. All measurements were performed at 25 
°C with the excitation and emission wavelengths of 328 and 408 nm respectively, and 
excitation and emission slits at 2 nm bandpass. 
The corrected and normalized fluorescence signal is plotted as a function of the ratio of added 
biotin/GdL
3-4
 to avidin (Fig. 2-6). Since three, rather than four binding sites are available on 
the avidin tetramer, this stoichiometry was used to develop a linear relationship used to 
determine the conditional stability constant value Ks for the reaction of avidin-2,6-ANS 
complex with biotin (Eq. 6-1), as well as with GdL
3,4
. 
 
                                     
               
 
                
 Eq. (6-1) 
 
If the basic avidin-ANS and avidin-biotin reactions are considered: 
                 ,       
   
          
          
 Eq. (6-2) 
  
                ,           
    
          
          
 Eq. (6-3) 
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Figure 6-1: Conditional stability constant (Ks) determination according to Eq. 6-6. 
 
Table 6-1: Conditional stability constant values (Ks) obtained as the slope of the linear fit 
based on Eq. 6-1 
 
Sample 
fluorescence 
Titration 
Ks ± SD 
Av-Bio Av-GdL
3 
Av-GdL
4 
1. 302 ± 11 413 ± 24 464 ± 19 
2. 417 ± 16 735 ± 30 618 ± 22 
3. 527 ± 22 541 ± 21 751 ± 29 
4. 379 ± 12 625 ± 23 676 ± 16 
5. 487 ± 18 662 ± 33 818 ± 29 
<Ks> ± SD (4.2 ± 0.9)x10
2 
(6 ± 1)x10
2
 (7 ± 1)x10
2
 
 
 
then Ks from Eq. 6-1 can be rearranged: 
 
    
               
 
                
 
    
    
 
  
  
   
 Eq. (6-4) 
 
to give the linear dependence: 
 
          
          
    
      
      
 Eq. (6-5) 
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where [ANS] represents the fixed concentration of ANS (experimental details given in the 
Experimental section), [Bio] is the concentration of added biotin in each titration point, and 
[Av(Bio)3] and [Av(ANS)3] are the concentrations of avidin-biotin and avidin-ANS 
complexes, respectively. As these concentrations are proportional to measured fluorescence 
intensities,
143
 the obtained experimental data (Figure 6-6) can be used for conditional stability 
constant determination: 
 
    
      
    
      
      
 Eq. (6-6) 
 
where Y0 is the fluorescence intensity at the beginning of titration (no biotin added), Ylim is an 
average value of all measured fluorescence intensities after the equivalence point was 
reached, and Y stands for measured fluorescence intensities during the titration (as reaction 
(1) proceeds). The measured fluorescence intensities were corrected for inner-filter effects
144
 
and normalized. The conditional stability constant values Ks for avidin-biotin, avidin-GdL
3
 
and avidin-GdL
4
 are obtained as slopes from the linear fit based on Eq. 6-6, with R
2
>0.98 
(Figure 6-1). Ks values are obtained as mean values of five times repeated titrations. Results 
are shown in Table 5-2. As the dissociation constant of the avidin(monomer)-ANS was 
already reported (Kd=203 µM)
[3]
,   
  value (Eq. 5-2) is calculated (  
  
 
    
        
   , 
and used for the overall stability constants   
   (Eq. 5-4) calculation, resulting in 
  
  (Av(Bio)3)=5.1x10
13
,   
  (Av(GdL
3
)3)=7.1x10
13
,   
  (Av(GdL
4
)3)=8.0x10
13
. 
6.5 MRI phantom experiments 
MR imaging of the samples was performed at 3T (123 MHz, 21 °C) on a clinical human MR 
scanner (MAGNETOM Tim Trio, Siemens Healthcare, Germany). Stock solutions of GdL
3-4
 
(0.25 mM) and avidin (0.225 mM) were prepared in HEPES buffer (25 mM, pH 7.4) and 
water, respectively. The concentration of GdL
3-4
 was kept constant (0.125 mM) while the 
concentration of avidin varied up to a ratio of 0.9 avidin:GdL
3-4
 . The mixtures were kept for 
3 h at 37 °C for incubation, followed by the measurement in 3T MRI scanner. For the 
subsequent pH-dependant MRI experiments of GdL
3-4
 with avidin, the following buffers 
were used to adjust pH: MES buffer for pH 5.5 and 6.3, HEPES buffer for pH 7.0, 7.5 and 
8.0, and CHES buffer for pH 8.6 and 9.0. 
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Longitudinal relaxation times (T1) were measured using an inversion recovery sequence to 
obtain images from an axial slice of 1 mm thickness through the samples. The inversion time 
(Ti) was varied from 23 ms to 3000 ms in 12 steps. Images were read out with a turbo spin 
echo technique, acquiring 5 echoes per scan. The repetition time (TR) was 10,000 ms to 
ensure complete relaxation. Six averages per Ti were possible within 18 min. For T2, a home-
written spin-echo sequence was used with echo times varying from 25 ms to 275 ms in 10 
steps and a repetition time of 8 s. Diffusion sensitivity was reduced by minimizing the 
crusher gradients surrounding the refocusing pulse. A matrix of 256 x 256 voxels was used 
over a field-of-view of 110 x 110 mm
2
 resulting in a voxel volume of 0.43 × 0.43 × 1 mm
3
. 
Data analysis was performed by fitting of relaxation curves with self-written routines under 
MATLAB 7.1 R14 (The Mathworks Inc., United States). The series of T1 (with varying t = 
TI) and T2 (with varying t = TE) relaxation data were fitted to the equations 6-7 and 6-8. 
 
S = S0 (1 - exp(-t / T1)) + S(TI = 0) exp(-t / T1) Eq. (6-7) 
 
S = S0 exp(-t / T2) 
 
Eq. (6-8) 
 
Nonlinear least-squares fitting of three parameters S0, S(TI = 0), and T1/T2 was done for 
manually selected regions of interest with the Trust-Region Reflective Newton algorithm 
implemented in MATLAB. The quality of the fit was controlled by visual inspection and by 
calculating the mean errors and residuals. The obtained T1/T2 values of the samples were 
converted to R1 (= 1/T1) and R2 (= 1/T2). 
 
r1,2 = (R1,2obs – R1,2dia)/[SCA] Eq. (6-9) 
 
Relaxivities r1/r2 were calculated by using equation 6-9, where R1,2obs – observed relaxation 
rate, R1,2dia – diamagnetic contribution to the relaxation rate and [SCA] – applied 
concentration of SCA. The curves obtained from the MRI E-titrations were fitted based on 
the previously published formula
145
, however they were slightly modified to use relaxivity 
values instead of relaxation rates (Eq. 6-10). 
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               )} 
Eq. (6-10) 
 
where: 
    
     observed longitudinal or transversal relaxivity 
   : concentration of SCA in M 
 
(set to 0.001 M since relaxivities are used) 
    
 
: longitudinal or transversal relaxivity of the free SCA 
    
 : longitudinal or transversal relaxivity of the avidin bound SCA 
 : number of binding sites on the avidin tetramer (set to n=3 as obtained from 
fluorescence displacement assay) 
   : normalized concentration of avidin in M 
  : binding constant of respective SCA (set to 7.1×10
13
 and 8.0×10
13
 for GdL
3
 and GdL
4
, 
respectively, as obtained from the fluorescence displacement assay). 
 
6.6 Competitive MRI assay 
Stock solutions of avidin and GdL
3
/GdL
4
 were prepared at 0.225 mM and 0.250 mM 
respectively in HEPES buffer (25 mM, pH 7). A series of different concentrations of biotin 
were prepared from 250 mM to 1 mM also in HEPES buffer. Avidin (66.7 µL) was mixed 
with GdL
3
/GdL
4
 (200 µL) and samples with a 0 to 500 times excess of biotin were obtained 
by adding different volumes of biotin stock solutions 10 min after the preparation of avidin-
GdL
3
/GdL
4
 mixture. The volume was adjusted to 400 µL by adding HEPES buffer. Mixtures 
were incubated at 37 °C for 5 h. Longitudinal and transverse relaxations times were recorded 
on the 3T MRI scanner.  
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6.7 Experimental synthetic procedures 
6-(1,3-dioxoisoindolin-2-yl) hexanoic acid (2-7) 
 
 
 
6-amino hexanoic acid (5.00 g, 38.16 mmol) and phthalic anhydride (5.64 g, 38.16 mmol) 
were mixed and stirred at 170 °C for 5 h. Reaction mixture was cooled to room temperature 
and dissolved into dichloromethane (200 mL). Organic layer was washed with 0.1 M HCl (2 
× 50 mL), dried over Na2SO4 and concentrated to get pure white solid of acid 2-7 after 
triturating with diethyl ether (9.50 g, 95%). 
1
H NMR (300 MHz, CDCl3), δppm)1.26-1.47 (m, 2H) 1.53- 1.77 (m, 4H) 2.31 (t, J = 7.5 
Hz, 2H), 3.64 (t, J = 7.5 Hz, 2H), 7.66 (dd, J = 3, 3 Hz, 2H, ArH) 7.79 (dd, J = 3, 3 Hz, 2H, 
ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δppm): 24.0, 28.1, 33.7, 37.6, 123.1, 132.0, 133.8, 
168.3, 179.4. 
 
ESI-MS for C14H14NO4 [(M - H)
-
] m/z calcd. 260.1, found 259.9. 
 
tert-butyl-2-bromo-6-(1,3-dioxoisoindolin-2-yl)hexanoate (2-8) 
 
 
 
Acid 2-7 (2.00 g, 7.66 mmol)  was dissolved in thionyl  chloride (2.20 mL, 30.65 mmol) and 
stirred at 75 °C for 24 h. Bromine (450 µL, 8.42 mmol) was slowly added to the mixture at 
70 °C over 30 min. and the reaction mixture was stirred at same temperature for another 16 h. 
The volatiles were removed under reduced pressure. Diethyl ether (3 × 20 mL) was added 
and removed under reduced pressure to remove traces of volatiles. The residue was dissolved 
into diethyl ether (20 mL) and added to the mixture of tert-butanol (1.10 mL, 11.49 mmol) 
and triehtyl amine (1.60 mL, 11.49 mL) in anhydrous diethyl ether (80 mL). The mixture was 
stirred at room temperature for 16 h. Reaction mixture was diluted with diethyl ether (150 
mL) and water (50 mL). Organic layer was separated washed with water (3 × 50 mL), brine 
(50 mL) and concentrated under reduced pressure. The resultant residue was purified by silica 
gel column chromatography (2% ethyl acetate/hexanes) to afford the title phthalimide 2-8 as 
orange oil (2.0 g, 66%). 
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1
H NMR (300 MHz, CDCl3), δppm): 1.29-1.60 (m, 11H, C(CH3)3), 1.60- 1.84 (m, 2H), 
1.84-2.18 (m, 2H), 3.67(t, J = 7.5 Hz, 2H, NCH2), 4.08 (t, J = 7.5 Hz, 1H, CHBrCH2), 7.69 
(dd, J = 3, 3 Hz, 2H, ArH),7.82 (dd, J = 3, 3 Hz, 2H, ArH). 
13
C{1H}  NMR (75 MHz, CDCl3), δppm): 24.5, 27.6 (C(CH3)3), 27.8, 34.3, 37.5, 47.3, 
82.3 (C(CH3)3), 123.1, 132.0, 133.9 (ArC), 168.2, 168.6 (C=O). 
 
Compound 2-11 
 
 
 
To a mixture of bis-tert-butyl DO2A 2-10 (0.50 g, 1.25 mmol) and K2CO3 (0.40 g, 1.00 
mmol) in anhydrous acetonitrile (40 mL) was added solution of phthalimide 2-8 (84 mg, 1.00 
mmol) in acetonitrile (20 mL) slowly over 30 minutes. The resultant solution was stirred at 
room temperature for 2 days. A residue was obtained after filtration and concentration of the 
reaction mixture under reduced pressure which was purified by silica gel column 
chromatography (3% methanol/dichloromethane) provided pure white solid of amine 2-11 
(0.55 g, 61%). 
1
H NMR (300 MHz, CDCl3), δppm) 1.08-1.49 (m, 29H, C(CH3)3), 1.53-1.78 (m, 4H), 
1.86-3.90 (m, 23H, CH2 ring, CH, CH2 acetate arm, NCH2CH2), 7.65 (dd, J = 3, 3 Hz, 2H, 
ArH), 7.77(dd, J = 3, 3 Hz, 2H, ArH), 9.42 (br., 1H, NH). 
13
C{1H}  NMR (75 MHz, CDCl3), δppm): 23.7, 28.0 (C(CH3)3), 28.1, 29.1, 37.3 
(NCH2CH2), 46.6, 49.4, 50.7, 51.1 (CH2 ring), 56.3(CH2’s acetate arm), 61.5(CH acetate 
arm), 81.3, 81.6 (C(CH3)3), 123.0, 131.9, 133.8, 168.3 (ArC), 170.2, 171.2 (C=O). 
ESI-MS for C38H62N5O8 [(M + H)
+
] m/z calcd. 716.5, found 716.4. 
 
Compound 2-12 
 
 
 
Amine 2-11 (0.40 g, 0.55 mmol) was dissolved into anhydrous acetonitrile (10 mL), 
potassium carbonate (0.15 g, 1.12 mmol) and diethyl(3-bromopropyl)phosphonate (214 µL, 
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1.12 mmol) were added under nitrogen atmosphere at room temperature. The reaction was 
heated at 70 °C for 16 h. The insoluble solids were removed by filtration; filtrate was 
concentrated to obtain a residue, which was purified by silica gel column chromatography 
(1:1:0.1 Methanol/dichloromethane/ammonia solution). Removal of solvents yielded light 
yellow oil of phthalimide 2-12 (0.39 g, 78%). 
1
H NMR (300 MHz, CDCl3), δppm) 1.27 (t, J = 6 Hz, OCH2CH3), 1.32-1.52 (m, 27H, 
C(CH3)3), 1.53-1.87 (m, 8H), 1.94-3.97 (m, 27H, CH2 ring, CH, CH2 acetate arm, 
NCH2CH2), 3.92-4.18 (m, 4H, OCH2CH3), 7.71 (dd, J = 3, 3 Hz, 2H, ArH), 7.81 (dd, J = 3, 3 
Hz, 2H, ArH). 
13
C{1H}  NMR (75 MHz, CDCl3), δppm): 16.4 (d, J = 6 Hz, CH2CH3), 19.2 (d, J = 5.3 
Hz), 23.6, 23.9, 26.3, 28.4, 37.4, 44.7, 47.2, 48.5, 49.3, 49.3, 50.7, 52.5, 53.2, 54.7, 55.0, 
56.1, 57.1, 61.4 (d, J = 6 Hz), 61.5(CH acetate arm), 82.2, 82.5, 83.0 (C(CH3)3), 123.1, 131.9, 
134.2 (ArC), 168.4, 173.3, 174.2, 174.6 (C=O).  
31
P NMR (75 MHz, CDCl3), δppm): 31.0(s). 
ESI-MS for C45H77N5O11P [(M + H)
+
] m/z calcd. 894.5, found 894.6. 
 
tert-butyl-6-(((benzyloxy)carbonyl)amino)-2-bromohexanoate (2-15) 
  
 
 
Potassium bromide (2.96 g, 12.50 mmol) was added to the solution of H-Lys(Z)-OH (2.00 g, 
7.13 mmol) in HBr (16 mL, 1N). The resultant mixture was cooled to 0 °C, sodium nitrite 
(0.59 g, 8.56 mmol) was added portion wise over 1 h and the mixture was stirred for a further 
2 h. Conc. sulfuric acid (1 mL) was added slowly at 0 °C and the solution was allowed to 
reach room temperature. The mixture was extracted with diethyl ether (3 × 150 mL). The 
combined organic layers were dried over anhydrous sodium sulphate and concentrated to 
afford bromo derivative of acid as slight yellow syrup. This acid (0.50 g, 1.45 mmol) was 
suspended in chloroform (5 mL) and tert-butyl-2, 2, 2-trichloroacetimidate (0.64 g, 2.90 
mmol) in chloroform (5 mL) was added drop wise. After 10 minutes a catalytic amount of 
trifluoroborane diethyl etherate (10 µL) was added and the resultant mixture was stirred at 
room temperature for 16 h under a nitrogen atmosphere. Sodium bicarbonate (1.00 g) was 
added to the mixture and stirred for another 10 minutes. The insoluble salts were removed by 
filtration and residue was obtained after concentration of filtrate. The residue was purified 
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using silica gel column chromatography (6% ethyl acetate/hexane) to obtain light yellow oil 
of bromide 2-15 (0.30 g, 51%). 
1
H NMR (300 MHz, CDCl3) δ (ppm): 1.41-1.63 (m, 13H, CH2CH2CH2CH2, (CH3)3C), 
1.87-2.12 (m, 2H, CH2CHBrCO), 3.19 (t, J = 6 Hz, 2H, NHCH2CH2), 4.10 (t, J = 6 Hz, 1H, 
CH2CHBrCO), 4.84 (br. s, 1H, NHCH2), 5.10 (s, 2H, PhCH2OCO), 7.37- 7.32 (m, 5H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 24.4 (NHCH2CH2CH2), 27.7 ((CH3)3C), 29.2 
(CHBrCH2CH2), 34.4 (NCH2CH2CH2), 40.6 (CHBrCH2CH2), 47.4 (COCHBrCH2), 66.6 
(PhCH2OCO), 82.4 ((CH3)3C) 128.1, 128.5, 136.5, (ArC) 156.3, 168.7 (C=O). 
ESI-HRMS for C18H26BrNNaO4 [M+Na
+
]
 +
, m/z calcd. 422.0937, found 422.0937. 
 
tert-butyl-2-bromo-4-(4-nitrophenyl)butanoate (2-17)  
 
 
 
4-(4-nitrophenyl)-butyric acid (3.00 g, 14.34 mmol) was dissolved in thionyl chloride (4.16 
mL, 57.36 mmol) and the mixture was stirred at 75 °C for 16 h. Bromine (0.82 mL, 15.78 
mmol) was added drop wise at the same temperature and mixture was again stirred for 16 h. 
The reaction was cooled to room temperature and the mixture was poured over ice and stirred 
for 2 h. The aqueous layer was extracted with diethyl ether (3 x 200 mL). The combined 
organic phases were washed with brine (200 mL), dried over Na2SO4 and concentrated under 
reduced pressure. The residue was redissolved in chloroform (30 mL) and a solution of tert-
butyl-2, 2, 2-trichloro acetimidate (6.27 g, 28.68 mmol) in chloroform (20 mL) was added 
slowly followed by boron trifluoride etherate (100 µL). The resultant mixture was stirred at 
room temperature for 16 h. Sodium bicarbonate (2.00 g) was added and stirred for 30 
minutes. The inorganic impurities were removed by filtration, the filtrate was concentrated 
and the residue was purified by silica gel column chromatography (2% ethyl acetate/hexane) 
to afford light yellow oil of bromide 2-17 (3.80 g, 77%). 
1
H NMR (300 MHz, CDCl3) δ (ppm): 1.49 (s, 9H, (CH3)3C), 2.21-2.43 (m, 2H, 
CH2CH2CHBr), 2.77-3.00 (m, 2H, CH2CH2CHBr), 4.07 (dd, J= 9, 6 Hz, 1H, CH2CH2CHBr), 
7.38 (d, J= 9 Hz, 2H, ArH), 8.18 (d, J= 9 Hz, 2H, ArH).  
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13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 27.7 ((CH3)3C), 33.1 (ArCH2CH2CHBr), 35.7 
(ArCH2CH2CHBr), 46.4 (ArCH2CH2CHBr), 82.8 (CH3)3C), 123.9, 129.3, 146.7, 147.9 
(ArC), 168.3 (C=O).  
ESI-HRMS for C14H18BrNO4 [M+Na]
+
, m/z calcd. 366.0311, found 366.0307. 
 
Compound 2-18  
 
 
 
A solution of tert-butyl DO2A 2-10 (2.00 g, 5.00 mmol) in anhydrous acetonitrile (50 mL) 
was added drop wise over 2 h to the mixture of bromide 2-15 (2.50 g, 6.25 mmol) and 
sodium bicarbonate (0.42 g, 5.00 mmol) in anhydrous acetonitrile (100 mL) at room 
temperature. The resultant mixture was stirred at room temperature for 2 days. The insoluble 
salts were removed by filtration and the filtrate was concentrated under reduced pressure. 
Pure product was afforded by silica gel column chromatography (3% 
methanol/dichloromethane) to give amine 2-18 as off-white solid (1.65 g, 46%). 
1
H NMR (300 MHz, CDCl3) δ (ppm):  1.43 (m, 27H, (CH3)3C), 1.56-1.68 (m, 4H, 
CH2CH2CH2CH2), 2.32-3.53 (br, 21H, CH2 ring, CHCOOtBu and CH2COOtBu), 5.06 (s, 2H, 
PhCH2CO), 5.79 (br s, 1H, CH2NHCOOCH2), 7.19-7.39 (m, 5H, ArH), 9.49 (br s, 1H, NH 
ring).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 23.8, 28.1, 28.2 ((CH3)3C), 29.2, 30.0, 40.4 
(NHCH2CH2), 45.6 48.5, 49.9, 50.9 (CH2 ring), 56.1 (CH2COOtBu), 61.9 (CHCOOtBu), 66.1 
(PhCH2OCO), 81.5, 81.7, ((CH3)3C), 127.7, 127.8, 128.3, 136.9, (ArC), 156.6, 170.1, 171.4 
(C=O).  
ESI-HRMS for C38H66N5O8 [M+H
+
]
 +
, m/z calcd. 720.4911, found 720.4901. 
 
Compound 2-19.  
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Potassium carbonate (0.27 g, 1.99 mmol) and diethyl(3-bromopropyl)phosphonate (0.38 mL, 
1.99 mmol) were added to the solution of amine 2-18 (1.30 g, 1.80 mmol) in anhydrous 
acetonitrile (15 mL). The reaction was heated to 70 °C for 16 h. The insoluble solids were 
removed by filtration, the filtrate was concentrated under reduced pressure and the residue 
was purified by silica gel column chromatography (50% methanol/dichloromethane/10% 
ammonia). Removal of solvents yielded light yellow oil of carbamate 2-19 (1.20 g, 74%). 
1
H NMR (300 MHz, CDCl3) δ (ppm): 1.29 (t, J = 6 Hz,  6H, OCH2CH3), 1.36-1.80 (m, 
37H, CH2CH2PO, (CH3)3C), 2.28-2.94 (br, 18H, CH2 ring), 3.12-3.22 (m, 7H, CHCOOtBu 
and CH2COOtBu), 4.94-4.17 (m, 4H, P(O)CH2), 5.07 (s, 2H, PhCH2OC(O)), 5.46 (br s, 1H, 
CH2NHCbz), 7.21-7.42 (m, 5H, ArH).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm):  16.3 (d, J = 6 Hz, OCH2CH3), 20.2 (d, J = 4.5 
Hz, POCH2CH2), 23.3 (d, 
1
JPC = 141 Hz, P(O)CH2CH2), 23.3, 28.1, 28.2, 29.3, 29.5, 40.7 
(CH2CH2NHCOO), 49.5 (NCH2CH2), 52.3, 52.5, 52.6, 56.0 (CH2 ring), 61.2, 61.2 
(CH2COOtBu), 64.1 (CHCOOtBu), 66.2 (OCH2CH3), 80.4, 80.5 ((CH3)3C), 127.8, 128.0, 
128.3, 136.7 (ArC), 156.3, 170.8, 172.8 (C=O).  
31
P{
1
H} NMR (122 MHz, CDCl3) δ (ppm): 32.9 (s).  
ESI-HRMS for C45H81N5O11P [M+H]
+
, m/z calcd. 898.5670, found 898.5659. 
 
Compound 2-20 
 
 
 
Carbamate 2-19 (0.68 g, 0.75 mmol) was dissolved in absolute ethanol (20 mL) and 10% Pd-
C (70 mg, 10% w/w) was added. The heterogeneous mixture was shaken for 16 h under a 
hydrogen atmosphere (35 psi) in a Parr hydrogenator apparatus. The catalyst was removed by 
filtration through the celite and the filtrate was concentrated to obtain light yellow oil of the 
amine 2-20 (0.50 g, 86%). 
1
H NMR (300 MHz, CDCl3) δ (ppm): 1.31 (t, J = 6 Hz, 6H, OCH2CH3), 1.37-1.95 (br, 37H, 
P(O)CH2CH2CH2, NHCH2CH2CH2CH2, (CH3)3C), 2.15-3.45 (br, 25H), 3.95-4.20 (m, 4H, 
OCH2CH3).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 16.5 (d, J = 6 Hz, OCH2CH3), 20.0 (d, J = 4.5 
Hz, P(O)CH2CH2), 23.5 (d, 
1
JPC = 140 Hz,P(O)CH2CH2), 23.6, 28.2, 28.3 (CH3)3C), 29.9, 
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33.5, 42.1 (CH2CH2NH2), 49.6 (NCH2CH2), 52.3, 52.3, 52.7, 56.2 (CH2 ring), 61.3, 61.4 
(CH2COOtBu, OCH2CH3), 64.2 (CHCOOtBu), 80.5, 80.6 (CH3)3C), 171.0, 172.9 (C=O). 
31
P{
1
H} NMR (122 MHz, CDCl3) δ (ppm): 31.0 (s), 32.9 (s).  
ESI-HRMS: for C21H41N5O9P [M+H]
+
, m/z calcd. 764.5296, found 764.5294. 
 
Ligand L
1
  
 
 
 
Bromotrimethylsilane (0.62 g, 3.90 mmol) was added slowly at 0 
o
C to the solution of the 
amine 2-20 (0.30 g, 0.39 mmol) in anhydrous dichloromethane (20 mL). The reaction 
mixture was stirred for 12 h at room temperature. The solvent was removed under reduced 
pressure and the residue was dissolved in formic acid (4 mL) and stirred at 60 °C for 16 h. 
The reaction mixture was cooled to room temperature and excess volatiles were removed 
under reduced pressure. The residue was dissolved in water (2 mL) and added slowly to 
acetone (200 mL) under vigorous stirring. The solution was cooled to -20 °C for 12 h. The 
solid product was isolated by filtration, dried under reduced pressure to afford an off-white 
solid of L
1
 (0.30 g, quant.) 
1
H NMR (300 MHz, D2O) δ (ppm): 1.40-2.15 (br, 10H), 2.80-3.35 (br, 23H, CH2 ring, CH2 
acid arm), 4.09 (m, 1H, NCH(COOH)CH2).  
13
C{1H} NMR (75 MHz, D2O) δ (ppm):  17.2, 23.6, 23.6 (d, 
1
JPC = 137 Hz, POCH2CH2), 
24.8, 26.5, 39.0, 46.9, 47.2, 48.3, 49.6, 49.9, 50.0, 50.1, 53.3, 54.2, 54.4, 63.1 (CHCOOH), 
170.8, 173.6, 174.58 (C=O).
 
31
P{
1
H} NMR (122 MHz, D2O) δ (ppm): 27.2 (s).  
ESI-HRMS for C21H41N5O9P: [M-H
+
]
-
, m/z calcd. 538.2647, found 538.2648. 
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Compound 2-21  
 
 
 
Sodium bicarbonate (0.37 g, 4.40 mmol) and a solution of bromide 2-17 (1.51 g, 4.40 mmol) 
in anhydrous acetonitrile (50 mL) were added slowly to a solution of bis-tert-butyl DO2A 2-
10 (2.20 g, 5.50 mmol) in anhydrous acetonitrile (100 mL) over 3 h at room temperature. The 
resultant mixture was stirred at room temperature for 2 days. The inorganic impurities were 
removed by filtration, the filtrate was concentrated under reduced pressure and the residue 
was purified with silica gel column chromatography (3% methanol/dichloromethane). The 
amine 2-21 was isolated as an off-white solid after recrystallization from cold diethyl ether 
(1.90 g, 65%).  
1
H NMR (300 MHz, CDCl3) δ (ppm): 1.40 (s, 9H, (CH3)3C)  1.49 (s, 18H, (CH3)3C), 1.93-
2.25 (br, 2H, CHCH2CH2), 2.38 (d, J= 12 Hz, 2H, ArCH2CH2), 2.53-3.37 (br, 21H, 
CHCOOtBu and CH2COOtBu, CH2 ring), 7.63 (d, J = 9 Hz, 2H, ArH), 8.17 (d, J = 9 Hz, 2H, 
ArH).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 28.0, 28.3 ((CH3)3C), 31.6 (ArCH2CH2), 32.3 
(ArCH2CH2), 45.8, 48.2, 49.5, 50.8 (CH2 ring), 55.5 (CH2COOtBu), 60.3 (CHCOOtBu), 
81.6, 82.2 ((CH3)3C), 123.7, 130.1, 146.6, 148.9 (ArC), 170.04, 170.9 (C=O).  
ESI-HRMS for C34H57N5O8 [M+H]
+
, m/z calcd. 664.4279, found 664.4282. 
 
Compound 2-22  
 
 
 
Amine 2-21 (0.93 g, 1.40 mmol) was dissolved into anhydrous acetonitrile (20 mL) and 
potassium carbonate (0.23 g, 1.68 mmol), diethyl-(3-bromopropyl) phosphonate (0.32 mL, 
1.68 mmol) and catalytic amount of potassium iodide were added at room temperature. The 
resultant mixture was stirred at 70 °C for 16 h. After cooling to room temperature, the 
insoluble materials were removed by filtration, the filtrate was concentrated under reduced 
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pressure to afford a residue which was purified by silica gel column chromatography (50% 
methanol/dichloromethane/2% ammonia) to obtain nitro 2-22 as light yellow oil (0.75 g, 
63%). 
1
H NMR (300 MHz, CDCl3) δ (ppm): 1.30 (t, J= 7.5 Hz, 6H, P(O)OCH2CH3)2), 1.37-1.56 
(m, 27H, (CH3)3C), 1.61-2.22 (br, 6H, ArCH2CH2, P(O)CH2CH2CH2), 2.31-3.05 (br, 20H, 
CH2 ring), 3.10-3.35 (m, 5H, CHCOOtBu, CH2COOtBu), 3.96-4.18 (m, 4H, OCH2CH3),  
7.38 (d, J= 7.5 Hz, 2H, ArH), 8.13 (d, J = 7.5, 2H, ArH).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 16.5 (d, J= 5.3 Hz, P(O)OCH2CH3), 20.1 (d, J = 
2.3 Hz, P(O)CH2CH2), 23.5 (d, 
1
JPC = 140 Hz, P(O)CH2CH2), 28.2, 28.3 ((CH3)3C), 31.4, 
32.6 (ArCH2-CH2-CH-), 49.8 (NCH2CH2), 52.5, 52.5, 52.7, 56.2 (CH2 ring), 61.3, 61.4 
(CH2COOtBu, OCH2CH3), 64.1 (CHCOOtBu), 80.7, 81.0 ((CH3)3C), 123.6, 129.3, 146.3, 
150.2 (ArC), 170.8, 172.3 (C=O).  
31
P{
1
H} NMR (122 MHz, D2O) δ (ppm): 32.8 (s). 
ESI-HRMS for C41H72N5O11P [M+H]
+
, m/z calcd. 842.5038, found 842.5038. 
 
Compound 2-23 
 
 
 
 A mixture of nitro 2-22 (0.45 g, 0.53 mmol) and 10% Pd-C (90 mg, 20% w/w) in absolute 
ethanol (20 mL) was shaken under a hydrogen atmosphere (35 psi) in a Parr hydrogenator. 
After completion of the reaction, the catalyst was removed by filtration through celite and the 
solvent was removed under reduced pressure. The residue was purified through alumina 
column chromatography (3% methanol/dichloromethane) to obtain a pure light yellow oil of 
amine 2-23 (0.37 g, 78%). 
1
H NMR (300 MHz, CDCl3) δ (ppm):  1.29 (t, J= 7.5 Hz, 6H, P(O)OCH2CH3), 1.35-1.47 
(br, 27H, (CH3)3C), 1.60-1.87(br, 6H, ArCH2CH2CHBr, P(O)CH2CH2CH2), 2.36-2.95 (br, 
20H, CH2 ring), 3.10-3.33 (m, 5H, CHCOOtBu, CH2COOtBu) 3.55 (br s, 2H, ArNH2),  3.93-
4.16 (m, 4H, OCH2CH3),  6.60 (d, J= 7.5 Hz, 2H, ArH), 6.97 (d, J = 7.5, 2H, ArH).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 16.4 (d, J = 6 Hz, P(O)OCH2CH3), 20.0 (d, J = 
4.5 Hz, P(O)CH2CH2CH2), 23.4 (d, 
1
JPC = 140 Hz, P(O)CH2CH2CH2), 28.1, 28.3 (CH3)3C), 
29.6 (P(O)CH2CH2CH2), 31.8 (ArCH2CH2), 32.3 (ArCH2CH2), 49.7 (NCH2CH2), 52.2, 52.3, 
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52.8, 53.3, 55.6, 55.9 (CH2 ring), 56.13 (CH2COOtBu), 61.3 (d, J = 3 Hz,-P(O)OCH2CH3), 
61.3, 64.5 (CHCOOtBu), 80.5, 80.5 ((CH3)3C), 115.1, 129.1, 132.0, 144.2 (ArC), 171.0, 
172.8(C=O).  
31
P{
1
H} NMR (122 MHz, CDCl3) δ (ppm): 32.9 (s), 31.0 (s).  
ESI-HRMS for C41H74N5O9P [M+H]
+
, m/z calcd. 812.5296, found 812.5296. 
 
Ligand L
2
  
 
 
Bromotrimethylsilane (0.57 mL, 4.31 mmol) was added to a solution of amine 2-23 (0.35 g, 
0.431 mmol) in anhydrous dichloromethane (15 mL) cooled at 0 °C. The reaction was 
allowed to warm up to room temperature and was stirred for 16 h. The reaction mixture was 
concentrated under reduced pressure to remove excess reagent and solvent. The residue was 
suspended in anhydrous dichloromethane (15 mL), trifluoroacetic acid (10 mL) was added at 
0 °C and the solution was stirred at room temperature for 16 h. The reaction mixture was 
concentrated under reduced pressure, the residue was dissolved in methanol and added to 
diethyl ether under vigorous stirring. After filtration and drying, L
2
 was obtained as off-white 
solid (0.21 g, 84%). 
1
H NMR (300 MHz, D2O) δ (ppm): 1.53-2.50 (br, 8H, ArCH2CH2, P(O)CH2CH2CH2), 
2.50-4.0 (br, 23H, CH2 ring, CH2COOH and CHCOOH, NCH2CH2CH2P(O)), 7.34 (d, J= 7.5 
Hz, 2H, ArH), 7.42 (d, J = 7.5 Hz, 2H, ArH).  
13
C{1H} NMR (75 MHz, D2O) δ (ppm): 17.4, 23.9 (d, 
1
JPC = 135 Hz), 26.4, 31.7, 47.0, 
47.3, 47.4, 48.1, 49.4, 49.6, 49.8, 50.2, 53.6, 54.2, 54.5, 61.3, 123.4, 128.3, 130.6, 141.3 
(ArC), 171.3, 173.3, 174.5 (C=O). 
31
P{
1
H} NMR (122 MHz, D2O) δ (ppm): 26.6 (s).  
ESI-HRMS for C25H42N5O9P:[M-H]
-
, m/z calcd. 586.2647, found 586.2643. 
 
Compound 2-24 
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1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (58 mg, 0.301 mmol) was added to a 
suspension of biotin (88 mg, 0.36 mmol) and 4-dimethylamino pyridine (76 mg, 0.60 mmol) 
in anhydrous dimethylformamide (8 mL) at room temperature. The solution of amine 2-20 
(0.23 g, 0.30 mmol) in anhydrous dimethylformamide (6 mL) was added slowly over 10 
minutes, and the mixture was stirred for another 16 h. The reaction mixture was concentrated 
under reduced pressure and resultant residue was dissolved in dichloromethane (100 mL) and 
water (100 mL). The organic layer was separated and aqueous layer was extracted with 
dichloromethane (2 × 75 mL). The combined organic layers were washed by brine, dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography (10% methanol/dichloromethane) to yield product biotinylated ester 
2-24 as off-white solid (0.16 g, 54%). 
1
H NMR (300 MHz, CDCl3) δ (ppm): 1.20 (t, J = 6 Hz, 6H, (P(O)OCH2CH3), 1.26 -1.44 
(br, 33H,), 1.44-1.84  (br, 12H), 1.87-2.60 (br, 13H), 2.61-3.40 (br, 16 H,), 3.81-4.06 (m, 4 H, 
OCH2CH3), 4.24 (m, 1 H, CH), 4.39 (m, 1H, CH), 5.91 (br s, 1H, NH), 6.33 (br s, 1H, NH), 
8.48 (br s, 1H, NH).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 16.2 (d, J = 5.3 Hz, P(O)OCH2CH3), 18.9, 22.5, 
24.4, 25.6,26.2, 27.6, 27.6, 27.8, 29.0, 35.44, 4.34, 40.4, 44.5, 47.0, 48.1, 49.0, 50.6, 52.3, 
53.2, 54.6, 54.8, 55.3, 55.8, 57.0, 59.9, 61.2, 61.3, 61.5, 82.2, 82.2, 83.0, 172.80, 173.6, 
173.8, 174.9.  
31
P NMR (75 MHz, CDCl3) δ (ppm): 26. 6 (s).  
ESI-HRMS for C47H89N7O11PS:[M-H]
-
, m/z calcd. 990.6072, found 990.6080. 
 
Compound 2-25 
 
 
 
 Following the same procedure as described for biotinylated ester 2-24, biotinylated ester 2-
25 was isolated as light yellow solid (98 mg, 56%). 
1
H NMR (300 MHz, CDCl3) δ (ppm):  1.28 (t, J = 6 Hz, 6H, OCH2CH3), 1.40 -1.53 (br, 
27H, (CH3)3C), 1.54 - 3.73  (br, 39H), 3.91-4.18 (br, 5 H, CHCOOtBu, OCH2CH3), 4.30 (s, 
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1H, NHCH(CH)CH2), 4.48 (s, 1H, NHCH(CH)CH2), 5.42-5.88(m, 2H, SCH2CH), 7.01 (d, J 
= 6 Hz, 2H, ArH), 7.53 9d, J = 6 Hz, 2H, ArH), 8.34 (br, 1H, -NH). 
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm):  14.1, 16.3 (d, J = 6 Hz, P(O)OCH2CH3), 18.9, 
23.4(d, 
1
JPC = 135 Hz, P(O)CH2CH2CH2), 25.5, 27.7, 27.8, 28.0 (CH3)3C), 29.6, 33.4, 36.6, 
40.2, 43.9, 47.0, 47.8, 48.5, 50.7, 52.5, 54.6, 54.9, 55.4, 55.9, 56.5, 58.9, 60.4, 61.47, 61.5, 
61.9, 82.2, 82.5, 82.9 ((CH3)3C), 120.3, 129.0, 135.9, 137.0 (ArC), 164.5, 172.5, 173.0, 
174.3, 175.0 (C=O).  
31
P{
1
H} NMR (122 MHz, CDCl3) δ (ppm): 31.1 (s).  
ESI-HRMS for C51H89N7O11PS:[M-H]
-
, m/z calcd. 1038.6072, found 1038.6073. 
 
Ligand L
3
  
 
 
 
L
3
 was synthesized from ester 2-24 following the same procedure as described for L
2
. The 
purification was accomplished by RP-HPLC, following the method C (0.16 g, 49%). 
1
H NMR (300 MHz, D2O) δ (ppm): 1.01-2.43(br, 18H), 2.49-4.06 (br, 28H), 4.35 (s, 1H), 
4.53 (s, 1H).  
13
C{1H} NMR (75 MHz, D2O) δ (ppm):  17.4, 24.1, 25.0 (d, 
1
Jpc = 134 Hz, P(O)CH2CH2), 
25.2, 25.4, 27.7, 28.0, 28.3, 35.5, 38.6, 39.8, 47.9, 48.2, 49.5, 52.5, 53.1, 53.8, 54.0, 54.3, 
54.5, 55.4, 60.2, 62.1, 64.6, 165.2, 172.0, 173. 7, 174.6, 176.5(C=O).  
 31
P{
1
H} NMR (122 MHz, D2O) δ (ppm): 23.6 (s), 24.0 (s).  
ESI-HRMS for C31H56N7O11PS:[M-H]
-
, m/z calcd. 764.3423, found 764.3422. 
 
Ligand L
4
  
 
 
 
L
4
 was synthesized from ester 2-25 following the same procedure as described for L
2
. The 
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purification was accomplished by RP-HPLC, following the method C (68 mg, 58%). 
 
1
H NMR (300 MHz, D2O) δ (ppm): 1.00-2.00 (br, 12H), 2.00-3.85 (br, 30H), 4.31 (s, 1 H), 
4.51 (s, 1H), 7.29 (m, 4H).  
13C{1H} NMR (75 MHz, D2O) δ (ppm):  16.8, 24.8 (d, J = 134 Hz, POCH2CH2), 25.1, 
27.7, 28.0, 29.1, 31.6, 36.2, 39.7, 46.8, 48.7, 48.9, 49.3, 49.5, 50.3, 53.5, 53.8, 55.3, 56.4, 
57.5, 60.2, 62.0, 63.5, 122.2, 129.4, 135.2, 137.6 (ArC), 165.2, 173.1, 175.2, 175.2, 175.4 
(C=O). 
  
31
P{
1
H} NMR (122 MHz, D2O) δ (ppm): 23.0 (s), 23.7(s).  
ESI-HRMS: for C35H56N7O11PS [M-H]
-
, m/z calcd. 812.3423, found 812.3426. 
 
Compound 3-6 
 
 
 
Benzyl amine 3-11 (0.65 g, 0.60 mmol) was dissolved in ethanol (15 mL) with 10% Pd-C (65 
mg, 10% w/w) and shaken for 16 h in a Parr apparatus under H2 (50 psi). The residue was 
obtained after reaction mixture was filtered and solvent was evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography to obtain the pure 
amine 3-6 as white fluffy powder (0.54 g, 91%). 
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.25-1.55 (m, 45H, C(CH)3), 1.59-1.87 (m, 2H, 
NCH2CH2CH2), 1.94-3.84 (m, 44H), 8.09(br. s, 1H, NH). 
ESI-HRMS for C49H94N7O13 [(M + H)
+
] m/z calcd. 988.690413, found 988.690172. 
 
Compound 3-7 
 
 
To a mixture of amine 3-15 (0.65 g, 0.90 mmol) and triethylamine (0.15 mL, 1.08 mmol) in 
dichloromethane (10 mL) a solution of chloroacetic anhydride (0.19 g, 1.08 mmol) 
dichloromethane (5 mL) at 0 °C was added slowly. The resultant mixture was stirred at 0 °C 
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to room temperature for 2 h. This was diluted with dichloromethane (100 mL), and washed 
by water (2 × 100 mL). The organic layer was dried over sodium sulphate, and concentrated 
under reduced pressure to obtain a residue which was purified by alumina column 
chromatography (4% methanol/dichloromethane) to afford chloride 3-7 as light yellow oil 
(0.48 g, 67%).  
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.30-1.52 (br., 27H, C(CH)3), 1.57-1.72 (m, 2H, 
NCH2CH2CH2), 1.74-2.07 (m, 2H, ArCH2CH2CH), 2.32-3.01 (m,  20H), 3.03-3.52 (m, 7H, 
CH and CH2’s acetate arm, NHCH2CH2CH2), 3.96 (s, 2H, ClCH2CO), 7.33 (d, J = 7.5 Hz, 
2H, ArH), 7.73 (br., s, NHCOCH2Cl), 8.10 (d, J = 7.5 Hz, 2H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 25.97, 28.16, 28.30 (C(CH)3), 31.43, 32.58, 
38.97, 42.74, 49.99 (NCH2-CH2), 52.24, 53.08, 53.23, 53.37 (CH2 ring), 56.44 (CH2 acetate 
arm), 64.00 (CH acetate arm), 80.84, 81.05 (C(CH)3), 123.58, 129.25, 146.32, 150.10 (ArC), 
166.09, 170.66, 172.22 (C=O). 
ESI-HRMS for C39H66N6O9 [(M + H)
+
] m/z calcd. 797.457432, found 797.457079. 
 
Compound 3-9 
 
 
 
 
 
To a mixture of amine 3-10 (2.0 g, 5.32 mmol) and cesium carbonate (1.36 g, 4.26 mmol) in 
anhydrous acetonitrile (100 mL) at room temperature was added slowly a solution of benzyl 
chloride (85 mM solution in acetonitrile, 4.26 mmol). The resultant solution was stirred at 
room temperature for 2 days. The Insoluble salts were removed by filtration and the filtrate 
was concentrated under reduced pressure. The residue was dissolved into dichloromethane 
(200 mL) and water (100 mL). Organic layer was separated; the aqueous phase was extracted 
with dichloromethane (2 × 100 mL).  The combined organic layers were dried over sodium 
sulphate, filtered through cotton plug, and concentrated under reduced pressure. Purification 
of the residue by silica gel column chromatography (3% methanol/dichloromethane) gave the 
mono benzyl amine derivative 3-9 as light yellow oil (1.00 g, 45%). 
1
H NMR (300 MHz, CDCl3), ppm): 1.46 (s, 18H, C(CH3)3), 2.68-3.01 (m, 5H, 
NHCH2CH2), 3.21-3.39(m, 4H, NCH2COO
t
Bu), 3.59 (br., 8H, CH2’s next to oxygen), 3.85 
(s, 2H, NCH2Ph), 7.10-7.44 (m, 5H, ArH). 
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13
C{1H} NMR (75 MHz, CDCl3), ppm): 27.9, 28.1 (C(CH3)3), 48.5, 51.3, 52.9, 55.6, 
58.5, 69.8, 70.0, 70.1, 70.2, 80.6, 81.0 (C(CH3)3), 126.9, 128.1, 128.8, 138.9 (ArC), 170.9, 
171.1(C=O). 
ESI-MS for C25H43N2O6 [(M + H)
+
] m/z calcd. 467.311564, found 467.311887. 
 
Compound 3-11 
 
 
 
 
To a solution of amine 3-9 (0.70 g, 1.50 mmol) and potassium carbonate (0.25 g, 1.80 mmol) 
in anhydrous acetonitrile (20 mL) at room temperature was added slowly into the solution of 
DO3A-PA-bromide (1.24 g, 1.80 mmol). The resultant solution was stirred at 70 °C for 4 h. 
The insoluble materials were removed by filtration and the filtrate was concentrated under 
reduced pressure. Residue was dissolved into dichloromethane (100 mL) and water (50 mL) 
was added. The organic layer separated, washed by water (2 x 40 mL).  The organic layer 
was dried over sodium sulphate, filtered, and concentrated under reduced pressure. 
Purification of the residue by silica gel column chromatography (4% 
methanol/dichloromethane) gave benzyl amine 3-11 as a white flocculent powder (1.25 g, 
77%). 
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.31-1.56 (m, 45H, C(CH)3), 1.56-1.87 (m, 2H, 
NCH2-CH2-CH2-), 1.97-3.88 (m, 46H), 7.27 (br., 5H, ArH), 8.31(br. s, 1H, NH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 27.65, 27.85, 28.00 (C(CH)3), 29.48, 37.40, 
50.08, 51.84, 52.54, 52.89, 53.37, 54.23, 55.01, 55.47, 56.49, 56.71, 58.46, 58.83, 59.18, 
59.59, 67.01, 67.09, 69.05, 69.15, 70.05, 81.51, 82.12, 82.25, 82.51(C(CH)3), 127.74, 128.47, 
129.68, 135.56(ArC), 169.81, 170.20, 171.41, 172.24, 172.33, 172.43(C=O). 
ESI-HRMS for C56H100N7O13 [(M + H)
+
] m/z calcd. 1078.737363, found 1078.736514. 
 
Compound 3-12 
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To a mixture of amine 3-10 (0.35 g, 0.93 mmol) in 1,4-dioxane (20 mL) and 10% acetic acid 
(20 mL, pH 3.5–4) at room temperature was added slowly benzyl chloroformate (133 µL, 
0.93 mmol), pH was maintained in between 3.5-4 1N NaOH. The resultant solution was 
stirred at room temperature for 16 days. Reaction mixture was concentrated under reduced 
pressure on rotary evaporator. Residue was dissolved into dichloromethane (70 mL) and 
water (70 mL). Organic layer was separated; the aqueous phase was extracted by 
dichloromethane (2 × 50 mL).  The combined organic layers were dried over sodium 
sulphate, filtered through cotton plug, and concentrated under reduced pressure. Purification 
of the residue by silica gel column chromatography (3% methanol/dichloromethane) gave 
mono Cbz protected carbamate 3-12 as light yellow oil (50 mg, 10%). 
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.30-1.48(s, 18H), 1.97 (br s, 1H), 3.27 (s, 2H), 
3.39-3.68 (m, 10H), 3.90-4.02 (d, 2H), 5.04-5.15 (s, 2H), 7.19-7.36 (m, 5H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 27.9, 28.0, 47.7, 48.4, 48.6, 50.7, 51.6, 67.1, 
67.3, 70.0, 70.1, 70.2, 70.3, 70.4, 70.6, 70.7, 76.6, 80.9, 81.3, 81.4, 127.6, 127.6, 127.8, 
127.9, 128.3, 128.4, 136.4, 136.5, 156.0, 156.2, 168.9, 171.4. 
ESI-HRMS for C26H43N2O8 [(M + H)
+
] m/z calcd. 511.301393, found 511.301221. 
 
Compound 3-13 
 
 
To a mixture of amine 3-10 (0.3 g, 0.80 mmol) and cesium carbonate (0.21 g, .64 mmol) in 
anhydrous acetonitrile (15 mL) at room temperature was added slowly a solution of 4-
methoxybenzyl chloride (85 µL, 4.26 mmol) in acetonitrile (7 mL). The resultant solution 
was stirred at room temperature for 2 days. The insoluble salts were removed by filtration; 
the filtrate was concentrated under reduced pressure. The residue was dissolved in 
dichloromethane (50 mL) and water (50 mL) was added. The organic layer was separated and 
the aqueous phase was extracted by dichloromethane (2 × 50 mL).  The combined organic 
layers were dried over sodium sulphate, filtered through cotton plug, and concentrated under 
reduced pressure. Purification of the residue by silica gel column chromatography (3% 
methanol/dichloromethane) gave mono para methoxy benzyl amine 3-13 as light yellow oil 
(0.17 g, 39%).  
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1
H NMR (300 MHz, CDCl3), δ (ppm): 1.46 (s, 18H, C(CH3)3), 2.68-3.01 (m, 5H, 
NHCH2CH2), 3.21-3.39(m, 4H, NCH2COO
t
Bu), 3.59 (br., 8H, CH2’s next to oxygen), 3.85 
(s, 2H, NCH2Ph), 7.10-7.44 (m, 5H, ArH). 
 
Compound 3-14 
 
 
 
To a mixture of amine 2-21 (1.00 g, 1.50 mmol) and K2CO3 (0.46 g, 3.31 mmol) in 
anhydrous acetonitrile (15 ml), N-(3-bromopropyl)phthalamide (0.48 g, 1.80 mmol) was 
added and reaction mixture was stirred at 70 °C for 16 h. It was then cooled to room 
temperature and volatiles were removed under reduced pressure. Water (70 mL) was added 
and the resultant mixture was extracted with dichloromethane (3 × 100 mL). The organic 
layer was dried over anhydrous sodium sulphate, filtered, and evaporated to obtain yellow oil. 
The crude product was purified by alumina column chromatography (4% 
methanol/dichloromethane) to obtain phthalimide 3-14 as white flocculent powder (1.80 g, 
66%).  
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.43 (br., 27H, C(CH)3), 1.66-2.06 (m, 4H, 
NCH2CH2CH2, ArCH2CH2), 2.25-3.91 (m, 27H), 7.28 (d, J = 6 Hz, 2H, ArH), 7.54.7.87 (m, 
4H, phthamide ArH), 8.03 (d, J = 6 Hz, 2H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 26.29, 28.17, 28.28 (C(CH)3), 31.48, 32.64, 
36.62, 49.85 (NCH2CH2), 52.45, 52.75, 52.84, 53.06 (CH2 ring), 56.09 (CH2 acetate arm), 
64.27(CH acetate arm), 80.57, 80.88 (C(CH)3), 122.96, 123.46, 129.19, 132.05, 133.73, 
146.13, 150.33 (ArC), 168.15, 170.84, 172.33 (C=O). 
ESI-HRMS for C45H67N6O10 [(M + H)
+
] m/z calcd. 851.491319, found 851.491835. 
 
Compound 3-15 
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To a solution of phthalimide 3-14 (0.81 g, 0.95 mmol) in 2-propanol (10 mL) was added 
ethylenediamine (0.32 mL, 4.76 mmol) and reaction was heated to reflux for 16 h. A residue 
was obtained after filtration and concentration of the filtrate under reduced pressure. This was 
dissolved into 30% dichloromethane/diethyl ether and insolubles were removed by filtration. 
Concentration of filtrate under reduced pressure yielded amine 3-15 as light yellow oil (0.65 
g, 95%). 
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.34-1.49 (br., 27H, C(CH)3), 1.49-1.66 (m, 2H, 
NCH2CH2CH2), 1.76-2.07 (m, 2H, ArCH2CH2CH), 2.32-3.07 (m,  22H), 3.11-3.39 (m, 5H, 
CH and CH2’s acetate arm), 7.37 (d, J = 7.5 Hz, 2H, ArH), 8.13 (d, J = 7.5 Hz, 2H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 27.99, 28.18, 28.33 (C(CH)3), 31.46, 32.67, 
40.38, 49.80 (NCH2CH2), 52.30, 52.56, 52.76, 53.05 (CH2 ring), 56.29 (CH2 acetate arm), 
64.38 (CH acetate arm), 80.79, 81.09 (C(CH)3), 123.59, 129.34, 146.30, 150.24 (ArC), 
170.82, 172.49 (C=O). 
ESI-HRMS for C37H65N6O8 [(M + H)
+
] m/z calcd. 721.485840, found 721.485209. 
 
Compound 3-17 
 
 
 
A mixture of pthaimide 3-14 (0.55 mg, 0.65 mmol) and 10% Pd-C (0.10 g, 20% w/w) in 
absolute ethanol (25 mL) was shaken under a hydrogen atmosphere (35 psi) in a Parr 
hydrogenator. After completion of the reaction, the catalyst was removed by filtration 
through celite and the solvent was removed under reduced pressure to obtain pure light 
yellow oil of amine 3-17 (0.50 g, 78%).  
1
H NMR (300 MHz, CDCl3) δ (ppm):  1.26-1.58 (m, 27H, (C(CH3)3), 1.57-2.10 (m, 4H), 
2.10-3.18 (br, 21H, CH2 ring, CHCOO
t
Bu and CH2COO
t
Bu), 6.52 (d, J = 7.5 Hz, 2H, ArH), 
6.91 (d, J = 7.5 Hz, 2H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 26.1, 28.1 (C(CH3)3), 31.9, 32.2, 36.5, 49.7, 
52.1, 52.3, 52.8, 53.0,(CH2 ring), 56.1 (CH2COO
t
Bu), 64.4 (CHCOO
t
Bu), 80.3, 80.4, 
(C(CH3)3), 115.1, 122.9, 129.0, 131.9, 132.0, 133.6, 144.1 (ArC), 168.1, 171.0, 172.8 (C=O).  
ESI-HRMS for C45H69N6O8 [M+H]
+
, m/z calcd. 821.517140, found 821.516412. 
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Compound 3-20 
 
 
To a solution of the amine 3-19 (0.25 g, 0.32 mmol) in of dichloromethane (10 mL) was 
added drop wise at 0 °C N,N-diisopropylethylamine (62 µl, 0.38 mmol) followed by 
chloroacetic anhydride (64 mg, 0.38 mmol) in dichloromethane (10 mL). The solution was 
stirred at 0 °C for 45 min and at room temperature for 2 h. The reaction mixture was diluted 
with dichloromethane (50 mL) and water (30 mL). The aqueous layer was separated and 
extracted with dichloromethane (3 × 20ml) and the combined organic layers were dried over 
sodium sulfate. The solvent was evaporated in vacuo and the resultant oil was purified by 
alumina column chromatography (4% methanol/dichloromethane) to yield chloride 3-20 as 
white flocculent powder (0.16 g, 94%). 
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.31-1.58 (br., 36H, C(CH3)3), 1.58-1.72 (m, 2H, 
NCH2CH2CH2), 1.72-2.11 (m, 2H, ArCH2CH2CH), 2.30-3.69 (m,  27H), 3.85-4.27 (s, 2H, 
ClCH2CO), 6.63 (br., s, NHBoc), 7.09 (d, J = 6 Hz, 2H, ArH), 7.86 (br s, 1H, NHCOCH2Cl), 
7.27 (d, J = 6 Hz, 2H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 23.8, 28.1, 28.2 (C(CH3)3), 31.9, 32.0, 38.9, 
42.7, 49.9 (NCH2CH2), 51.9, 52.0, 53.0, (CH2 ring), 56.3 (CH2 acetate arm), 64.2 (CH acetate 
arm), 80.1, 80.6, 80.7 (C(CH3)3), 118.7, 128.8, 136.2, 136.5 (ArC), 152.8, 166.2, 170.7, 172.5 
(C=O). 
ESI-HRMS for C44H76ClN6O9 [(M + H)
+
] m/z calcd. 867.535682, found 867.536426. 
 
Compound 3-21 
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To a solution of amine 3-6 (0.30 g, 0.30 mmol) and potassium carbonate (62 mg, 1.03 mmol) 
in anhydrous acetonitrile (8 mL) was added chloride 3-20 (0.29 g, 0.33 mmol). The resultant 
solution was stirred at 70 °C for 16 h. The insoluble material was removed by filtration and 
the filtrate was concentrated under reduced pressure to get brown oil, which was purified by 
silica gel column chromatography (12% methanol/dichloromethane) to afford light yellow 
flocculent powder of ester 3-21 (0.25 g, 45%). 
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.28-1.54 (br., 81H, (C(CH3)3), 1.55-1.87 (m, 6H, 
NCH2CH2CH2, ArCH2CH2CH), 1.89-3.94 (m,  73H), 6.70 (br., s, NHBoc), 6.93-7.16 (m, 2H, 
ArH), 7.21-7.43 (m, 2H, ArH), 8.03 (br.s, 2H, NHCH2CH2). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 24.2, 25.5, 29.2, 33.1, 37.1, 44.2, 46.8, 47.4, 
47.9, 48.5, 49.8, 50.4, 50.6, 50.9, 51.6, 52.3, 55.3, 55.4, 55.6, 56.3, 56.8, 57.9, 58.2, 58.6, 
58.6, 66.9, 68.9, 80.0, 81.2, 81.3, 82.0, 82.3, 82.4, 118.5, 128.7, 134.5, 136.6, 152.4, 169.5, 
169.6, 170.9, 171.1, 171.4, 172.0, 172.4, 173.2, 173.9, 174.3. 
ESI-HRMS for C93H169N13O22 [(M +2H)+Na]
 2+
 m/z calcd. 614.41288, found 614.41377. 
 
Compound 3-22 
 
 
 
A mixture of ester 3-35 (0.50 g, 0.57 mmol) and 10% Pd-C (50 mg, 10% w/w) in ethanol (15 
mL) was stirred under a H2 atmosphere (35 psi) for 16 h. The reaction mixture was filtered 
through a celite bed and concentrated under reduced pressure to obtain light brown oil. The 
residue was dissolved in dichloromethane (50 mL) and water (30 mL). The organic layer was 
separated washed by brine, dried over sodium sulphate and concentrated under reduced 
pressure to afford a white flocculent powder of acid 3-22 (0.46 g, 99%). 
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.26-1.57 (m, 45H, C(CH)3), 1.57-3.79 (m, 48H). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 27.5, 27.7, 27.8, 37.1, 47.5, 49.8, 49.9, 51.2, 
51.6, 52.4, 52.6, 53.3, 55.2, 55.4, 56.3, 56.5, 57.6, 57.9, 58.14, 58.4, 58.5, 67.4, 67.7, 69.1, 
81.3, 82.1, 82.4, 169.8, 170.1, 171.2, 171.4, 172.1, 173.2, 174.0. 
ESI-HRMS for C51H96N7O15 [(M + H)
+
] m/z calcd. 1046.695892, found 1046.696059. 
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Compound 3-24 
 
 
 
To a solution of amine 3-10 (2.0 g, 5.32 mmol) and cesium carbonate (1.36 g, 4.26 mmol) in 
anhydrous acetonitrile (100 mL) at room temperature was added slowly solution of benzyl 
bromoacetate (85 mmol solution in acetonitrile, 4.26 mmol). The resultant solution was 
stirred at room temperature for 2 days. The insoluble materials were removed by filtration 
and the filtrate was concentrated under reduced pressure. The residue was dissolved in 
dichloromethane (200 mL) and water (100 mL). The organic layer was separated; the 
aqueous phase was extracted by dichloromethane (2 × 100 mL).  The combined organic layer 
was dried over sodium sulphate, filtered, and concentrated under reduced pressure. 
Purification of the residue by silica gel column chromatography (3% 
methanol/dichloromethane) gave ester 3-24 as light yellow oil (1.00 g, 36%).  
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.38-1.54 (s, 18H, (C(CH3)3), 1.95 (br., s, 1H, NH), 
2.74 (t, J = 6 Hz, 2H), 2.95 (t, J = 6 Hz, 2H), 3.29, 3.31(s, 2H, NHCOOBn), 3.44-3.71 (m, 
12H), 5.12, 5.17 (s, 2H, CH2 benzyl), 7.29-7.41 (m, 5H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 28.0, 28.1 (C(CH3)3), 48.7, 51.6, 53.5, 55.8, 
56.6, 66.1, 70.2, 70.3, 70.6, 80.9, 80.9(C(CH3)3), 128.2, 128.5, 135.7 (ArC), 170.6, 171.3, 
171.4 (C=O). 
ESI-HRMS for C27H44N2O8Na [(M + Na)
+
] m/z calcd. 547.298987, found 547.298984. 
 
Compound 3-25 
 
 
 
To a solution of amine 3-24 (0.70 g, 1.50 mmol) and potassium carbonate (0.25 g, 1.80 
mmol) in anhydrous acetonitrile (20 mL) at room temperature was added slowly to a solution 
of DO3A-PA-bromide (1.24 g, 1.80 mmol). The resultant solution was stirred at 70 °C for 4 
h. The insoluble materials were removed by filtration; the filtrate was concentrated under 
reduced pressure. The residue was dissolved into dichloromethane (100 mL) and water (50 
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mL). The organic layer separated and washed by water (2 x 40 mL).  The organic layer was 
dried over sodium sulphate, filtered, and concentrated under reduced pressure. Purification of 
the residue by silica gel column chromatography (4% methanol/dichloromethane) gave ester 
3-25 as a white flocculent powder (1.25 g, 77%).  
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.29-1.58 (m, 45H, C(CH)3), 1.58-1.86 (m, 2H, 
NCH2CH2CH2), 1.88-3.88 (m, 46H), 5.11 (s, 2H), 7.15-7.42 (br., 5H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 27.5, 27.6, 27.8, 37.1, 47.4,49.7, 49.8, 49.9, 
50.0, 50.4, 50.6,  51.5, 52.3, 53.2, 55.3, 56.2, 56.4, 58.5, 66.1, 69.1, 69.7, 69.8, 81.3, 82.0, 
82.3, 127.8, 128.0, 128.2, 135.2, 169.6, 170.0, 171.2, 172.2, 173.3. 
ESI-MS calculated for C58H102N7O15 [(M + H)
+
] m/z: 1136.7, found 1136.7. 
 
Compound 3-29 
 
 
 
To 3-28 (0.12 g, 0.07 mmol) was added with formic acid (30 mL) and resultant mixture was 
stirred at 60 °C for 16 h. The volatiles were removed under reduced pressure and methanol (3 
× 20 mL) was added and again concentrated. The residue was purified by RP-HPLC using 
method B to obtain nitro 3-29 (27 mg, 13 % over two steps). 
1
H NMR (300 MHz, D2O), δ (ppm): 1.58-2.49 (m, 8H), 1.58-4.02 (m, 65H), 4.15 (br. s, 
4H), 7.49 (d, J = 7.5 Hz, 2H), 8.16 (d, J = 7.5 Hz, 2H). 
ESI-MS for C56H92N13O22 [(M - H)
-
] m/z calcd. 1298.6, found 1298.6. 
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Ligand L
5 
 
 
 
A mixture of nitro 3-29 (27 mg, 0.02 mmol) and 10% Pd-C (10 mg, 40% w/w) in water (15 
mL) was shaken under H2 (35 psi) for 16 h. The reaction mixture was filtered through a celite 
bed. The filtrate was concentrated under reduced pressure to obtain pure ligand L
5
 (27 mg, 
quant.).  
1
H NMR (300 MHz, D2O), δ (ppm): 1.14-2.40 (m, 10H), 2.40-4.20 (m, 69H), 4.15 (br. s, 
4H), 6.95 (d, J = 7.5 Hz, 2H), 7.18 (d, J = 7.5 Hz, 2H). 
ESI-MS for C56H94N13O20 [(M - H)
-
] m/z calcd. 1268.7, found 1268.6. 
 
Ligand L
6 
 
 
 
A mixture of L
5
 (75 mg, 0.06 mmol) in water (7 mL) and chloroform (7 mL) was added with 
thiophosgene (9 µl, 0.18 mmol) and stirred at room temperature for 30 minutes. Organic layer 
was removed and aqueous layer was washed with chloroform (3 × 15 mL). Aqueous layer 
was concentrated to afford L
6
 (27 mg, quant.). 
 1
H NMR (300 MHz, D2O), δ (ppm): 1.46-2.37 (m, 6H), 2.41-2.41 (m, 73H), 6.91 (d, J = 
7.5 Hz, 2H), 7.07 (d, J = 7.5 Hz, 2H). 
13
C{1H} NMR (75 MHz, D2O), δ (ppm): 25.5, 28.7, 34.3, 39.2, 49.4,49.5, 49.6, 50.6, 51.1, 
52.3, 52.6, 54.6, 55.6, 56.0, 57.0, 58.0, 58.6, 58.9, 63.6, 67.2, 72.2, 128.7, 131.3, 132.8, 
136.6, 142.0, 167.5, 170.5, 170.7, 171.2, 172.9, 175.8, 176.7, 177.0.  
Chapter 6 
 
128 
 
ESI-MS for C57H92N13O20S [(M - H)
-
] m/z calcd. 1310.6, found 1310.7. 
 
Compound 4-3 
 
 
 
To a suspension of alloc 4-14 (0.06 mmol) in degassed DMF by nitrogen gas (5 mL) was 
added Pd(PPh3)4 (14 mg, 0.012 mmol) and morpholine (26 mg, 0.30 mmol). The resultant 
mixture was again degassed with nitrogen gas for 10 minutes and agitated for 16 h. The 
solvents were drained out and resin was washed with DMF (3 mL × 3) dichloromethane (3 
mL × 3), methanol (3 mL × 3) ending with a final washing with dichloromethane (3 mL) to 
accomplish resin bound amine 4-3. 
 
Compound 4-4 
 
 
 
To a suspension of the resin-bound amine 4-8 (0.06 mmol) in DMF (3 mL) was added pre-
made (10 minute before addition) mixture of acid 4-19 (0.15 g, 0.12 mmol), HBTU (46 mg, 
0.12 mmol) and N,N-diisopropylethylamine (21 µl, 0.12 mmol) and gently shaken for 18 h at 
room temperature. The solution was filtered through a phase extraction frit cartridge and 
washed with DMF (3 mL × 3) dichloromethane (3 mL × 3), methanol (3 mL × 3), 
alternatively, ending with a final washing with dichloromethane (3 mL). The procedure was 
repeated for two more times to afford alloc 4-4. 
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Compound 4-7 
 
To a suspension of the resin-bound amine 4-8 (0.06 mmol) in DMF (3 mL) was added pre-
made (10 minute before addition) mixture of acid 4-15 (61 mg, 0.12 mmol), HBTU (45 mg, 
0.12 mmol) and N,N-diisopropylethylamine (21 µl, 0.12 mmol) and gently shaken for 18 h at 
room temperature. The solution was filtered through a phase extraction frit cartridge and 
washed with DMF (3 mL × 3) dichloromethane (3 mL × 3), methanol (3 mL × 3), 
alternatively, ending with a final washing with dichloromethane (3 mL). The procedure was 
repeated for two more times to afford ester 4-7. 
 
Compound 4-8 
 
 
 
A resin-bound protected amine 4-10 (0.06 mmol) was suspended in iso-propanol (7 mL) in 
the 25 mL round bottom flask and the mixture was added with ethylenediamine (32 µl, 0.5 
mmol) and heated to reflux for 16 h. Reaction mixture was transferred into a phase extraction 
frit and extensively washed by methanol (10 × 5 mL), DMF (10 × 5 mL) and 
dichloromethane (10 × 5 mL) to afford resin bound amine 4-8. 
 
Compound 4-10 
 
 
 
The resin bound amine 4-12 (0.06 mmol) was swelled in CH2Cl2 (5 mL) for 1 h, and then it 
was washed with CH2Cl2 (3 × 5 mL) and DMF (3 × 5 mL). A solution of N,N-
Chapter 6 
 
130 
 
diisopropylethylamine (104 µL, 0.60 mmol) and di-tert butyl dicarbonate (131 mg, 0.25 
mmol) in DMF (5 mL) was added and the resultant mixture was agitated on orbital shaker for 
18 h. The resin was drained and washed with DMF (4 × 7 mL), methanol (4 × 7 mL), 
dichloromethane (4 × 7 mL) to obtain pthalimide 4-10. 
 
Compound 4-11 
 
To a suspension of the resin-bound amine 4-8 (0.06 mmol) in DMF (3 mL) was added pre-
made (10 minute before addition) mixture of acid 3-22 (95 mg, 0.09 mmol), HBTU (35 mg, 
0.09 mmol) and N,N-diisopropylethylamine (21 µl, 0.12 mmol) and gently shaken for 18 h at 
room temperature. The solution was filtered through a phase extraction frit cartridge and 
washed with DMF (3 mL × 3) dichloromethane (3 mL × 3), methanol (3 mL × 3), 
alternatively, ending with a final washing with dichloromethane (3 mL). The procedure was 
repeated for two more times to afford ester 4-11. 
 
Compound 4-12 
 
 
 
A 2-chloro trityl chloride resin (50 mg, 0.06 mmol, loading 1.22 mmol/g) was swelled in 
dichloromethane (7 mL) for 1 h and then it was washed with DMF (3 × 5 mL) and 
dichloromethane (3 × 5 mL). The resin was again suspended in dichloromethane (5 mL) and 
amine 3-14 (50 mg, 0.06 mmol) was added followed by N,N-diisopropylethylamine (10 µL, 
0.06 mmol). After agitating the mixture for 10 minutes another portion of diisopropylethyl 
amine (20 ul, 0.12 mmol) was added and reaction mixture was agitated for another 18 h. The 
solution was filtered through a phase extraction frit cartridge and washed with DMF (3 mL × 
3) and CH2Cl2 (3 mL × 3). The resin was added with methanol (0.5 mL) in CH2Cl2 (5 mL) 
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and agitated for 30 min. to endcap reactive sites and filtered off to eliminate any remaining 
reactive site in resin. The resin was washed extensively with DMF (3 mL × 3) and CH2Cl2 (3 
mL × 3) to accomplish resin bound pthalimide 4-12. 
 
Compound 4-13 
 
 
 
To a solution of amine 3-10 (6.0 g, 15.95 mmol) and cesium carbonate (4.10 g, 12.78 mmol) 
in anhydrous acetonitrile (200 mL) at room temperature was added slowly solution of benzyl 
bromoacetate (255 mmol solution in acetonitrile, 12.78 mmol). The resultant solution was 
stirred at room temperature for 2 days. The insoluble materials were removed by filtration 
and the filtrate was concentrated under reduced pressure. The residue was dissolved in 
dichloromethane (200 mL) and water (100 mL). The organic layer was separated; the 
aqueous phase was extracted by dichloromethane (2 × 100 mL).  The combined organic layer 
was dried over sodium sulphate, filtered, and concentrated under reduced pressure. 
Purification of the residue by silica gel column chromatography (3% 
methanol/dichloromethane) gave the benzyl ester 4-13 as light yellow oil (3.50 g, 42%).  
1
H NMR (300 MHz, CDCl3), δ (ppm): 1.38-1.54 (s, 18H, (C(CH3)3), 1.95 (br., s, 1H, NH), 
2.74 (t, J = 6 Hz, 2H), 2.95 (t, J = 6 Hz, 2H), 3.29, 3.31(s, 2H, NHCOOBn), 3.44-3.71 (m, 
12H), 5.12, 5.17 (s, 2H, CH2 benzyl), 7.29-7.41 (m, 5H, ArH). 
13
C{1H} NMR (75 MHz, CDCl3), δ (ppm): 28.0, 28.1 (C(CH3)3), 48.7, 51.6, 53.5, 55.8, 
56.6, 66.1, 70.2, 70.3, 70.6, 80.9, 80.9(C(CH3)3), 128.2, 128.5, 135.7 (ArC), 170.6, 171.3, 
171.4 (C=O). 
ESI-HRMS for C27H44N2O8Na [(M + Na)
+
] m/z calcd. 547.298987, found 547.298984 
 
Compound 4-14 
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A solution of methyl bromoacetate (167 µL, 1.76 mmol) in acetonitrile (3 mL) was added 
drop wise to a mixture of amine 4-13 (0.77 g, 1.46 mmol), potassium carbonate (0.24 g, 1.76 
mmol), and acetonitrile (10 mL) at room temperature. After 16 h of heating at 70 °C, the 
mixture was cooled to room temperature and concentrated under reduced pressure. The 
residue was partitioned between water (75 mL) and dichloromethane (75 mL), the layers 
were separated, and the organic phase was washed with water (3 × 50 mL) brine, dried over 
sodium sulphate, filtered through a plug of cotton, and concentrated under reduced pressure. 
Purification by silica gel column chromatography (3% methanol/dichloromethane) afforded 
ester 4-14 as light yellow oil (0.63 g, 72%). 
1
H NMR (300 MHz, CDCl3) δ (ppm):  1.44 (s, 18H, (C(CH3)3), 2.94 (q, J = 6 Hz, 4H), 
3.44-3.64(m, 14H), 3.66 (s, 2H), 3.68 (s, 2H), 5.13(major), 5.19 (minor) (s, 2H, PhCH2), 
7.29-7.37 (m, 5H, ArH).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 28.0, 28.1 (C(CH3)3), 51.4, 53.4, 55.6, 55.8, 
56.6, 66.0, 70.1, 70.2, 70.3, 80.8(C(CH3)3), 128.2, 128.4, 135.7 (ArC), 170.4, 170.5, 171.3, 
171.9 (C=O).  
ESI-HRMS for C30H48N2O10Na [M+Na]
+
, m/z calcd. 619.320117, found 619.320600. 
 
Compound 4-15 
 
   
 
A mixture of ester 4-14 (0.63 mg, 1.06 mmol) and 10% Pd-C (0.12 g, 20% w/w) in absolute 
ethanol (25 mL) was shaken under a hydrogen atmosphere (35 psi) in a Parr hydrogenator. 
After completion of the reaction, the catalyst was removed by filtration through plug of celite 
and the solvent was removed under reduced pressure to obtain a pure light yellow oil of acid 
4-15 (0.54 g, 78%). 
1
H NMR (300 MHz, CDCl3) δ (ppm):  1.43 (s, 18H, (C(CH3)3), 2.90 (t, J = 6 Hz, 4H), 3.32-
3.77(m, 19H).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 27.7, 27.8 (C(CH3)3), 51.6, 55.1, 56.3, 56.5, 
57.1, 58.7, 60.9, 66.9, 67.3, 68.8, 68.9, 81.2, 81.3(C(CH3)3), 171.3, 172.2, 172.5, 174.7 
(C=O).  
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ESI-HRMS for C23H41N2O10 [M-H]
-
, m/z calcd. 505.276121, found 505.275832. 
 
Compound 4-16 
 
 
 
To a mixture of aime 3-14 (0.48 mg, 0.58 mmol) in dioxane (15 mL) and water (7 mL) the 
solution of allyl chloroformate (68 uL, 0.64 mmol) in dioxane (5 mL) was added slowly. The 
resultant mixture was stirred at room temperature for 16 h. The volatiles were removed under 
reduced pressure and residue was dissolved into dichloromethane (40 mL) and water (20 
mL). The aqueous layer was removed and organic layer was washed with saturated aqueous 
sodium bicarbonate (20 mL) followed by water (2 × 20 mL). The organic layer was dried 
over sodium sulphate and concentrated to obtain light yellow syrup of alloc 4-16 (0.42 g, 
79%).  
1
H NMR (300 MHz, CDCl3) δ (ppm):  1.30-1.64 (m, 27H, (C(CH3)3), 1.64-2.15 (m, 6H), 
2.15-4.06 (br, 25H, CH2 ring, CHCOO
t
Bu and CH2COO
t
Bu), 4.65 (d, J = 7.5 Hz, 2H), 4.98-
5.49 (m, 2H), 5.74-6.14 (m, 1H), 6.77-7.92 (m, 8H, ArH).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 26.1, 28.1, 28.2 (C(CH3)3), 29.5, 30.2, 32.0, 
36.5, 49.7, 52.2, 52.4, 52.8, 53.0,(CH2 ring), 56.0 (CH2COOtBu), 60.2, 64.3 (CHCOOtBu), 
65.5, 80.4, 80.5, (C(CH3)3), 117.9, 118.9, 123.0, 128.8, 132.0, 132.5, 135.5, 137.1, 153.2, 
144.1, 168.1, 170.9, 172.6 (C=O).  
ESI-HRMS for C49H73N6O10 [M+H]
+
, m/z calcd. 905.538269, found 905.538035. 
 
Compound 4-17 
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To a solution of alloc 4-16 (0.70 g, 0.77 mmol) in 2-propanol (10 mL) was added 
ethylenediamine (0.26 mL, 3.86 mmol) and the mixture stirred at 90 °C for 16h. The reaction 
mixture was cooled to room temperature and concentrated under reduced pressure. The 
residue was dissolved in dichloromethane (40 mL) and water (20 mL). After removal of 
aqueous layer, the organic layer was washed with water (2 × 25 mL) and brine (25 mL). The 
organic layer was dried over sodium sulphate. Pure amine 4-17 as light brown semi solid was 
obtained after concentration of organic layer under reduced pressure (0.46 g, 77%). 
1
H NMR (300 MHz, CDCl3) δ (ppm):  1.33-1.66 (m, 27H, (C(CH3)3), 1.67-2.29 (m, 2H), 
2.32-4.13 (br, 27H, CH2 ring, CHCOO
t
Bu and CH2COO
t
Bu), 4.65 (d, J = 7.5 Hz, 2H), 5.08-
5.44 (m, 2H), 5.84-6.08 (m, 1H), 6.78-7.80 (m, 8H, ArH).  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 25.2, 27.9, 28.1, 28.2 (C(CH3)3), 30.2, 31.8, 
40.2, 44.5, 49.6, 52.1, 52.3, 52.8, 53.3,(CH2 ring), 56.2 (CH2COO
t
Bu), 63.7, 64.4 
(CHCOO
t
Bu), 65.5, 80.5, 80.6, 82.1, 82.3, 82.7(C(CH3)3), 115.1, 117.8, 118.7, 123.1, 125.3, 
128.8, 132.5, 133.9, 135.7, 136.9, 153.3, 168.1, 170.9, 172.8, 173.7 (C=O).  
ESI-HRMS for C41H71N6O8 [M+H]
+
, m/z calcd. 775.532790, found 775.532317. 
 
Ligand L
7
 
 
 
 
The resin-bound amine 4-29 was treated with a 90% solution of trifluoroacetic acid in CH2Cl2 
for 16 h. The solution was drained into a round-bottom flask, and the resin was washed twice 
with anhydrous CH2Cl2. The solvents were removed under reduced pressure and the residue 
was dissolved into methanol (10 mL) and concentrated further. This procedure was repeated 
for three more times. The residue was re-dissolved into methanol (1 mL) and added drop wise 
to cold diethyl ether (100 mL). Mixture was stirred at room temperature for 16 h. Diethyl 
ether was removed using a centrifuge to obtain ligand L
7
. 
1
H NMR (300 MHz, D2O), δ (ppm): 1.58-2.22 (m, 8H), 2.24-4.36 (m, 74H), 7.31 (d, J = 7.5 
Hz, 2H), 7.40 (d, J = 7.5 Hz, 2H). 
ESI-MS for C64H103N14O20 [(M - H)
-
] m/z calcd. 1387.7, found 1387.6. 
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Acid (1.00 g, 5.74 mmol) was dissolved into thionyl chloride (1.67 mL, 22.98 mmol) and 
stirred at 75 °C for 24 h. Bromine (0.326 mL, 6.32 mmol) was added to the reaction mixture 
at 75 °C and stirred at same temperature for 24 h. The reaction mixture was concentrated 
under reduced pressure and diethyl ether (3 × 20 mL) was added and evaporated to remove 
traces of volatiles. The residue was dissolved into diethyl ether (20 mL) and added drop 
wisely to the mixture of tert-butanol (810 µL, 8.62 mmol) and triethylamine (1.20 mL, 8.62 
mmol) also in diethyl ether (20 mL) at room temperature and the mixture was stirred at this 
temperature for 16 h. The reaction mixture was diluted with diethyl ether (150 mL) and 
washed with water (3 × 50 mL) and brine (50 mL). The organic layer was dried over sodium 
sulphate, filtered through cotton plug and concentrated under reduced pressure. Purification 
of the residue by silica gel column chromatography (4% ethyl acetate/hexanes) gave bromide 
(0.90 g, 50%).  
1
H NMR (300 MHz, CDCl3), δ (ppm) 1.26 (t, J = 9 Hz, 3H, OCH2CH3), 1.31-1.58 (m, 
11H, C(CH3)3), 1.58-1.76 (m, 2H), 1.85-2.13 (m, J = 9 Hz, 2H), 2.30 (t, J = 6 Hz, 2H), 4.08-
4.15 (m, 3H, OCH2CH3, CH(Br)CO). 
13
C NMR (75 MHz, CDCl3), δ (ppm): 14.2, 24.2, 26.7, 27.7 (C(CH3)3), 33.9, 34.49, 47.4, 
60.3 (CCH(Br)CO), 82.3 (C(CH3)3), 168.7, 173.2 (C=O). 
 
 
 
To a solution of bis-tert butyl ester DO2A 2-10 (1.00 g, 2.50 mmol) in anhydrous acetonitrile 
(50 mL) sodium bicarbonate (0.168 g, 2.00 mmol) was added followed by solution of benzy-
3-bromopropyl carbamate (0.54 g, 2.00 mmol) also in anhydrous acetonitrile (20 mL) slowly 
at room temperature. The resultant mixture was stirred at room temperature for 2 days. The 
insoluble solids were removed by filtration and the filtrate was concentrated under reduced 
pressure to obtain a residue which was purified by silica gel column chromatography (2% 
methanol/dichloromethane) to obtain amine as white solid (0.57 g, 38%). 
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1
H NMR (300 MHz, CDCl3), δ (ppm)   1.45 (s, 18H, C(CH3)3), 1.57-1.78 (m, 2H, 
CH2CH2CH2), 2.43-3.47 (m, 24H,), 5.10 (s,  2H, OCH2Ph), 5.79 (br s, , 1H, NHCO), 7.18- 
7.41 (m, 5H, ArH), 10.19 (br s, 1H, NH ring),  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 24.1 (CH2CH2CH2), 28.06 (C(CH3)3), 29.6 
(NCOCH2CH2), 39.1 (NCH2CH2), 46.3, 48.8, 50.2, 52.2, (CH2 ring), 57.2 (CH2 acetate arm), 
66.3 (OCH2Ph), 81.5 (C(CH3)3), 136.6, 128.4, 128.0, 127.9 (ArC), 156.7, 170.3 (C=O).  
ESI-MS for C31H53N5O6 [(M + H)
+
] m/z calcd. 592.4, found 592.4 
 
 
 
 
 
 
To a solution of bis-tert butyl ester DO2A 2-10 (2.10 g, 5.25 mmol) and sodium bicarbonate 
(0.35 g, 4.20 mmol) in anhydrous acetonitrile (100 mL) was added a solution of diethyl(3-
bromopropyl)phosphonate (1.09 g, 4.20 mmol) in acetonitrile (40 mL) over 1 h. The resultant 
mixture was stirred at room temperature for 2 days. The residue obtained after filtration and 
concentration under reduced pressure was purified by silica gel column chromatography (3% 
methanol/dichloromethane) to afford amine as white solid (1.2 g, 39%)  
1
H NMR (300 MHz, CDCl3), δ (ppm)  1.28 (t, J = 7.5 Hz, 6H, OCH2CH3), 1.41 (s, 18H, 
C(CH3)3), 1.50-1.72 (m, 4H, NCH2CH2CH2), 2.43-3.15 (m, 18H, CH2 ring, NCH2CH2), 3.34 
(s, 4H, CH2 acetate arm), 3.95-4.16 (m, 4H, OCH2CH3), 10.17(br.s, 1H, NH ring),  
13
C{1H} NMR (75 MHz, CDCl3) δ (ppm): 14.5(d, J = 4.5 Hz ,NCH2CH2CH2), 16.4(d, J 
=5.3 Hz, OCH2CH3), 23.1 (d, J = 141.8 Hz, P(O)CH2CH2), 28.0 (C(CH3)3), 47.4 (NCH2CH2), 
48.9, 50.4, 50.8, 53.3 (CH2 ring), 57.8 (CH2’s acetate arm), 61.6 (d, J = 6 Hz, OCH2CH3), 
81.5 (C(CH3)3), 170.4 (C=O).  
ESI-MS for C27H56N4O7P [(M + H)
+
] m/z calcd. 579.4, found 579.4 
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Annexure I 
1
H, 
13
C and 
31
P NMR spectra of ligands L
1-7 
All spectra were recorded in D2O 
Annexure I 
 
139 
 
 
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
10.0023.951.000.10
1
.5
0
1
.6
1
1
.6
4
1
.6
61
.6
8
1
.7
3
1
.7
4
1
.9
9
2
.0
3
2
.9
2
2
.9
5
2
.9
6
3
.0
0
3
.0
73
.1
6
3
.2
9
3
.3
3
3
.5
0
3
.6
8
3
.7
1
3
.7
5
4
.0
8
4
.1
0
4
.7
5
 
 
 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
1
7
.1
7
2
2
.6
8
2
3
.5
8
2
6
.5
5
3
8
.9
7
4
6
.9
1
4
7
.1
6
4
8
.3
4
4
9
.9
24
9
.9
8
5
0
.1
4
5
3
.2
6
5
4
.4
4
6
3
.1
5
1
7
0
.8
3
1
7
3
.6
4
1
7
4
.5
8
 
L1 
L1 
Annexure I 
 
140 
 
88 80 72 64 56 48 40 32 24 16 8 0 -8 -16 -24 -32
Chemical Shift (ppm)
2
7
.2
4
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
7.9626.244.00
1
.1
9
1
.2
0
1
.2
1
1
.2
4
1
.2
6
1
.2
8
1
.6
6
1
.6
8
1
.7
1
1
.7
4
1
.9
2
2
.0
2
2
.0
5
2
.0
9
2
.3
3
2
.7
3
2
.8
8
2
.9
1
2
.9
5
3
.1
03
.1
2
3
.1
5
3
.2
0
3
.2
4
3
.2
9
3
.3
9
3
.4
7
3
.5
3
3
.6
8
3
.8
2
3
.8
5
4
.6
8
4
.7
5
4
.8
4
4
.8
8
7
.3
2
7
.3
5
7
.4
0
7
.4
3
7
.4
7
 
L2 
L1 
Annexure I 
 
141 
 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
1
7
.4
3
2
2
.9
7
2
4
.7
8
2
6
.4
2
3
1
.6
6
4
7
.2
6
4
8
.0
6
4
9
.3
74
9
.6
3
4
9
.7
8
5
0
.2
25
3
.6
1
5
4
.2
1
5
4
.4
7
6
1
.3
0
1
2
3
.4
1
1
2
8
.3
4
1
3
0
.6
0
1
4
1
.2
9
1
7
1
.3
3
1
7
3
.2
9
1
7
4
.4
7
 
 
88 80 72 64 56 48 40 32 24 16 8 0 -8 -16 -24 -32 -40
Chemical Shift (ppm)
2
6
.5
6
 
 
L2 
L2 
Annexure I 
 
142 
 
120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220
Chemical Shift (ppm)
-1
1
6
.3
8
-8
8
.5
8
0
.0
0
2
4
.1
9
 
 
90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110
Chemical Shift (ppm)
0
.0
0
2
2
.0
9
 
 
EuL1 at pD 7 
EuL1 at pD 5 
Annexure I 
 
143 
 
80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160
Chemical Shift (ppm)
2
3
.0
5
0
.0
0
-1
1
9
.1
7
 
 
120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220
Chemical Shift (ppm)
2
0
.3
5
0
.0
0
 
 
EuL2 at pD 5 
EuL2 at pD 7 
Annexure I 
 
144 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
18.3528.001.120.47
1
.3
3
1
.3
4
1
.5
5
1
.8
92
.1
8
2
.6
8
2
.7
2
2
.9
0
3
.1
3
3
.2
5
3
.4
8
3
.6
3
3
.6
7
3
.7
0
3
.8
0
4
.3
5
4
.5
3
4
.7
5
8
.1
8
 
 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
Chemical Shift (ppm)
1
7
.4
0
2
3
.6
1
2
4
.0
7
2
5
.2
22
7
.9
6
2
8
.2
7
3
5
.5
5
3
8
.6
1
3
9
.7
6
4
7
.9
3
4
9
.5
4
4
9
.7
2
5
2
.5
4
5
3
.7
6
5
5
.4
2
6
0
.2
3
6
2
.0
9
6
4
.6
1
1
6
5
.1
6
1
6
6
.0
6
1
7
2
.0
0
1
7
4
.6
4
1
7
6
.5
2
 
L3 
L3
4 
Annexure I 
 
145 
 
65 60 55 50 45 40 35 30 25 20 15 10 5 0 -5 -10 -15 -20
Chemical Shift (ppm)
2
3
.5
7
2
3
.9
6
 
 
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
11.9331.871.201.233.981.55
1
.4
0
1
.5
3
1
.6
6
1
.8
2
2
.1
42
.3
6
2
.6
8
2
.7
2
2
.9
0
3
.1
1
3
.2
9
3
.5
4
3
.5
7
3
.6
6
4
.3
1
4
.5
1
4
.7
5
7
.2
5
7
.3
3
8
.4
0
 
 
L4 
L3 
Annexure I 
 
146 
 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
1
6
.8
2
2
3
.9
6
2
5
.1
32
7
.7
1
2
7
.9
8
2
9
.0
9
3
1
.6
5
3
6
.1
9
3
9
.7
4
4
6
.7
8
4
8
.6
8
4
8
.9
34
9
.3
5
4
9
.4
7
5
3
.8
3
5
5
.3
5
5
6
.3
9
6
0
.2
2
6
2
.0
3
6
3
.4
6
1
2
2
.2
01
2
9
.4
4
1
3
5
.2
4
1
3
7
.6
3
1
6
5
.2
4
1
7
0
.9
7
1
7
5
.1
6
1
7
5
.3
6
 
 
50 45 40 35 30 25 20 15 10 5 0 -5 -10 -15 -20 -25
Chemical Shift (ppm)
2
2
.9
9
2
3
.7
0
 
 
L4 
L4 
Annexure I 
 
147 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
6.3673.001.511.80
1
.7
9
1
.8
1
1
.8
3
1
.8
51
.8
9
2
.6
4
2
.8
2
2
.8
2
2
.8
5
2
.8
7
2
.8
92
.9
1
2
.9
5
3
.1
4
3
.1
9
3
.2
8
3
.3
0
3
.4
9
3
.6
5
3
.7
7
3
.8
2
4
.0
3
4
.7
5
4
.8
2
6
.9
4
6
.9
7
7
.1
7
7
.2
0
 
 
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
7.5873.004.09
1
.8
1
2
.9
4
3
.1
5
3
.2
5
3
.3
6
3
.3
8
3
.4
4
3
.6
3
3
.6
8
3
.8
5
4
.0
8
4
.1
2
4
.7
5
6
.8
9
6
.9
1
7
.0
5
7
.0
8
7
.6
1
 
 
L6 
L5 
Annexure I 
 
148 
 
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
2
5
.5
5
2
8
.6
6
3
4
.2
6
3
9
.2
0
4
9
.5
0
4
9
.6
1
5
0
.6
3
5
1
.0
6
5
2
.5
9
5
4
.5
6
5
5
.5
6
5
7
.9
6
5
8
.9
0
6
3
.5
8
6
7
.2
1
7
2
.1
7
1
2
8
.6
6
1
3
1
.3
5
1
3
2
.7
6
1
3
6
.5
6
1
4
2
.0
1
1
6
7
.5
3
1
7
0
.4
9
1
7
0
.7
1
1
7
5
.7
9
1
7
6
.7
3
1
7
6
.9
8
 
 
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
8.8974.548.00
0
.9
2
0
.9
3
1
.2
4
1
.2
6
1
.7
2
1
.7
4
1
.8
6
1
.8
7
1
.8
7
1
.9
0
2
.1
1
2
.1
2
2
.1
2
2
.1
3
2
.1
4
2
.7
6
2
.8
7
2
.8
7
2
.9
02
.9
6
3
.2
5
3
.2
5
3
.3
4
3
.3
9
3
.5
2
3
.6
6
3
.7
1
3
.8
7
3
.9
3
4
.1
5
4
.6
9
4
.7
5
4
.8
8
4
.9
6
4
.9
6
7
.2
9
7
.3
2
7
.3
8
7
.4
1
8
.2
6
 
L7 
L6 
Annexure II 
 
149 
 
Annexure II 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure II 
 
150 
 
 
Annexure II 
 
151 
 
1. James, M. L.; Gambhir, S. S., A molecular imaging primer: modalities, imaging 
agents, and applications. Physiological Reviews 2012, 92, 897-965. 
2. Merbach, A. E.; Toth, E., The chemistry of contrast agents in medical magnetic 
resonance imaging. Wiley: Chichester, 2001; p xii, 471 p. 
3. Bloch, F.; Hansen, W. W.; Packard, M., The nuclear induction experiment. Physical 
Review 1946, 70, 474-485. 
4. Dutton, P. L.; Leigh, J. S.; Scarpa, A., Frontiers of biological energetics : electrons to 
tissues. Academic Press: New York, 1978; p P. 752. 
5. Ananta, J. S.; Godin, B.; Sethi, R.; Moriggi, L.; Liu, X. W.; Serda, R. E.; 
Krishnamurthy, R.; Muthupillai, R.; Bolskar, R. D.; Helm, L.; Ferrari, M.; Wilson, L. J.; 
Decuzzi, P., Geometrical confinement of gadolinium-based contrast agents in nanoporous 
particles enhances T(1) contrast. Nat. Nanotechnol. 2010, 5, 815-821. 
6. Johansson, L.; Bjornerud, A., The utility of superparamagnetic contrast agents in 
MRI: theoretical consideration and applications in the cardiovascular system. Nmr in 
Biomedicine 2004, 17, 465-477. 
7. Wang, Y. X. J.; Hussain, S. M.; Krestin, G. P., Superparamagnetic iron oxide contrast 
agents: physicochemical characteristics and applications in MR imaging. European 
Radiology 2001, 11, 2319-2331. 
8. Weissleder, R.; Bogdanov, A.; Neuwelt, E. A.; Papisov, M., Long-circulating iron-
oxides for MR imaging. Advanced Drug Delivery Reviews 1995, 16, 321-334. 
9. Weissleder, R.; Moore, A.; Mahmood, U.; Bhorade, R.; Benveniste, H.; Chiocca, E. 
A.; Basilion, J. P., In vivo magnetic resonance imaging of transgene expression. Nature 
Medicine 2000, 6, 351-354. 
10. Bulte, J. W. M.; Kraitchman, D. L., Iron oxide MR contrast agents for molecular and 
cellular imaging. Nmr in Biomedicine 2004, 17, 484-499. 
11. Dobson, J.; Pankhurst, Q. A.; Connolly, J.; Jones, S. K., Applications of magnetic 
nanoparticles in biomedicine. Journal of Physics D-Applied Physics 2003, 36, R167-R181. 
12. Toth, E.; Kubicek, V., Design and function of metal complexes as contrast agents in 
MRI. In Advances in Inorganic Chemistry, Vol 61: Metal Ion Controlled Reactivity, 
VanEldik, R.; Hubbard, C. D., Eds.2009; Vol. 61, pp 63-129. 
13. Cotton, S., Lanthanide and actinide chemistry. Wiley: Chichester, 2006; p xiv, 263 p. 
14. Port, M.; Idee, J.-M.; Medina, C.; Robic, C.; Sabatou, M.; Corot, C., Efficiency, 
thermodynamic and kinetic stability of marketed gadolinium chelates and their possible 
clinical consequences: a critical review. Biometals 2008, 21, 469-490. 
15. Thomsen, H. S., Nephrogenic systemic fibrosis: a serious late adverse reaction to 
gadodiamide. European Radiology 2006, 16, 2619-2621. 
16. Aime, S.; Botta, M.; Fasano, M.; Terreno, E., Lanthanide(III) chelates for NMR 
biomedical applications. Chemical Society Reviews 1998, 27, 19-29. 
17. Lauffer, R. B., Paramagnetic metal-complexes as water proton relaxation agents for 
NMR imaging-Theory and design. Chem. Rev. 1987, 87, 901-927. 
18. Solomon, I., Relaxation processes in a system of 2 spins. Physical Review 1955, 99, 
559-565. 
19. Solomon, I.; Bloembergen, N., Nuclear magnetic interactions in the HF molecule. 
Journal of Chemical Physics 1956, 25, 261-266. 
20. Bloembergen, N.; Morgan, L. O., Proton relaxation times in paramagnetic solutions 
effects of electron spin relaxation. Journal of Chemical Physics 1961, 34, 842-&. 
21. Raymond, K. N.; Werner, E. J.; Datta, A.; Jocher, C. J., High-Relaxivity MRI 
Contrast Agents: Where Coordination Chemistry Meets Medical Imaging. Angewandte 
Chemie-International Edition 2008, 47, 8568-8580. 
Annexure II 
 
152 
 
22. Aime, S.; Calabi, L.; Cavallotti, C.; Gianolio, E.; Giovenzana, G. B.; Losi, P.; 
Maiocchi, A.; Palmisano, G.; Sisti, M., Gd-AAZTA (-): A new structural entry for an 
improved generation of MRI contrast agents. Inorganic Chemistry 2004, 43, 7588-7590. 
23. Angelovski, G.; Mamedov, I., Cation-Responsive MRI Contrast Agents Based on 
Gadolinium(III). Current Inorganic Chemistry 2011, 1, 76-90. 
24. Bruce, J. I.; Dickins, R. S.; Govenlock, L. J.; Gunnlaugsson, T.; Lopinski, S.; Lowe, 
M. P.; Parker, D.; Peacock, R. D.; Perry, J. J. B.; Aime, S.; Botta, M., The selectivity of 
reversible oxy-anion binding in aqueous solution at a chiral europium and terbium center: 
Signaling of carbonate chelation by changes in the form and circular polarization of 
luminescence emission. Journal of the American Chemical Society 2000, 122, 9674-9684. 
25. Alpoim, M. C.; Urbano, A. M.; Geraldes, C.; Peters, J. A., Determinatio of the 
number of inner-sphere water-molecules in lanthanide(III)polyaminocarboxylate complexes 
J. Chem. Soc.-Dalton Trans. 1992, 463-467. 
26. Horrocks, W. D.; Sudnick, D. R., Lanthanide ion probes of stucture in biology- Laser 
induced luminescence decay contants provide a direct measure of the number of metal-
coordinated watr-molecules. Journal of the American Chemical Society 1979, 101, 334-340. 
27. Horrocks, W. D.; Schmidt, G. F.; Sudnick, D. R.; Kittrell, C.; Bernheim, R. A., Laser-
induced lanthanide ion luminescence lifetime measurement by direct excitation of metal-ion 
levels-New class of structural probe for calcium-binding proteins and nucleic-acids. Journal 
of the American Chemical Society 1977, 99, 2378-2380. 
28. Parker, D.; Williams, J. A. G., Getting excited about lanthanide complexation 
chemistry. J. Chem. Soc.-Dalton Trans. 1996, 3613-3628. 
29. Beeby, A.; Clarkson, I. M.; Dickins, R. S.; Faulkner, S.; Parker, D.; Royle, L.; de 
Sousa, A. S.; Williams, J. A. G.; Woods, M., Non-radiative deactivation of the excited states 
of europium, terbium and ytterbium complexes by proximate energy-matched OH, NH and 
CH oscillators: an improved luminescence method for establishing solution hydration states. 
Journal of the Chemical Society-Perkin Transactions 2 1999, 493-503. 
30. Caravan, P.; Raitsimring, A. M.; Astashkin, A. V.; Baute, D.; Goldfarb, D.; 
Poluektov, O. G.; Lowe, M. P.; Zech, S. G., Determination of the hydration number of 
gadolinium(III) complexes by high-field pulsed O-17 ENDOR spectroscopy. Chemphyschem 
2006, 7, 1590-1597. 
31. Lukes, I.; Hermann, P.; Kotek, J.; Kubicek, V., Gadolinium(III) complexes as MRI 
contrast agents: ligand design and properties of the complexes. Dalton Transactions 2008, 
3027-3047. 
32. Lukes, I.; Rudovsky, J.; Botta, M.; Hermann, P.; Hardcastle, K. I.; Aime, S., PAMAM 
dendrimeric conjugates with a Gd-DOTA phosphinate derivative and their adducts with 
polyaminoacids: The interplay of global motion, internal rotation, and fast water exchange. 
Bioconjugate Chemistry 2006, 17, 975-987. 
33. Revel, D.; Casali, C.; Janier, M.; Canet, E.; Obadia, J. F.; Benderbous, S.; Corot, C., 
Evaluation of Gd-DOTA-labeled dextran polymer as an intravascular MR contrast agent for 
myocardial perfusion. Academic Radiology 1998, 5, S214-S218. 
34. Caravan, P.; Cloutier, N. J.; Greenfield, M. T.; McDermid, S. A.; Dunham, S. U.; 
Bulte, J. W. M.; Amedio, J. C.; Looby, R. J.; Supkowski, R. M.; Horrocks, W. D.; McMurry, 
T. J.; Lauffer, R. B., The interaction of MS-325 with human serum albumin and its effect on 
proton relaxation rates. Journal of the American Chemical Society 2002, 124, 3152-3162. 
35. Merbach, A. E.; Livramento, J. B.; Weidensteiner, C.; Prata, M. I. M.; Allegrini, P. 
R.; Geraldes, C. F. G. C.; Helm, L.; Kneuer, R.; Santos, A. C.; Schmidt, P.; Toth, E., First in 
vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable 
high field relaxivity. Contrast Media & Molecular Imaging 2006, 1, 30-39. 
Annexure II 
 
153 
 
36. Aime, S.; Barge, A.; Botta, M.; Parker, D.; DeSousa, A. S., Prototropic vs whole 
water exchange contributions to the solvent relaxation enhancement in the aqueous solution 
of a cationic Gd3+ macrocyclic complex. Journal of the American Chemical Society 1997, 
119, 4767-4768. 
37. Aime, S.; Botta, M.; Fasano, M.; Paoletti, S.; Terreno, E., Relaxometric determination 
of the exchange rate of the coordinated water protons in a neutral Gd-III chelate. Chemistry-a 
European Journal 1997, 3, 1499-1504. 
38. Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B., Gadolinium(III) chelates as 
MRI contrast agents: Structure, dynamics, and applications. Chem. Rev. 1999, 99, 2293-2352. 
39. Raymond, K. N.; Thompson, M. K.; Botta, M.; Nicolle, G.; Helm, L.; Aime, S.; 
Merbach, A. E., A highly stable gadolinium complex with a fast, associative mechanism of 
water exchange. Journal of the American Chemical Society 2003, 125, 14274-14275. 
40. Botta, M.; Hardcastle, K. I.; Fasano, M.; Digilio, G., Experimental evidence for a 
second coordination sphere water molecule in the hydration structure of YbDTPA - Insights 
for a re-assessment of the relaxivity data of GdDTPA. European Journal of Inorganic 
Chemistry 2000, 971-977. 
41. Mamedov, I.; Mishra, A.; Angelovski, G.; Mayer, H. A.; Palsson, L. O.; Parker, D.; 
Logothetis, N. K., Synthesis and characterization of lanthanide complexes of DO3A-
alkylphosphonates. Dalton Trans 2007, 5260-7. 
42. Mordon, S.; Devoisselle, J. M.; Maunoury, V., In-vivo pH measurement and imaging 
of tumor-tissue using a pH-sensitive fluorescent-probe (5,6-carboxyfluorescein)-Instrumental 
and experimental studies. Photochemistry and Photobiology 1994, 60, 274-279. 
43. Perez-Mayoral, E.; Negri, V.; Soler-Padros, J.; Cerdan, S.; Ballesteros, P., Chemistry 
of paramagnetic and diamagnetic contrast agents for Magnetic Resonance Imaging and 
Spectroscopy pH responsive contrast agents. European Journal of Radiology 2008, 67, 453-
458. 
44. Sherry, A. D.; De Leon-Rodriguez, L. M.; Lubag, A. J. M.; Malloy, C. R.; Martinez, 
G. V.; Gillies, R. J., Responsive MRI Agents for Sensing Metabolism in Vivo. Accounts of 
Chemical Research 2009, 42, 948-957. 
45. Sherry, A. D.; Zhang, S. R.; Wu, K. C., A novel pH-sensitive MRI contrast agent. 
Angewandte Chemie-International Edition 1999, 38, 3192-3194. 
46. Yoo, B.; Pagel, M. D., An overview of responsive MRI contrast agents for molecular 
imaging. Front. Biosci. 2008, 13, 1733-1752. 
47. Chang, C. J.; Que, E. L., Responsive magnetic resonance imaging contrast agents as 
chemical sensors for metals in biology and medicine. Chemical Society Reviews 2010, 39, 51-
60. 
48. Yang, C.-T.; Chuang, K.-H., Gd(III) chelates for MRI contrast agents: from high 
relaxivity to "smart", from blood pool to blood-brain barrier permeable. Medchemcomm 
2012, 3, 552-565. 
49. Li, W. H.; Meade, T. J.; Fraser, S. E., A calcium-sensitive magnetic resonance 
imaging contrast agent. Journal of the American Chemical Society 1999, 121, 1413-1414. 
50. Angelovski, G.; Fouskova, P.; Mamedov, I.; Canals, S.; Toth, E.; Logothetis, N. K., 
Smart magnetic resonance imaging agents that sense extracellular calcium fluctuations. 
Chembiochem 2008, 9, 1729-34. 
51. Dhingra, K.; Fouskova, P.; Angelovski, G.; Maier, M. E.; Logothetis, N. K.; Toth, E., 
Towards extracellular Ca2+ sensing by MRI: synthesis and calcium-dependent H-1 and O-17 
relaxation studies of two novel bismacrocyclic Gd3+ complexes. Journal of Biological 
Inorganic Chemistry 2008, 13, 35-46. 
Annexure II 
 
154 
 
52. Dhingra, K.; Maier, M. E.; Beyerlein, M.; Angelovski, G.; Logothetis, N. K., 
Synthesis and characterization of a smart contrast agent sensitive to calcium. Chemical 
Communications 2008, 3444-3446. 
53. Mishra, A.; Fouskova, P.; Angelovski, G.; Balogh, E.; Mishra, A. K.; Logothetis, N. 
K.; Toth, E., Facile synthesis and relaxation properties of novel bispolyazamacrocyclic Gd3+ 
complexes: An attempt towards calcium-sensitive MRI contrast agents (vol 47, pg 1375, 
2008). Inorganic Chemistry 2008, 47, 3460-3460. 
54. Mamedov, I.; Henig, J.; Fouskova, P.; Toth, E.; Logothetis, N. K.; Angelovski, G.; 
Mayer, H. A., Influence of Calcium-Induced Aggregation on the Sensitivity of 
Aminobis(methylenephosphonate)-Containing Potential MRI Contrast Agents. Inorganic 
Chemistry 2011, 50, 6472-6481. 
55. Mamedov, I.; Logothetis, N. K.; Angelovski, G., Structure-related variable responses 
of calcium sensitive MRI probes. Organic & Biomolecular Chemistry 2011, 9, 5816-5824. 
56. Mamedov, I.; Canals, S.; Henig, J.; Beyerlein, M.; Murayama, Y.; Mayer, H. A.; 
Logothetis, N. K.; Angelovski, G., In Vivo Characterization of a Smart MRI Agent That 
Displays an Inverse Response to Calcium Concentration. Acs Chemical Neuroscience 2010, 
1, 819-828. 
57. Chang, C. J.; Que, E. L., A smart magnetic resonance contrast agent for selective 
copper sensing. Journal of the American Chemical Society 2006, 128, 15942-15943. 
58. Que, E. L.; Gianolio, E.; Baker, S. L.; Wong, A. P.; Aime, S.; Chang, C. J., Copper-
Responsive Magnetic Resonance Imaging Contrast Agents. Journal of the American 
Chemical Society 2009, 131, 8527-8536. 
59. Hanaoka, K.; Kikuchi, K.; Urano, Y.; Nagano, T., Selective sensing of zinc ions with 
a novel magnetic resonance imaging contrast agent. Journal of the Chemical Society-Perkin 
Transactions 2 2001, 1840-1843. 
60. Major, J. L.; Parigi, G.; Luchinat, C.; Meade, T. J., The synthesis and in vitro testing 
of a zinc-activated MRI contrast agent. Proceedings of the National Academy of Sciences of 
the United States of America 2007, 104, 13881-13886. 
61. Youn, J. H.; McDonough, A. A., Recent Advances in Understanding Integrative 
Control of Potassium Homeostasis. In Annual Review of Physiology,2009; Vol. 71, pp 381-
401. 
62. Hifumi, H.; Tanimoto, A.; Citterio, D.; Komatsu, H.; Suzuki, K., Novel 15-crown-5 
ether or beta-diketone incorporated gadolinium complexes for the detection of potassium ions 
or magnesium and calcium ions. Analyst 2007, 132, 1153-1160. 
63. Livramento, J. B.; Toth, E.; Sour, A.; Borel, A.; Merbach, A. E.; Ruloff, R., High 
relaxivity confined to a small molecular space: A metallostar-based, potential MRI contrast 
agent. Angewandte Chemie-International Edition 2005, 44, 1480-1484. 
64. Paris, J.; Gameiro, C.; Humblet, V.; Mohapatra, P. K.; Jacques, V.; Desreux, J. F., 
Auto-assembling of ditopic macrocyclic lanthanide chelates with transition-metal ions. Rigid 
multimetallic high relaxivity contrast agents for magnetic resonance Imaging. Inorganic 
Chemistry 2006, 45, 5092-5102. 
65. Ruloff, R.; van Koten, G.; Merbach, A. E., Novel heteroditopic chelate for self-
assembled gadolinium(III) complex with high relaxivity. Chemical Communications 2004, 
842-843. 
66. Aime, S.; Botta, M.; Fasano, M.; Terreno, E., Paramagnetic Gd-III-Fe-III 
heterobimetallic complexes of DTPA-bis-salicylamide. Spectrochimica Acta Part a-
Molecular and Biomolecular Spectroscopy 1993, 49, 1315-1322. 
67. Moats, R. A.; Fraser, S. E.; Meade, T. J., A ''smart'' magnetic resonance imaging agent 
that reports on specific enzymatic activity. Angewandte Chemie-International Edition in 
English 1997, 36, 726-728. 
Annexure II 
 
155 
 
68. Louie, A. Y.; Huber, M. M.; Ahrens, E. T.; Rothbacher, U.; Moats, R.; Jacobs, R. E.; 
Fraser, S. E.; Meade, T. J., In vivo visualization of gene expression using magnetic resonance 
imaging. Nature Biotechnology 2000, 18, 321-325. 
69. Duimstra, J. A.; Femia, F. J.; Meade, T. J., A gadolinium chelate for detection of beta-
glucuronidase: A self-immolative approach. Journal of the American Chemical Society 2005, 
127, 12847-12855. 
70. Giardiello, M.; Lowe, M. P.; Botta, M., An esterase-activated magnetic resonance 
contrast agent. Chemical Communications 2007, 4044-4046. 
71. Nivorozhkin, A. L.; Kolodziej, A. F.; Caravan, P.; Greenfield, M. T.; Lauffer, R. B.; 
McMurry, T. J., Enzyme-activated Gd3+ magnetic resonance imaging contrast agents with a 
prominent receptor-induced magnetization enhancement. Angewandte Chemie-International 
Edition 2001, 40, 2903-2906. 
72. Arena, F.; Singh, J. B.; Gianolio, E.; Stefania, R.; Aime, S., beta-Gal Gene Expression 
MRI Reporter in Melanoma Tumor Cells. Design, Synthesis, and in Vitro and in Vivo 
Testing of a Gd(III) Containing Probe Forming a High Relaxivity, Melanin-Like Structure 
upon beta-Gal Enzymatic Activation. Bioconjugate Chemistry 2011, 22, 2625-2635. 
73. Griffiths, J. R., Are cancer cells acidic. British Journal of Cancer 1991, 64, 425-427. 
74. Vaupel, P.; Kallinowski, F.; Okunieff, P., Blood-flow, oxygen and nutrient supply, 
and metabolic microenvironment of human-tumors-A review. Cancer Research 1989, 49, 
6449-6465. 
75. Wikehooley, J. L.; Haveman, J.; Reinhold, H. S., The relevance of tumor pH to the 
treatment of malignant disease. Radiotherapy and Oncology 1984, 2, 343-366. 
76. Tannock, I. F.; Rotin, D., Acid pH in tumors and its potential for therapeutic 
exploitation. Cancer Research 1989, 49, 4373-4384. 
77. Van Den Berg, A. P.; Wike-Hooley, J. L.; Van Den Berg-Blok, A. E.; Vna Der Zee, 
J.; Reinhold, H. S., Tumar pH in human mammary carcinoma. European Journal of Cancer 
and Clinical Oncology 1982, 18, 457-462. 
78. Calderwood, S. K.; Dickson, J. A., pH and tumar response to hyperthermia. Advances 
in Radiation Biology 1983, 10, 135-190. 
79. Martin, G. R.; Jain, R. K., Noninvasive measurement of interstitial pH profiles in 
normal and neoplastic tissue using flurescence ratio imaging microscopy. Cancer Research 
1994, 54, 5670-5674. 
80. Stubbs, M.; Bhujwalla, Z. M.; Tozer, G. M.; Rodrigues, L. M.; Maxwell, R. J.; 
Morgan, R.; Howe, F. A.; Griffiths, J. R., An assessment of P-31 MRS as a method of 
measuring pH in rat-tumors. Nmr in Biomedicine 1992, 5, 351-359. 
81. Lyng, H.; Olsen, D. R.; Southon, T. E.; Rofstad, E. K., P-31 nuclear magnetic 
resonance spectroscopy in-vivo of 6-human-melanoma xenograft lines-Tumor bioenergetic 
status and blood-supply. British Journal of Cancer 1993, 68, 1061-1070. 
82. Mordon, S.; Devoisselle, J. M.; Soulie, S., Fluorescence spectroscopy of pH in-vivo 
using a dual-emission fluorophore (C-SNAFL-1). Journal of Photochemistry and 
Photobiology B-Biology 1995, 28, 19-23. 
83. Frullano, L.; Catana, C.; Benner, T.; Sherry, A. D.; Caravan, P., Bimodal MR-PET 
Agent for Quantitative pH Imaging. Angewandte Chemie-International Edition 2010, 49, 
2382-2384. 
84. Lowe, M. P.; Parker, D.; Reany, O.; Aime, S.; Botta, M.; Castellano, G.; Gianolio, E.; 
Pagliarin, R., pH-dependent modulation of relaxivity and luminescence in macrocyclic 
gadolinium and europium complexes based on reversible intramolecular sulfonamide 
ligation. Journal of the American Chemical Society 2001, 123, 7601-7609. 
85. Caravan, P., Strategies for increasing the sensitivity of gadolinium based MRI contrast 
agents. Chemical Society Reviews 2006, 35, 512-523. 
Annexure II 
 
156 
 
86. Aime, S.; Caravan, P., Biodistribution of Gadolinium-Based Contrast Agents, 
Including Gadolinium Deposition. Journal of Magnetic Resonance Imaging 2009, 30, 1259-
1267. 
87. Sherry, A. D.; Ali, M. M.; Woods, M.; Caravan, P.; Opina, A. C. L.; Spiller, M.; 
Fettinger, J. C., Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI 
contrast agent. Chemistry-a European Journal 2008, 14, 7250-7258. 
88. Aime, S.; Gianolio, E.; Napolitano, R.; Fedeli, F.; Arena, F., Poly-beta-cyclodextrin 
based platform for pH mapping via a ratiometric (19)F/(1)H MRI method. Chemical 
Communications 2009, 6044-6046. 
89. Green, N. M., Avidin and Streptavidin. Methods in Enzymology 1990, 184, 51-67. 
90. Guenin, E.; Monteil, M.; Bouchemal, N.; Prange, T.; Lecouvey, M., Syntheses of 
phosphonic esters of alendronate, pamidronate and neridronate. European Journal of Organic 
Chemistry 2007, 3380-3391. 
91. Lowe, M. P.; Giardiello, M.; Botta, M., An esterase-activated magnetic resonance 
contrast agent. Chemical Communications 2007, 4044-4046. 
92. Kovacs, Z.; Sherry, A. D., pH-controlled selective protection of polyaza macrocycles. 
Synthesis 1997, 759-763. 
93. Eisenwiener, K. P.; Powell, P.; Macke, H. R., A convenient synthesis of novel 
bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. 
Bioorganic & Medicinal Chemistry Letters 2000, 10, 2133-2135. 
94. Wardle, N. J.; Herlihy, A. H.; So, P.-W.; Bell, J. D.; Bligh, S. W. A., Synthesis of a 
novel 'smart' bifunctional chelating agent 1-(2- beta,D-galactopyranosyloxylethyl)-7-(1-
carboxy-3- 4-aminophenyllpr opyl)-4,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
(Gal-PA-DO3A-NH2) and its Gd(III) complex. Bioorganic & Medicinal Chemistry 2007, 15, 
4714-4721. 
95. Corsi, D. M.; Platas-Iglesias, C.; van Bekkum, H.; Peters, J. A., Determination of 
paramagnetic lanthanide(III) concentrations from bulk magnetic susceptibility shifts in NMR 
spectra. Magnetic Resonance in Chemistry 2001, 39, 723-726. 
96. Horrocks, W. D.; Bolender, J. P.; Smith, W. D.; Supkowski, R. M., Photosensitized 
near infrared luminescence of ytterbium(III) in proteins and complexes occurs via an internal 
redox process. Journal of the American Chemical Society 1997, 119, 5972-5973. 
97. Wilchek, M.; Bayer, E. A., Introduction to avidin-biotin technology. Methods in 
Enzymology 1990, 184, 5-13. 
98. Lehtolainen, P.; Wirth, T.; Taskinen, A. K.; Lehenkari, P.; Leppanen, O.; 
Lappalainen, M.; Pulkkanen, K.; Marttila, A.; Marjomaki, V.; Airenne, K. J.; Horton, M.; 
Kulomaa, M. S.; Yla-Herttuala, S., Targeting of biotinylated compounds to its target tissue 
using a low-density lipoprotein receptor-avidin fusion protein. Gene Therapy 2003, 10, 2090-
2097. 
99. Breitz, H. B.; Weiden, P. L.; Press, O.; Appelbaum, J. W.; Bryan, J. K.; Gaffigan, S.; 
Stone, D.; Axworthy, D.; Fisher, D.; Reno, J., Pretargeted radioimmunotherapy (PRIT (TM)) 
for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer 
Biother. Radiopharm. 2000, 15, 15-29. 
100. Su, J.; Chen, F.; Cryns, V. L.; Messersmith, P. B., Catechol Polymers for pH-
Responsive, Targeted Drug Delivery to Cancer Cells. Journal of the American Chemical 
Society 2011, 133, 11850-11853. 
101. Horowitz, P.; Mock, D. M.; Langford, G.; Dubois, D.; Criscimagna, N., A 
fluorometric assay for the biotin avidininteraction based on displacement of the fluorescent-
probe 2-anilinonaphthalene-6-sulfonic acid. Anal. Biochem. 1985, 151, 178-181. 
102. Dwek, R. A., Nuclear magnetic resonance (N.M.R.) in biochemistry: applications to 
enzyme systems. Clarendon Press: Oxford, 1973; p xviii, 395 p. 
Annexure II 
 
157 
 
103. Livramento, J. B.; Weidensteiner, C.; Prata, M. I. M.; Allegrini, P. R.; Geraldes, C.; 
Helm, L.; Kneuer, R.; Merbach, A. E.; Santos, A. C.; Schmidt, P.; Toth, E., First in vivo MRI 
assessment of a self-assembled metallostar compound endowed with a remarkable high field 
relaxivity. Contrast Media & Molecular Imaging 2006, 1, 30-39. 
104. Meldolesi, J., Calcium signalling - Oscillation, activation, expression. Nature 1998, 
392, 863-+. 
105. Burgoyne, R. D., Neuronal calcium sensor proteins: generating diversity in neuronal 
Ca
2+
 signalling. Nature Reviews Neuroscience 2007, 8, 182-193. 
106. Silver, I. A.; Erecinska, M., Intracellular and extracellular changes of Ca
2+ 
in hypoxia 
and ischema in rat-brain in vivo. Journal of General Physiology 1990, 95, 837-866. 
107. Pawley, J. B., Handbook of biological confocal microscopy. 3rd ed.; Springer: New 
York, NY, 2006; p xxviii, 985 p. 
108. Somjen, G. G., Ions in the brain : normal function, seizures, and strokes. Oxford 
University Press: New York; Oxford, 2004; p xxix, 470 p. 
109. Popov, K.; Ronkkomaki, H.; Lajunen, L. H. J., Critical evaluation of stability 
constants of phosphonic acids (IUPAC technical report). Pure Appl. Chem. 2001, 73, 1641-
1677. 
110. Matczak-Jon, E.; Kurzak, B.; Kamecka, A.; Sawka-Dobrowolska, W.; Kafarski, P., 
Interactions of zinc(II), magnesium(II) and calcium(II) with iminodimethylenediphosphonic 
acids in aqueous solutions. Journal of the Chemical Society-Dalton Transactions 1999, 3627-
3637. 
111. Dhingra, K.; Fouskova, P.; Angelovski, G.; Maier, M. E.; Logothetis, N. K.; Toth, E., 
Towards extracellular Ca
2+
 sensing by MRI: synthesis and calcium-dependent 
1
H and 
17
O 
relaxation studies of two novel bismacrocyclic Gd
3+
 complexes. Journal of Biological 
Inorganic Chemistry 2008, 13, 35-46. 
112. Merrifield, R. B., Solid phase peptide synthesis. I. Synthesis of a tetrapeptide. Journal 
of the American Chemical Society 1963, 85, 2149-&. 
113. Lam, K. S., Application of combinatorial library methods in cancer research and drug 
discovery. Anti-Cancer Drug Design 1997, 12, 145-167. 
114. Lam, K. S.; Lebl, M.; Krchnak, V., The ''one-bead-one-compound'' combinatorial 
library method. Chem. Rev. 1997, 97, 411-448. 
115. Chillemi, F.; Merrifie.Rb, Use of min-dinitrophenylhistidine in solid-phase synthesis 
of tricosapeptides 124-146 of human hemoglobin beta chain. Biochemistry 1969, 8, 4344-&. 
116. Merrifie.Rb, Automated synthesis of peptides. Science 1965, 150, 178-&. 
117. Huo, C.; Chan, T. H., A novel liquid-phase strategy for organic synthesis using 
organic ions as soluble supports. Chemical Society Reviews 2010, 39, 2977-3006. 
118. Lu, J.; Toy, P. H., Organic Polymer Supports for Synthesis and for Reagent and 
Catalyst Immobilization. Chem. Rev. 2009, 109, 815-838. 
119. Boas, U.; Brask, J.; Jensen, K. J., Backbone Amide Linker in Solid-Phase Synthesis. 
Chem. Rev. 2009, 109, 2092-2118. 
120. Dioos, B. M. L.; Vankelecom, I. F. J.; Jacobs, P. A., Aspects of immobilisation of 
catalysts on polymeric supports. Advanced Synthesis & Catalysis 2006, 348, 1413-1446. 
121. Guillier, F.; Orain, D.; Bradley, M., Linkers and cleavage strategies in solid-phase 
organic synthesis and combinatorial chemistry. Chem. Rev. 2000, 100, 2091-2157. 
122. James, I. W., Linkers for solid phase organic synthesis. Tetrahedron 1999, 55, 4855-
4946. 
123. Pedersen, S. L.; Tofteng, A. P.; Malik, L.; Jensen, K. J., Microwave heating in solid-
phase peptide synthesis. Chemical Society Reviews 2012, 41, 1826-1844. 
124. Sammelson, R. E.; Kurth, M. J., Carbon-carbon bond-forming solid-phase reactions. 
Part II. Chem. Rev. 2001, 101, 137-202. 
Annexure II 
 
158 
 
125. Isidro-Llobet, A.; Alvarez, M.; Albericio, F., Amino Acid-Protecting Groups. Chem. 
Rev. 2009, 109, 2455-2504. 
126. Pattabiraman, V. R.; Bode, J. W., Rethinking amide bond synthesis. Nature 2011, 
480, 471-479. 
127. Eifler-Lima, V. L.; Graebin, C. S.; Uchoa, F. D. T.; Duarte, P. D.; Correa, A. G., 
Highlights in the Solid-Phase Organic Synthesis of Natural Products and Analogues. Journal 
of the Brazilian Chemical Society 2010, 21, 1401-1423. 
128. Lorsbach, B. A.; Kurth, M. J., Carbon-carbon bond forming solid-phase reactions. 
Chem. Rev. 1999, 99, 1549-1581. 
129. Bhorade, R.; Weissleder, R.; Nakakoshi, T.; Moore, A.; Tung, C. H., Macrocyclic 
chelators with paramagnetic cations are internalized into mammalian cells via a HIV-tat 
derived membrane translocation peptide. Bioconjugate Chem. 2000, 11, 301-305. 
130. Heppeler, A.; Froidevaux, S.; Eberle, A. N.; Maecke, H. R., Receptor targeting for 
tumor localisation and therapy with radiopeptides. Curr. Med. Chem. 2000, 7, 971-994. 
131. Hsieh, H. P.; Wu, Y. T.; Chen, S. T.; Wang, K. T., Direct solid-phase synthesis of 
octreotide conjugates: Precursors for use as tumor-targeted radiopharmaceuticals. Bioorg. 
Med. Chem. 1999, 7, 1797-1803. 
132. Peterson, J. J.; Pak, R. H.; Meares, C. F., Total solid-phase synthesis of 1,4,7,10-
tetraazacyclododecane-N,N ',N '',N '''-tetraacetic acid-functionalized peptides for 
radioimmunotherapy. Bioconjugate Chem. 1999, 10, 316-320. 
133. De Leon-Rodriguez, L. M.; Kovacs, Z.; Dieckmann, G. R.; Sherry, A. D., Solid-phase 
synthesis of DOTA-peptides. Chemistry-a European Journal 2004, 10, 1149-1155. 
134. Kiviniemi, A.; Makela, J.; Makila, J.; Saanijoki, T.; Liljenback, H.; Poijarvi-Virta, P.; 
Lonnberg, H.; Laitala-Leinonen, T.; Roivainen, A.; Virta, P., Solid-Supported NOTA and 
DOTA Chelators Useful for the Synthesis of 3 '-Radiometalated Oligonucleotides. 
Bioconjugate Chem. 2012, 23, 1981-1988. 
135. Masuda, R.; Oishi, S.; Ohno, H.; Kimura, H.; Saji, H.; Fujii, N., Concise site-specific 
synthesis of DTPA-peptide conjugates: Application to imaging probes for the chemokine 
receptor CXCR4. Bioorg. Med. Chem. 2011, 19, 3216-3220. 
136. Yoo, B.; Sheth, V. R.; Pagel, M. D., An amine-derivatized, DOTA-loaded polymeric 
support for Fmoc solid phase peptide synthesis. Tetrahedron Letters 2009, 50, 4459-4462. 
137. De Leon-Rodriguez, L. M.; Kovacs, Z., The synthesis and chelation chemistry of 
DOTA-peptide conjugates. Bioconjugate Chem. 2008, 19, 391-402. 
138. Kovacs, Z.; De Leon-Rodriguez, L. M., Conjugation of 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTA) and its derivatives to peptides: 
Synthesis, applications and future prospects. Mini-Reviews in Organic Chemistry 2007, 4, 
281-291. 
139. Langereis, S.; Dirksen, A.; De Waal, B. F. M.; Van Genderen, M. H. P.; De Lussanet, 
Q. G.; Hackeng, T. M.; Meijer, E. W., Solid-phase synthesis of a cyclic NGR-functionalized 
Gd(III)DTPA complex. Eur. J. Org. Chem. 2005, 2534-2538. 
140. Jensen, K. J.; Alsina, J.; Songster, M. F.; Vagner, J.; Albericio, F.; Barany, G., 
Backbone Amide Linker (BAL) strategy for solid-phase synthesis of C-terminal-modified 
and cyclic peptides. Journal of the American Chemical Society 1998, 120, 5441-5452. 
141. Bui, C. T.; Rasoul, F. A.; Ercole, F.; Pham, Y.; Maeji, N. J., Efficiencies of reductive 
amination reactions on different solid supports. Tetrahedron Letters 1998, 39, 9279-9282. 
142. Sherry, A. D.; Kovacs, Z., pH-controlled selective protection of polyaza macrocycles. 
Synthesis 1997, 759-763. 
143. Valeur, B., Molecular fluorescence : principles and applications. Wiley-VCH: 
Weinheim ; Chichester, 2002; p xiv, 387 p. 
Annexure II 
 
159 
 
144. Mock, D. M.; Lankford, G.; Horowitz, P., A study of the interaction of avidin with 2-
anilinonaphthalene-6-sulfonic acid as a probe of the biotin binding-site. Biochimica Et 
Biophysica Acta 1988, 956, 23-29. 
145. Parac-Vogt, T. N.; Kimpe, K.; Laurent, S.; Vander Elst, L.; Burtea, C.; Chen, F.; 
Muller, R. N.; Ni, Y. C.; Verbruggen, A.; Binnemans, K., Synthesis, characterization, and 
pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic 
centers with albumin binding affinity. Chemistry-a European Journal 2005, 11, 3077-3086. 
 
Curriculum vitae 
 
161 
 
Sandip M. Vibhute 
 
Date of Birth: 15
th
 November, 1981. 
 
Nationality: Indian 
 
Family status: Married 
 
E-mail: sandip.vibhute@tuebingen.mpg.de  
 
Education 
 PhD, pursuing since June 2009 
o Max Planck Institute for Biological Cybernetics, Tübingen and Dept. of 
Organic Chemistry, University of Tübingen, Germany. 
o Thesis Title: Synthetic Modifications of Responsive MRI Contrast Agents- 
Development of Multifunctional Conjugates for Novel Class of fMRI. 
o Supervisors: Priv.–Doz. Dr. Goran Angelovski, Prof. Nikos K. Logothetis and 
Prof. Martin E. Maier. 
 
 Master of Science, Organic Chemistry, 2003 – 2005. 
o University of Pune, India. 
o First class with distinction (76.65%). 
 
 Bachelor of Science, Chemistry, 2000 – 2003. 
o Shivaji University Kolhapur, India.  
o First class with distinction (80%). 
 
 Secondary school Certificate, 1998. 
o Board of Secondary and Higher Secondary School, Pune, India. 
o First class with distinction (77.73%). 
 
Curriculum vitae 
 
162 
 
Employment 
 Research Scientist I at Dept. of Medicinal Chemistry, Albany Molecular Research 
Inc., Singapore Research Centre, Singapore. Mar 2008 to Apr 2009. 
 
 Research Chemist at Dept. of Medicinal Chemistry, New Drug Discovery Research, 
Ranbaxy Research Laboratories Ltd., Gurgaon, India. Aug 2007 to Feb 2008. 
 
 Research Associate at Dept. of Synthetic Organic Chemistry, Jubilant Chemsys 
Ltd., Noida, India. Jan 2006 to Jul 2007. 
 
Publication/Conference Paper 
 
 S. M. Vibhute, J. Engelmann, T. Verbić, M. E. Maier, N. K. Logothetis, G. 
Angelovski. “Synthesis and Characterization of pH-sensitive, Biotinylated MRI 
Contrast Agents and Their Conjugates with Avidin” Org. Biomol. Chem. 2013, 11(8), 
1294-1305. Highlighted as cover picture. 
 
 S. M. Vibhute, J. Engelmann, T. Verbić, M. E. Maier, N. K. Logothetis, G. 
Angelovski. “Synthetic modifications of pH-sensitive contrast agents for attachment 
to functional molecules and its utilization in biotin-avidin system” Frontiers in 
Medicinal Chemistry, Munich, Germany (Mar 2013). 
Talk 
 S. M. Vibhute, J. Engelmann, T. Verbić, M. E. Maier, N. K. Logothetis, G. 
Angelovski. “Synthetic modifications of pH-sensitive contrast agents for attachment 
to functional molecules and its utilization in biotin-avidin system” COST Action 
TD1004 annual Meeting, Theranostics Imaging and Therapy, Kings College 
London, UK (Oct 2012). 
